<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11349682</article-id><article-id pub-id-type="pmcid-ver">PMC11349682.1</article-id><article-id pub-id-type="pmcaid">11349682</article-id><article-id pub-id-type="pmcaiid">11349682</article-id><article-id pub-id-type="pmid">39206192</article-id><article-id pub-id-type="doi">10.3389/fimmu.2024.1438030</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="WY">Wan-Ying</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2750064"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zheng</surname><given-names initials="XL">Xiao-Li</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Coghi</surname><given-names initials="PS">Paolo Saul</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1904390"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="JH">Jun-Hui</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Dong</surname><given-names initials="BJ">Bing-Jun</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Fan</surname><given-names initials="XX">Xing-Xing</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/707934"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Dr. Neher&#8217;s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology</institution>, <addr-line>Macao</addr-line>, <country>Macao SAR, China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Intervention and Cell Therapy Center, Peking University Shenzhen Hospital</institution>, <addr-line>Shenzhen</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Gynecology Department, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine</institution>, <addr-line>Zhuhai</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Srinivasa Reddy Bonam, University of Texas Medical Branch at Galveston, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Claudio Rhyner, Christine-K&#252;hne-Center for Allergy Research and Education (CK-Care), Switzerland</p><p>Amrita Das, Indian Institute of Chemical Biology (CSIR), India</p></fn><corresp id="fn001">*Correspondence: Bing-Jun Dong, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:zxydongbingjun@zhuhai.gov.cn">zxydongbingjun@zhuhai.gov.cn</email>; Xing-Xing Fan, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:xxfan@must.edu.mo">xxfan@must.edu.mo</email></corresp><fn fn-type="equal" id="fn003"><p>&#8224;These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">454094</issue-id><elocation-id>1438030</elocation-id><history><date date-type="received"><day>24</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-03 12:25:25.070"><day>03</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Zhang, Zheng, Coghi, Chen, Dong and Fan</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Zhang, Zheng, Coghi, Chen, Dong and Fan</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-15-1438030.pdf"/><abstract><p>With the COVID-19 pandemic, the importance of vaccines has been widely recognized and has led to increased research and development efforts. Vaccines also play a crucial role in cancer treatment by activating the immune system to target and destroy cancer cells. However, enhancing the efficacy of cancer vaccines remains a challenge. Adjuvants, which enhance the immune response to antigens and improve vaccine effectiveness, have faced limitations in recent years, resulting in few novel adjuvants being identified. The advancement of artificial intelligence (AI) technology in drug development has provided a foundation for adjuvant screening and application, leading to a diversification of adjuvants. This article reviews the significant role of tumor vaccines in basic research and clinical treatment and explores the use of AI technology to screen novel adjuvants from databases. The findings of this review offer valuable insights for the development of new adjuvants for next-generation vaccines.</p></abstract><kwd-group><kwd>AI drug discovery</kwd><kwd>vaccine adjuvant</kwd><kwd>cancer</kwd><kwd>immune agonist</kwd><kwd>small molecular</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was funded by FDCT project grant to Dr. Xing-Xing Fan (Grant no. 0058/2020/A2 and 0038/2023/RIB2).</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="5"/><equation-count count="0"/><ref-count count="236"/><page-count count="20"/><word-count count="9304"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Vaccines and Molecular Therapeutics</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>In the field of drug discovery and screening, artificial intelligence (AI) has become a dominant method in the community due to its unique advantages (<xref rid="B1" ref-type="bibr">1</xref>). Firstly, the AI-based process significantly reduces the time and resources required for the research because it can quickly screen, design, and optimize millions of compound structures with enhanced prediction accuracy (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). Moreover, AI facilitates studying specific targets and discovering suitable target compounds, often called the &#8220;automation&#8221; process (<xref rid="B4" ref-type="bibr">4</xref>). Cancer vaccines that use tumor antigens and adjuvants to identify and eliminate cancer cells are becoming a promising approach (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). As the main component of cancer vaccines, adjuvants mainly enhance the vaccine&#8217;s immune response speed, intensity, and persistence (<xref rid="B7" ref-type="bibr">7</xref>). At present, a variety of proteins/receptors are being studied as potential targets for vaccine adjuvant design, including Toll-like receptor (TLR) (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>), Stimulator of interferon genes (STING) (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>), Indoleamine 2, 3-dioxygenase (IDO) (<xref rid="B12" ref-type="bibr">12</xref>), Programmed Cell Death Protein 1 (PD-1)/Programmed Cell Death Ligand 1 (PD-L1) (<xref rid="B13" ref-type="bibr">13</xref>) and so on. Although many potential adjuvants have been evaluated in preclinical studies, the number of adjuvants successfully converted to approved vaccines is still minimal (<xref rid="B14" ref-type="bibr">14</xref>). With the researchers&#8217; mastery of the immune system and vaccine technology, it has been found that the classical licensed adjuvants have limited applicability to cancer antigens, especially nucleic acid antigens, because of their inefficiency. It can no longer meet the requirements of current cancer immunotherapy. Therefore, the integration of AI technology and tools to promote the generation of novel adjuvants is required. The limitations of adjuvants have many causes, including the small number of currently approved adjuvants for clinical use and the significant barriers to translating new adjuvants from the laboratory to clinical applications. The high cost of clinical approval for new adjuvants and the preference of developers for existing adjuvants due to their lower regulatory risk are also contributing factors (<xref rid="B15" ref-type="bibr">15</xref>). To address this issue, the Adjuvant Development Program of the National Institutes of Health (NIH) has provided crucial funding and support for the development and application of new adjuvants in recent years (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). Another pressing issue is the low response rate of adjuvants. Specifically, why do adjuvants added to vaccines fail to work effectively or meet expectations? In our literature review, we found that this problem is mainly because many adjuvants do not translate well from animal studies to clinical studies. For example, there are significant differences in TLRs (Toll-like receptors) between different species (<xref rid="B18" ref-type="bibr">18</xref>). Therefore, it is crucial to screen potential TLR agonists in appropriate animal models while considering species differences. AI and machine learning are transforming multiple fields, including vaccine adjuvant development. For instance, in the study of new human TLR9 ligands, A. Ahuja et&#160;al. developed a customized software program called the &#8216;Synthetic Chemist.&#8217; Specifically, 10<sup>16</sup> synthetic oligonucleotides were generated using a computer, and a second machine learning program, &#8216;Search Algorithms for Ligands,&#8217; was used to screen these ligands to find the best pan-species TLR9 ligand (CPG55.2) (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Subsequently, CPG55.2 was shown to be active across multiple species and successfully used in the development of vaccines for influenza (<xref rid="B21" ref-type="bibr">21</xref>), malaria (<xref rid="B22" ref-type="bibr">22</xref>), herpes simplex virus type 2 infection (<xref rid="B23" ref-type="bibr">23</xref>), poliovirus (<xref rid="B24" ref-type="bibr">24</xref>), and COVID-19 (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). This example illustrates the advantages of using AI to screen adjuvants and demonstrates how the developed software has played an important role in advancing new adjuvants in practical applications. This article summarizes prospective tactics and technology for generating cancer vaccine adjuvants, which can be helpful in the development of cancer vaccines.</p></sec><sec id="s2"><label>2</label><title>Status and challenges of cancer vaccine adjuvants</title><p>Cancer vaccine adjuvants are substances used in cancer vaccines to enhance the immune system&#8217;s response to antigens. They play a crucial role in improving the efficacy of cancer vaccines by enhancing the body&#8217;s immune response to cancer cells. Like an experienced coach, they are gradually rewriting the rules of immunotherapy (<xref rid="B27" ref-type="bibr">27</xref>). Adjuvants can help present antigens to the immune system, stimulate the production of cytokines, and activate various immune cells, making them an essential component in the development of effective cancer vaccines (<xref rid="B28" ref-type="bibr">28</xref>).In recent years, scientists have been continuously exploring how to best utilize these &#8220;coaches&#8221; to enhance patients&#8217; immune responses through precise immunological data and personalized treatment plans. To ensure safety and efficacy, ideal cancer vaccine adjuvants should possess several key characteristics: low or no toxicity, minimal side effects, the ability to enhance the immune response to vaccine antigens, specificity, stability, and ease of large-scale production. In a groundbreaking study, researchers developed a nanoparticle-based adjuvant that showed remarkable results in clinical trials, achieving unprecedented therapeutic outcomes by enhancing antigen presentation and stimulating immune cells (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). Cancer vaccine adjuvants can be broadly classified based on their mechanisms and sources into the following categories: biological adjuvants, chemical adjuvants, particulate adjuvants, and combination adjuvants.</p><sec id="s2_1"><label>2.1</label><title>Biological adjuvants</title><p>Biological adjuvants are natural or synthetic biological molecules that enhance vaccine efficacy by modulating the immune system. These adjuvants can enhance immune responses through various mechanisms, including enhancing antigen presentation, activating immune cells, and promoting cytokine production.</p><sec id="s2_1_1"><label>2.1.1</label><title>Cytokines</title><p>GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) is an important cytokine that enhances immune responses by promoting the maturation and function of dendritic cells and macrophages. It is widely used in cancer vaccines to enhance antigen presentation and T cell activation (<xref rid="B31" ref-type="bibr">31</xref>). Provenge (Sipuleucel-T), the first FDA-approved therapeutic cancer vaccine, uses GM-CSF as an adjuvant to enhance antigen presentation by dendritic cells, used for treating prostate cancer (<xref rid="B32" ref-type="bibr">32</xref>). DCVax<sup>&#174;</sup>-L, a personalized dendritic cell vaccine for glioblastoma, combines the patient&#8217;s own tumor antigens with GM-CSF, significantly extending patient survival (<xref rid="B33" ref-type="bibr">33</xref>).</p><p>IL-12 (Interleukin-12) is another key cytokine that induces Th1 immune responses, promoting the activation of cytotoxic T cells and NK cells, thereby enhancing immune attacks on tumor cells. NKTR-214 (Bempegaldesleukin) is an IL-2 pathway agonist that enhances T cell and NK cell activity. It is used in combination with immune checkpoint inhibitors to treat various solid tumors and can provide long-lasting immune responses to prevent tumor recurrence when combined with anti-CTLA-4 antibodies (<xref rid="B34" ref-type="bibr">34</xref>).</p></sec><sec id="s2_1_2"><label>2.1.2</label><title>Microbial components</title><p>BCG (Bacillus Calmette-Gu&#233;rin) is an attenuated live vaccine derived from Mycobacterium bovis, widely used for bladder cancer immunotherapy (<xref rid="B35" ref-type="bibr">35</xref>). Initially developed to prevent tuberculosis, BCG is used as an immunoadjuvant in cancer immunotherapy due to its ability to stimulate the innate immune system, activate macrophages and dendritic cells, and promote antigen presentation and specific T cell responses (<xref rid="B36" ref-type="bibr">36</xref>).</p><p>CpG (Cytosine-phosphate-Guanine) oligodeoxynucleotides are synthetic molecules that activate TLR9, inducing strong Th1 immune responses, promoting dendritic cell maturation, and enhancing antigen presentation. Several new adjuvants, including TLR3, TLR7, and TLR9 agonists, are undergoing clinical trials to enhance the efficacy of immune checkpoint inhibitors and improve cancer vaccine responses (<xref rid="B37" ref-type="bibr">37</xref>).</p></sec><sec id="s2_1_3"><label>2.1.3</label><title>Other biological molecules</title><p>Mitogens, such as superantigens and bacterial toxins, can strongly activate T cells and enhance immune responses. For example, Tetanus Toxoid Fragment C (TTFC) is used as an effective adjuvant to enhance the efficacy of various vaccines (<xref rid="B38" ref-type="bibr">38</xref>).</p></sec></sec><sec id="s2_2"><label>2.2</label><title>Chemical adjuvants</title><p>Chemical adjuvants are synthetically designed substances aimed at enhancing immune responses. They improve vaccine efficacy through various mechanisms, including enhancing antigen uptake, activating immune cells, and promoting inflammatory responses. The in-depth study and application of chemical adjuvants have significantly improved vaccine efficacy, providing more options and possibilities, especially in cancer vaccine development.</p><sec id="s2_2_1"><label>2.2.1</label><title>Aluminum salts (Alum)</title><p>Aluminum salts are among the earliest and most widely used vaccine adjuvants. They enhance immune responses by forming an antigen depot, prolonging antigen presence in the body, and promoting uptake by antigen-presenting cells (APCs) (<xref rid="B39" ref-type="bibr">39</xref>). Aluminum salts are widely used in various vaccines, including DTP (Diphtheria, Tetanus, Pertussis) vaccines (<xref rid="B40" ref-type="bibr">40</xref>), hepatitis B vaccines (<xref rid="B41" ref-type="bibr">41</xref>), and human papillomavirus (HPV) vaccines (<xref rid="B42" ref-type="bibr">42</xref>). In some cancer vaccines, aluminum salts are used as adjuvants to enhance immune responses. For instance, aluminum adjuvants in HPV vaccines such as Gardasil and Cervarix improve vaccine immunogenicity and effectively prevent HPV-related cancers (<xref rid="B43" ref-type="bibr">43</xref>).</p></sec><sec id="s2_2_2"><label>2.2.2</label><title>Saponins</title><p>Saponins, such as Quillaja saponaria extract QS-21, are the only saponin adjuvant approved for clinical use in humans and have demonstrated strong immunostimulatory activity. Traditional extraction methods for QS-21 are time-consuming and yield low amounts (<xref rid="B44" ref-type="bibr">44</xref>). Recently, Liu et&#160;al. developed a novel method to synthesize QS-21 analogs, laying a rational foundation for effective vaccine adjuvants (<xref rid="B45" ref-type="bibr">45</xref>).</p></sec></sec><sec id="s2_3"><label>2.3</label><title>Particulate adjuvants</title><sec id="s2_3_1"><label>2.3.1</label><title>PLGA nanoparticles</title><p>PLGA (Polylactic-co-glycolic acid)) is a biodegradable polymer commonly used to prepare nanoparticles. PLGA nanoparticles enhance immune responses by controlling antigen release rates, increasing antigen stability, and promoting uptake by antigen-presenting cells (<xref rid="B46" ref-type="bibr">46</xref>). PLGA nanoparticles have been studied in various vaccines, including rabies and tuberculosis vaccines, showing significant immune-enhancing effects (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>). Additionally, PLGA is often used as a stabilizer for solid particle-stabilized emulsions (Pickering emulsions) (<xref rid="B49" ref-type="bibr">49</xref>). Due to its high stability, biocompatibility, and large loading capacity, Pickering emulsions have been widely used in biomedicine. PLGA-based Pickering emulsions can adhere to cell membranes, increasing contact areas (<xref rid="B50" ref-type="bibr">50</xref>).</p></sec><sec id="s2_3_2"><label>2.3.2</label><title>Liposomes</title><p>Liposomes are tiny vesicles formed by phospholipid bilayers that can effectively encapsulate and deliver antigens and adjuvants. Liposomes enhance immune responses by improving antigen delivery, promoting uptake by antigen-presenting cells, and providing antigen protection (<xref rid="B51" ref-type="bibr">51</xref>). Liposomes are widely used in various vaccines, including influenza and COVID-19 vaccines. For example, mRNA vaccines (such as Pfizer-BioNTech&#8217;s COVID-19 vaccine) use liposomes as delivery systems, significantly improving vaccine immunogenicity and protective efficacy (<xref rid="B52" ref-type="bibr">52</xref>). Liposome adjuvants show promising applications in vaccine development. For instance, a study indicated that using liposomes as adjuvants in influenza vaccines significantly improved immune responses in elderly populations (<xref rid="B53" ref-type="bibr">53</xref>).</p></sec></sec><sec id="s2_4"><label>2.4</label><title>Combination adjuvants</title><p>Combination adjuvants use multiple adjuvants together to achieve synergistic effects and enhance vaccine immune responses. This strategy aims to utilize complementary mechanisms of different adjuvants to provide stronger and longer-lasting immune protection compared to single adjuvants.</p><sec id="s2_4_1"><label>2.4.1</label><title>Combination of cytokines and nanoparticles</title><p>Cytokines such as GM-CSF can enhance the function of antigen-presenting cells (APCs) and promote antigen presentation. Nanoparticles can efficiently deliver antigens and adjuvants to immune cells and provide sustained immune stimulation through controlled release mechanisms. A study combined GM-CSF with PLGA nanoparticles for melanoma vaccine development, showing that this combination significantly enhanced vaccine immunogenicity and anti-tumor efficacy (<xref rid="B54" ref-type="bibr">54</xref>).</p></sec><sec id="s2_4_2"><label>2.4.2</label><title>Combination of multiple nanoparticles</title><p>Different types of nanoparticles (e.g., gold nanoparticles and PLGA nanoparticles) can enhance immune responses through different mechanisms. Gold nanoparticles can improve antigen stability and delivery efficiency, while PLGA nanoparticles provide sustained immune stimulation. Research indicated that combining gold nanoparticles and PLGA nanoparticles in liver cancer vaccines significantly enhanced antigen-specific T cell responses and anti-tumor activity (<xref rid="B55" ref-type="bibr">55</xref>).</p></sec><sec id="s2_4_3"><label>2.4.3</label><title>Combination of TLR agonists and liposomes</title><p>TLR agonists (e.g., CpG oligodeoxynucleotides) can activate the innate immune system, promote antigen presentation, and T cell activation. Liposomes, as delivery systems, can effectively encapsulate and deliver antigens and adjuvants, protecting them from degradation. In HPV-related cancer vaccine research, combining TLR9 agonist CpG with liposomes significantly enhanced vaccine immune responses and protective efficacy. MPL, a TLR4 ligand derived from LPS, enhances the ability to prevent tuberculosis in mice and crab-eating monkeys when present in the Ag85B-ESAT-6&#8212;DDA liposome formulation (<xref rid="B56" ref-type="bibr">56</xref>).</p><p>Recent research has explored various novel adjuvants and delivery systems to enhance the efficacy of cancer vaccines. For instance, studies have shown that using bispecific antibodies (i.e., antibodies that target both tumor cells and immune cells simultaneously) can enhance immune responses against cancer. Bispecific antibodies have demonstrated significant potential in targeting tumor-associated antigens and activating immune cells, thereby improving therapeutic outcomes (<xref rid="B57" ref-type="bibr">57</xref>).</p><p>Despite the crucial role of adjuvants in vaccine development, their use and development still face many challenges. Safety issues have always been paramount in drug development, as many adjuvants can cause local or systemic reactions or autoimmune diseases. Therefore, it is necessary to develop new adjuvants that reduce side effects and increase safety. For example, optimizing dosage and administration methods, as well as conducting extensive clinical trials for validation, are important. Individual differences in immune responses also need to be considered. Due to differences in genetics (<xref rid="B58" ref-type="bibr">58</xref>), environment (<xref rid="B59" ref-type="bibr">59</xref>), age (<xref rid="B60" ref-type="bibr">60</xref>), sex (<xref rid="B61" ref-type="bibr">61</xref>), occupation (<xref rid="B62" ref-type="bibr">62</xref>), and other factors, individuals may exhibit varying intensities and types of immune responses when receiving the same vaccine or being exposed to the same pathogen.</p><p>Additionally, the production processes for adjuvants are complex, and quality control often presents significant challenges, with variations between different batches. Thus, it is crucial to establish and adhere to strict standardized procedures and employ advanced quality control techniques. Besides these issues, adjuvants also face challenges such as insufficient immune persistence, high costs, and inadequate regulation, all of which need to be addressed and improved.</p></sec></sec></sec><sec id="s3"><label>3</label><title>Online available algorithms and databases of AI Drug Discovery</title><p>Recently, many algorithms and databases have been rapidly established for AIDD. For example, DeepChem, a Multi-Layer Perceptron (MLP) model primarily using Python AI system to search for suitable drug candidates in drug discovery (<xref rid="B63" ref-type="bibr">63</xref>), and DeepTox, a software capable of predicting the toxicity of 12,000 drugs (<xref rid="B64" ref-type="bibr">64</xref>). For the development of small molecule drugs, there is a database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://smpdb.ca/" ext-link-type="uri">https://smpdb.ca/</ext-link>) that includes 49,833 pathways that can be found in databases that are not accessible through other routes (<xref rid="B65" ref-type="bibr">65</xref>). Furthermore, Shtar and colleagues have established the continuously updated Continuous Drug Combination Database (CDCDB). In this database, they use various methods, including natural language processing, to improve the drug combination discovery process and ensure the database is applicable for predicting drug synergies (<xref rid="B66" ref-type="bibr">66</xref>). In sum, we have summarized other related databases and open-source tools in <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Databases and open-source tools.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Tools</th><th valign="middle" align="center" rowspan="1" colspan="1">Explanation</th><th valign="middle" align="center" rowspan="1" colspan="1">Github/website</th><th valign="middle" align="center" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">GoPubMed</td><td valign="middle" align="center" rowspan="1" colspan="1">A specialized search engine for PubMed articles, using text mining to find relevant research papers</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.gopubmed.org" ext-link-type="uri">http://www.gopubmed.org</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B67" ref-type="bibr">67</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">BioRAT</td><td valign="middle" align="center" rowspan="1" colspan="1">A tool for searching full-text articles to mine text data for useful information</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://bioinf.cs.ucl.ac.uk/biorat/" ext-link-type="uri">http://bioinf.cs.ucl.ac.uk/biorat/</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B68" ref-type="bibr">68</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">DeepChem</td><td valign="middle" align="center" rowspan="1" colspan="1">A machine learning tool in Python to help find potential drug candidates</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/deepchem/deepchem" ext-link-type="uri">https://github.com/deepchem/deepchem</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B63" ref-type="bibr">63</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">DeepNeuralNetQSAR</td><td valign="middle" align="center" rowspan="1" colspan="1">Uses computational tools to predict how compounds will behave based on their molecular structure</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/Merck/DeepNeuralNet-QSAR" ext-link-type="uri">https://github.com/Merck/DeepNeuralNet-QSAR</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B69" ref-type="bibr">69</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">DeepTox</td><td valign="middle" align="center" rowspan="1" colspan="1">Software that predicts the toxicity of around 12,000 drugs</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bioinf.jku.at/research/DeepTox" ext-link-type="uri">www.bioinf.jku.at/research/DeepTox</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B64" ref-type="bibr">64</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">GeneWays</td><td valign="middle" align="center" rowspan="1" colspan="1">Extracts information about biological pathways<break/>from scientific texts.</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://geneways.genomeleft.columbia.edu" ext-link-type="uri">http://geneways.genomeleft.columbia.edu</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B70" ref-type="bibr">70</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">PotentialNet</td><td valign="middle" align="center" rowspan="1" colspan="1">Uses neural networks to predict how well ligands (small molecules) will bind to their targets</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/full/10.1021/acscentsci.8b00507" ext-link-type="uri">https://pubs.acs.org/doi/full/10.1021/acscentsci.8b00507</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B71" ref-type="bibr">71</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">ORGANIC</td><td valign="middle" align="center" rowspan="1" colspan="1">Generates new molecules with desired properties</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/aspuru-guzik-group/ORGANIC" ext-link-type="uri">https://github.com/aspuru-guzik-group/ORGANIC</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B72" ref-type="bibr">72</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">CancerDR</td><td valign="middle" align="center" rowspan="1" colspan="1">Database of cancer drug resistance, listing the effectiveness of 148 anticancer drugs on nearly 1,000 cancer cell lines</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://crdd.osdd.net/raghava/cancerdr/" ext-link-type="uri">http://crdd.osdd.net/raghava/cancerdr/</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B73" ref-type="bibr">73</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">PubChem</td><td valign="middle" align="center" rowspan="1" colspan="1">A database of chemical information and their biological activities</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B74" ref-type="bibr">74</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">BRENDA</td><td valign="middle" align="center" rowspan="1" colspan="1">Comprehensive database of drug and drug target information</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.brenda-enzymes.org" ext-link-type="uri">http://www.brenda-enzymes.org</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B76" ref-type="bibr">76</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">DrugBank</td><td valign="middle" align="center" rowspan="1" colspan="1">Comprehensive drug&#8211;target and drug data information database</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.drugbank.ca" ext-link-type="uri">http://www.drugbank.ca</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B77" ref-type="bibr">77</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">ChEMBL</td><td valign="middle" align="center" rowspan="1" colspan="1">Database of bioactive molecules with drug-like properties, based on published research</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ebi.ac.uk/chembl" ext-link-type="uri">https://www.ebi.ac.uk/chembl</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B78" ref-type="bibr">78</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">ChEBI</td><td valign="middle" align="center" rowspan="1" colspan="1">Database of chemical entities of biological interest</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ebi.ac.uk/chebi" ext-link-type="uri">http://www.ebi.ac.uk/chebi</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B79" ref-type="bibr">79</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">ZINC</td><td valign="middle" align="center" rowspan="1" colspan="1">Database containing curated chemical compounds<break/>&#8201;&gt;&#8201;750 Million compounds</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://zinc.docking.org/" ext-link-type="uri">http://zinc.docking.org/</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B80" ref-type="bibr">80</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Chemputer</td><td valign="middle" align="center" rowspan="1" colspan="1">Give detailed recipe for compound synthesis</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://zenodo.org/record/1481731" ext-link-type="uri">https://zenodo.org/record/1481731</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B81" ref-type="bibr">81</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Chemical VAE</td><td valign="middle" align="center" rowspan="1" colspan="1">AUses variational autoencoders to automatically design new chemicals</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/aspuru-guzik-group/chemical_vae" ext-link-type="uri">https://github.com/aspuru-guzik-group/chemical_vae</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B82" ref-type="bibr">82</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">VAE</td><td valign="middle" align="center" rowspan="1" colspan="1">Improve the chemical property prediction performance of machine learning models</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/znavoyan/vae-embeddings" ext-link-type="uri">https://github.com/znavoyan/vae-embeddings</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B83" ref-type="bibr">83</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Co-VAE</td><td valign="middle" align="center" rowspan="1" colspan="1">A tool that predicts drug-target affinity better than existing methods</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ieeexplore.ieee.org/document/9576631" ext-link-type="uri">https://ieeexplore.ieee.org/document/9576631</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B84" ref-type="bibr">84</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Cloud 3D-QSAR</td><td valign="middle" align="center" rowspan="1" colspan="1">A web tool for building models that relate<break/>chemical structures to their biological activities</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://agroda.gzu.edu.cn:9999/ccb/server/cloud3dQSAR/" ext-link-type="uri">http://agroda.gzu.edu.cn:9999/ccb/server/cloud3dQSAR/</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B85" ref-type="bibr">85</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Neural graph fingerprint</td><td valign="middle" align="center" rowspan="1" colspan="1">Uses convolutional neural networks to predict properties of new compounds</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/HIPS/neural-fingerprint" ext-link-type="uri">https://github.com/HIPS/neural-fingerprint</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B86" ref-type="bibr">86</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">BindingDB</td><td valign="middle" align="center" rowspan="1" colspan="1">Database of experimental data on how small molecules interact with proteins</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bindingdb.org" ext-link-type="uri">http://www.bindingdb.org</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B87" ref-type="bibr">87</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Therapeutic target database</td><td valign="middle" align="center" rowspan="1" colspan="1">Comprehensive resource on therapeutic protein and nucleic acid targets, diseases, pathways, and drugs</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://db.idrblab.net/ttd/" ext-link-type="uri">https://db.idrblab.net/ttd/</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B88" ref-type="bibr">88</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Cambridge structural database (CSD)</td><td valign="middle" align="center" rowspan="1" colspan="1">Repository for small molecule organic and metal-organic crystal structures</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ccdc.cam.ac.uk/solutions/software/csd/" ext-link-type="uri">https://www.ccdc.cam.ac.uk/solutions/software/csd/</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B89" ref-type="bibr">89</xref>, <xref rid="B90" ref-type="bibr">90</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">NCI open database</td><td valign="middle" align="center" rowspan="1" colspan="1">Database from the National Cancer Institute with a wide range of chemical compounds</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cactus.nci.nih.gov/download/nci/" ext-link-type="uri">https://cactus.nci.nih.gov/download/nci/</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B91" ref-type="bibr">91</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">ENAMINE database</td><td valign="middle" align="center" rowspan="1" colspan="1">The world&#8217;s largest collection of novel building blocks (more than 210 million)<break/>36B Billion REAL compounds and Custom Library Synthesis</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://enamine.net/" ext-link-type="uri">https://enamine.net/</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B92" ref-type="bibr">92</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">CHEMBRIDGE Database</td><td valign="middle" align="center" rowspan="1" colspan="1">Database of over 1.3 million small molecules for screening, including unique macrocycles and building blocks</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://chembridge.com/" ext-link-type="uri">https://chembridge.com/</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">AMTDB</td><td valign="middle" align="center" rowspan="1" colspan="1">Open-access repository specifically for anti-tumor autophagy modulators</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://amtdb.vercel.app/" ext-link-type="uri">https://amtdb.vercel.app/</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B93" ref-type="bibr">93</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">ChemSpider</td><td valign="middle" align="center" rowspan="1" colspan="1">Chemical database maintained by the Royal Society of Chemistry with extensive chemical information.</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.chemspider.com/" ext-link-type="uri">http://www.chemspider.com/</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">(<xref rid="B94" ref-type="bibr">94</xref>)</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">GRAC</td><td valign="middle" align="center" rowspan="1" colspan="1">Database focused on compounds related to G Protein-Coupled Receptors (GPCRs)</td><td valign="middle" align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.guidetopharmacology.org/about.jsp" ext-link-type="uri">http://www.guidetopharmacology.org/about.jsp</ext-link>
</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td></tr></tbody></table><table-wrap-foot><fn><p>N/A, Not Available.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4"><label>4</label><title>AIDD assists in the discovery of novel adjuvants</title><p>Depending on different technical routes and functions, AIDD could be divided into five subgroups, including <italic toggle="yes">De novo</italic> design, Virtual screening, Properties and Toxicity prediction, and Drug repurposing.</p><sec id="s4_1"><label>4.1</label><title>The &#8220;<italic toggle="yes">De novo</italic> design&#8221; in the discovery of adjuvant</title><p>The stages of drug design have always been a focal point in AI. &#8220;<italic toggle="yes">De novo</italic> design&#8221; is an indispensable aspect of using AI in drug development. Since the introduction of the first &#8220;<italic toggle="yes">De novo</italic> design&#8221; software, HSITE/2D Skeletons, which was developed in the 1980s (<xref rid="B95" ref-type="bibr">95</xref>&#8211;<xref rid="B97" ref-type="bibr">97</xref>), it has gradually replaced traditional methods in drug discovery design, encompassing scoring, assembly, and search strategies. It has been continuously used until today (<xref rid="B98" ref-type="bibr">98</xref>). Based on it, Popova et&#160;al. designed a reinforcement deep learning algorithm called ReLeaSE (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/isayev/ReLeaSE" ext-link-type="uri">https://github.com/isayev/ReLeaSE</ext-link>). This algorithm includes deep neural networks (DNN) for compound generation and prediction of compound properties (<xref rid="B99" ref-type="bibr">99</xref>). Open-sourced tools for finding the optimal pathways of target molecule synthesis were also available, called AiZynthFinder (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/MolecularAI/aizynthfinder" ext-link-type="uri">https://github.com/MolecularAI/aizynthfinder</ext-link>) (<xref rid="B100" ref-type="bibr">100</xref>).</p><p>To focus on exploring small molecule adjuvants for cancer vaccines, a practical and highly efficient tool to find specific inhibitors or agonists is necessary. Zhavoronkov et&#160;al. designed a tool called Generative Tensor Reinforcement Learning (GENTRL) for small molecule &#8220;<italic toggle="yes">De novo</italic> design&#8221;. GENTRL optimizes synthesis feasibility, novelty, and biological activity. Using GENTRL, they discovered a potent inhibitor of Discoidin Domain Receptor 1 (DDR1), a kinase target associated with fibrosis and other diseases, within 21 days (<xref rid="B101" ref-type="bibr">101</xref>). Chemistry42 is a platform for <italic toggle="yes">de novo</italic> small molecule design and optimization. It combines AI and medicinal chemistry to generate novel structural molecules efficiently with <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> validation. These approaches have effectively validated for DDR1 and CDK20 (<xref rid="B102" ref-type="bibr">102</xref>). All these advancements provide significant assistance to AIDD or adjuvant identification.</p></sec><sec id="s4_2"><label>4.2</label><title>Virtual screening</title><p>Virtual screening technology is widely applied to facilitate the screening of large compound libraries based on computer simulations and molecular modeling techniques (<xref rid="B103" ref-type="bibr">103</xref>), thus contributing to drug high-throughput screening (HTS) (<xref rid="B104" ref-type="bibr">104</xref>). It allows for assessing the biological activity of candidate compounds based on their chemical structures, thus predicting their interactions with specific targets (<xref rid="B105" ref-type="bibr">105</xref>). Therefore, it enables the rapid identification of potentially active compounds, saving time and resources during the early stages of drug development (<xref rid="B106" ref-type="bibr">106</xref>). Traditional HTS often faces high costs, time-consuming processes, and limited sample quantities (<xref rid="B107" ref-type="bibr">107</xref>). This fast and efficient screening provides crucial support to drug development and advances the progress of drug discovery (<xref rid="B108" ref-type="bibr">108</xref>).</p><p>There are two main technical routes for virtual screening, including Ligand-based or Structure-based virtual screening (LB/SBVS), which are all primarily attributed to the advancements in extensive databases of protein and chemical structures. With improved computational power and the accumulation of large compound libraries, virtual screening can more accurately predict the biological activity and efficacy of candidate compounds (<xref rid="B109" ref-type="bibr">109</xref>). This has led to successful discoveries of new bioactive molecules, particularly in drug repurposing (<xref rid="B110" ref-type="bibr">110</xref>).</p><sec id="s4_2_1"><label>4.2.1</label><title>Ligand-based virtual screening</title><p>LBVS is a computer-assisted drug discovery method that predicts compounds&#8217; binding ability and affinity by simulating their interactions with protein targets (<xref rid="B111" ref-type="bibr">111</xref>). This screening approach is commonly used to identify potential drug candidates, particularly for drug discovery targeting known protein targets. It typically involves data preparation, ligand preprocessing, target preprocessing, molecular docking, and result analysis (<xref rid="B112" ref-type="bibr">112</xref>). For instance, Luca et&#160;al. recently utilized LBVS to identify an effective &#945;-Syn amyloid formation inhibitor, MeSC-04 and demonstrated its binding mode. This work provided new insights for developing &#945;-Syn amyloid inhibitors from synthetic sources (<xref rid="B113" ref-type="bibr">113</xref>). Zarei et&#160;al. employed LBVS on the RON receptor homology model to screen the ZINC database, identifying two compounds, TKI1 and TKI2, further evaluated <italic toggle="yes">in vitro</italic>. This study laid the foundation for novel RON inhibitors applicable in cancer therapy and targeting CXCL12 (<xref rid="B114" ref-type="bibr">114</xref>). This small pro-inflammatory chemokine plays a significant role in tumor formation by binding to the specific receptor CXCR4. Using LBVS, Haider et&#160;al. identified three potential anti-cancer CXCL12 inhibitors (<xref rid="B115" ref-type="bibr">115</xref>). The above examples illustrate that LBVS holds extensive prospects for application. Its emergence provides researchers with an efficient, rapid, and cost-effective approach to identifying potential candidate compounds, thus advancing the development of computer-assisted research in this field.</p></sec><sec id="s4_2_2"><label>4.2.2</label><title>Structure-based virtual screening</title><p>SBVS approach relies on the three-dimensional structure of the target protein, often obtained through X-ray crystallography (<xref rid="B116" ref-type="bibr">116</xref>) or nuclear magnetic resonance (NMR) spectroscopy (<xref rid="B117" ref-type="bibr">117</xref>). SBVS is widely used to identify potential drug candidates and has proven to be an effective tool in the early-stage drug discovery process (<xref rid="B118" ref-type="bibr">118</xref>). It typically involves molecular docking, scoring, and filtering to prioritize compounds with high binding affinity and potential therapeutic activity against the target protein. Thus, SBVS significantly accelerates the drug discovery process by reducing the number of compounds that need to be experimentally tested (<xref rid="B119" ref-type="bibr">119</xref>). Here, we have presented numerous examples of drug screening based on SBVS, demonstrating its importance in enhancing drug screening efficiency and improving the accuracy of candidate drug selection. For instance, Mukherjee et&#160;al. discovered compound CID 88265020 with significant potential as a VGFR inhibitor among over 80 virtual screening compounds, which could be used for prospective future studies in ovarian cancer (<xref rid="B120" ref-type="bibr">120</xref>). Xie et&#160;al., based on the importance of FOXM1 in ovarian cancer treatment, selected XST-119 through SBVS and found that XST-119 exhibited apparent inhibitory activity in a xenograft mouse model, laying the foundation for further drug discovery (<xref rid="B121" ref-type="bibr">121</xref>). G9a, a lysine methyltransferase, was investigated by Bellver-Sanchis et&#160;al., who proposed a candidate G9a inhibitor, referred to as compound F., providing a lead for G9a inhibitor design and demonstrating their involvement in reducing Alzheimer&#8217;s disease (AD) (<xref rid="B122" ref-type="bibr">122</xref>). Guo et&#160;al. discovered novel Tropomyosin receptor kinases A (TrkA) allosteric inhibitors through SBVS and identified a promising hit (D5261, TrkA cell IC50 = 3.32 &#956;M). Their results suggest that D5261 could be a starting point for developing TrkA allosteric inhibitors (<xref rid="B123" ref-type="bibr">123</xref>). Lin et&#160;al. reported a novel non-covalent Bruton tyrosine kinase (BTK) inhibitor that could potentially target malignant tumors, laying the foundation for developing effective BTK inhibitors for solid tumors (<xref rid="B124" ref-type="bibr">124</xref>). Luo et&#160;al. performed PD-L1 screening on 52,765 marine natural products and identified compound 51320 as a PD-L1 small molecule inhibitor through SBVS and other methods (<xref rid="B125" ref-type="bibr">125</xref>). Similarly, Ge et&#160;al. identified two compounds through SBVS that could serve as scaffolds for IDO1 inhibitors (<xref rid="B126" ref-type="bibr">126</xref>).</p><p>Furthermore, the SBVS process involves the interaction between molecules and proteins, making it indispensable for studying molecular mechanisms within living organisms. It contributes to uncovering the foundations of diseases and potential therapeutic pathways. In summary, with the continuous expansion of computer model training, SBVS is poised to become one of the critical tools in drug discovery.</p></sec></sec><sec id="s4_3"><label>4.3</label><title>Predicting the physicochemical properties and biological activities of compound</title><sec id="s4_3_1"><label>4.3.1</label><title>Quantitative Structure-Activity Relationship</title><p>QSAR modeling is one of the most popular computer-aided tools in drug chemistry for drug discovery and lead compound optimization. It involves four main steps: selecting appropriate molecules, model construction, model validation, and model application (<xref rid="B127" ref-type="bibr">127</xref>). Since its introduction in the 1960s, QSAR modeling has been continuously refined and updated (<xref rid="B128" ref-type="bibr">128</xref>). One of the most representative 3D QSAR models is Comparative Molecular Field Analysis (CoMFA), considered the most classical and widely used. However, its development has been limited by certain drawbacks (<xref rid="B129" ref-type="bibr">129</xref>, <xref rid="B130" ref-type="bibr">130</xref>). To address these limitations, Wang and colleagues created the Cloud 3D-QSAR server, which can facilitate the development of robust QSAR models in drug discovery (<xref rid="B131" ref-type="bibr">131</xref>). With the advancement of QSAR techniques, applying 4D, 5D, 6D, and 7D models is becoming more prominent, as these methods can provide additional information on small molecules beyond traditional 3D-QSAR (<xref rid="B132" ref-type="bibr">132</xref>).</p></sec><sec id="s4_3_2"><label>4.3.2</label><title>Predicting physical and chemical properties and biological activity</title><p>The physical and chemical properties of compounds determine their binding efficiency with targets, and predicting the physicochemical properties and biological activities of drugs can expedite the decision-making process.</p><p>Currently, numerous software programs are utilized for predicting the physicochemical properties and biological activities of drugs. JunctionTree VAE (Variational Autoencoder) is an open-source tool capable of predicting compound properties (<xref rid="B133" ref-type="bibr">133</xref>). Conv_qsar_fast is another open-source toolkit that uses CNN (Convolutional Neural Network) methods to predict molecular properties (<xref rid="B134" ref-type="bibr">134</xref>). Additionally, InnerOuterRNN utilizes internal and external recursive neural networks to predict physical, chemical, and biological properties (<xref rid="B135" ref-type="bibr">135</xref>). In conclusion, predicting the physicochemical properties and biological activities of drugs by AIDD can significantly enhance the efficiency and success rate of research and provide valuable tools and resources for scientists, accelerating the discovery and development of new medicines.</p></sec></sec><sec id="s4_4"><label>4.4</label><title>Prediction of compound toxicity</title><p>Toxicity testing is an essential but resource-consuming task for drug discovery (<xref rid="B136" ref-type="bibr">136</xref>), and utilizing AIDD in toxicity prediction can reduce the need for animal experiments (<xref rid="B137" ref-type="bibr">137</xref>, <xref rid="B138" ref-type="bibr">138</xref>). To address this challenge, various tools have been developed. One of the most classic tools is Deep Tox, which employs deep learning methods to predict compound toxicity (<xref rid="B139" ref-type="bibr">139</xref>). Furthermore, eToxPred is a software capable of evaluating candidate compound toxicity based on machine learning methods (<xref rid="B140" ref-type="bibr">140</xref>). TargeTox can also predict drug safety related to toxicity (<xref rid="B141" ref-type="bibr">141</xref>). Therefore, compound toxicity prediction is crucial in drug development, contributing to improved research efficiency and risk reduction and providing robust support for drug safety assessment.</p></sec><sec id="s4_5"><label>4.5</label><title>Drug repurposing</title><p>Drug repurposing, also known as drug repositioning (<xref rid="B142" ref-type="bibr">142</xref>), is categorized into early-stage and late-stage repurposing. The former involves the identification of potential lead compounds through large-scale screening of compound libraries (<xref rid="B143" ref-type="bibr">143</xref>); the latter is used to complete the preparation of lead compounds. For clinical testing and evaluation (<xref rid="B144" ref-type="bibr">144</xref>).</p><p>Drug repurposing has shown many successful examples: Aspirin was initially introduced by Bayer in 1899 as an analgesic and was first repositioned in the 1980s as an antiplatelet aggregation drug using low doses (<xref rid="B145" ref-type="bibr">145</xref>). With further research, scientists have revealed the therapeutic role of aspirin in the field of cancer, especially in colorectal cancer (<xref rid="B146" ref-type="bibr">146</xref>), where its anticancer effect is believed to result from the inhibition of COX-2, thereby blocking the anti-apoptotic effect of COX-2 in malignant cells and promoting their apoptosis (<xref rid="B147" ref-type="bibr">147</xref>). The second is Propranolol, originally a classic drug for treating angina and hypertension, which has recently been discovered to be effective in the treatment of osteoporosis and melanoma (<xref rid="B148" ref-type="bibr">148</xref>). As is well known, the chiral drug Sildenafil was once withdrawn from the market due to its teratogenic effects. However, a serendipitous discovery revealed that Sildenafil has a significant therapeutic impact on erythema nodosum leprosum (a type of autoimmune complication of leprosy) by inhibiting the synthesis of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-&#945;). Therefore, in 1998, it was repositioned by Celgene as an orphan drug for treating leprosy complications of leprosy (<xref rid="B149" ref-type="bibr">149</xref>). However, these cases are often based on serendipitous clinical discoveries and lack systematic patterns. Therefore, it is essential to utilize network-based approaches to discover the potential molecular mechanisms of drug actions (<xref rid="B150" ref-type="bibr">150</xref>).</p><p>Currently, there are several databases available for drug repurposing. For instance, the NCGC Pharmaceutical Collection (NPC) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://tripod.nih.gov/npc/" ext-link-type="uri">http://tripod.nih.gov/npc/</ext-link>) is suitable for screening and research on numerous diseases, and it minimizes false negatives and false positives (<xref rid="B151" ref-type="bibr">151</xref>). DrugBank (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.drugbank.ca" ext-link-type="uri">www.drugbank.ca</ext-link>) is a network-based database that provides comprehensive molecular information about drugs, drug mechanisms, drug interactions, and their targets. It can offer crucial clues for drug repurposing (<xref rid="B77" ref-type="bibr">77</xref>). Moreover, Drugs@FDA and ClinicalTrial.gov provide the latest updates on drugs in clinical development, presenting new research directions and systematic applications in AIDD.</p></sec></sec><sec id="s5"><label>5</label><title>Big data improves the efficiency of adjuvant identification</title><p>The precision of AI-based drug screening is crucial to reduce the use of animal models. Big data technology and machine algorithms provide us with significant advantages. Optimizing AI models&#8217; algorithms and parameters can improve predictive accuracy. Specifically, data preprocessing and standardization are essential (<xref rid="B152" ref-type="bibr">152</xref>). Standardizing and unifying data formats ensure comparability across different data sources. Additionally, addressing noise and missing values in the data can enhance its quality (<xref rid="B153" ref-type="bibr">153</xref>). On this foundation, model selection and extensive training are indispensable steps. Cross-validation and hyperparameter methods can improve model prediction accuracy (<xref rid="B154" ref-type="bibr">154</xref>, <xref rid="B155" ref-type="bibr">155</xref>). Once we obtain raw data, converting it into features suitable for supervised learning, known as feature engineering, is necessary. This process includes feature creation, transformation, extraction, exploratory data analysis, and benchmarking, aimed at simplifying and accelerating data transformation while improving model accuracy (<xref rid="B156" ref-type="bibr">156</xref>). Finally, small-scale experimental validation of adjuvants generated by AI screening, followed by model adjustments based on the prediction results, can enhance screening precision. Currently, machine learning-based predictive models can leverage existing experimental and clinical data for training, thereby reducing the need for animal experiments (<xref rid="B157" ref-type="bibr">157</xref>).</p></sec><sec id="s6"><label>6</label><title>Successful examples of different targets</title><p>AI has aided researchers in streamlining the intricate process of identifying candidate compounds on various targets. Leveraging AI, novel adjuvants have been developed for several diverse functional targets (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). We will highlight the research progress of adjuvants in some of the most valuable target categories. The upper part of the figure, from left to right, describes how adjuvants are designed, screened, quantitatively structured, and eventually repurposed and added to vaccines. When a vaccine containing AI-screened adjuvants is injected into a patient, it triggers a series of immune responses, stimulating immune cells to produce and release cytokines or target and attack tumors.</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>The framework of AIDD of adjuvants and typical examples of cancer vaccine adjuvants based on the clinical trials.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-15-1438030-g001.jpg"/></fig><sec id="s6_1"><label>6.1</label><title>Toll-like receptor family</title><p>The TLR family plays a crucial role in the innate immune system, typically serving as a class of pattern recognition receptors (PRRs) capable of recognizing specific molecular patterns associated with pathogens such as bacteria, viruses, and fungi (<xref rid="B158" ref-type="bibr">158</xref>). Specifically, when TLRs recognize one of these patterns, they trigger an immune response to protect the body from infection (<xref rid="B159" ref-type="bibr">159</xref>).</p><p>Due to these characteristics of TLRs, their agonists are widely used as adjuvants in cancer vaccines to enhance the immune response (<xref rid="B14" ref-type="bibr">14</xref>). We have summarized some of the relevant clinical advancements of TLRs in <xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>. Depending on the recognized molecular patterns, they can be categorized into four classes: Recognizing Bacterial Molecules: TLR1, TLR2, TLR4, TLR5, TLR6; Recognizing Double-Stranded RNA (dsRNA): TLR3; Recognizing Single-Stranded RNA (ssRNA) from Viruses: TLR7, TLR8; Recognizing Unmethylated CpG DNA Motifs from Viral DNA: TLR9. Some representative agents are examined below.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>TLR-based cancer vaccines adjuvant in clinical application.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Category</th><th valign="middle" align="center" rowspan="1" colspan="1">Biological</th><th valign="middle" align="center" rowspan="1" colspan="1">Status</th><th valign="middle" align="center" rowspan="1" colspan="1">Conditions</th><th valign="middle" align="center" rowspan="1" colspan="1">NCT code</th><th valign="top" align="center" rowspan="1" colspan="1">Reasons for use as an adjuvant</th><th valign="top" align="center" rowspan="1" colspan="1">AI tool</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR3 agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">Poly I: Poly C</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I/II</td><td valign="middle" align="center" rowspan="1" colspan="1">Melanoma, Ocular Melanoma, Uveal Melanoma</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04364230">NCT04364230</ext-link></td><td valign="top" rowspan="4" align="center" colspan="1">Activates the TLR3 signaling pathway in the immune system and enhances anti-tumor immune responses</td><td valign="top" align="center" rowspan="1" colspan="1">DeepChem</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR3 agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">Poly I: Poly C</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I/II</td><td valign="middle" align="center" rowspan="1" colspan="1">Melanoma, Metastatic Melanoma, Mucosal Melanoma</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02126579">NCT02126579</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">Deep Neural Net QSAR</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR3 agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">Poly I: Poly C</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I/II</td><td valign="middle" align="center" rowspan="1" colspan="1">Melanoma</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01079741">NCT01079741</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">DeepChem</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR3 agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">Poly I: Poly C</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I/II</td><td valign="middle" align="center" rowspan="1" colspan="1">Influenza, Human</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01591473">NCT01591473</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">DeepChem</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR4 Agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">GLA-SE</td><td valign="middle" align="center" rowspan="1" colspan="1">Early Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Skin Melanoma</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02320305">NCT02320305</ext-link></td><td valign="top" rowspan="2" align="center" colspan="1">Stimulates the TLR4 signaling pathway and promotes anti-tumor immune responses</td><td valign="top" rowspan="2" align="center" colspan="1">GeneWays</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR4 agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">MPL</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I/II</td><td valign="middle" align="center" rowspan="1" colspan="1">Melanoma, Ovarian Cancer, Lung Cancer</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01584115">NCT01584115</ext-link></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR7 agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">R848 gel</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase II</td><td valign="middle" align="center" rowspan="1" colspan="1">Melanoma</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00960752">NCT00960752</ext-link></td><td valign="top" rowspan="4" align="center" colspan="1">Activates TLR7 signaling pathway and promotes antiviral immune response</td><td valign="top" rowspan="2" align="center" colspan="1">PotentialNet</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR7 agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">GS-9620</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase II</td><td valign="middle" align="center" rowspan="1" colspan="1">HIV/AIDS</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04364035">NCT04364035</ext-link></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR7 agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">imiquimod</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Melanoma (Skin), Metastatic Cancer</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00453050">NCT00453050</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">GeneWays</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR7 agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">R848</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Influenza, Vaccination in Seniors</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01737580">NCT01737580</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">PotentialNet</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR9 agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">DUK-CPG-001</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase II</td><td valign="middle" align="center" rowspan="1" colspan="1">Hodgkin Lymphoma, Non-Hodgkin Lymphoma</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02115126">NCT02115126</ext-link></td><td valign="top" rowspan="3" align="center" colspan="1">Stimulate the TLR9 signaling pathway, enhances B-cell and dendritic cell activity</td><td valign="top" rowspan="3" align="center" colspan="1">DeepTox</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR9 agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">CpG-7909</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I/II</td><td valign="middle" align="center" rowspan="1" colspan="1">Esophageal Cancer</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00669292">NCT00669292</ext-link></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">TLR9 agonist</td><td valign="middle" align="center" rowspan="1" colspan="1">CpG</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Hepatitis B</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04843852">NCT04843852</ext-link></td></tr></tbody></table></table-wrap><sec id="s6_1_1"><label>6.1.1</label><title>TLR 3 agonist</title><p>TLR 3 is a critical recognition receptor primarily identifying dsRNA, a hallmark of viral infection. It aids in combating viral infections mainly by activating the host&#8217;s innate immune response and is widely expressed in dendritic cells, macrophages, and some epithelial cells (<xref rid="B160" ref-type="bibr">160</xref>). TLR 3 adjuvants have been extensively studied for their ability to induce robust type I interferon responses, thereby enhancing vaccine efficacy. Numerous studies have reported the application of TLR3 agonists. For instance, some research suggests that polyinosinic polycytidylic acid (Poly (I:C)) as a vaccine adjuvant significantly enhances immune responses and shows promising anti-tumor effects in preclinical studies (<xref rid="B161" ref-type="bibr">161</xref>). RECEPTOR.AI offers a TLR 3 custom library predicted by Alphafold for on-demand applications, leveraging state-of-the-art virtual screening and parameter assessment technologies. They maintain a large virtual library with over 600 billion molecules to provide compounds with increased potency, selectivity, and safety. [RECEPTOR.AI Platform] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.receptor.ai/platform" ext-link-type="uri">https://www.receptor.ai/platform</ext-link>).</p></sec><sec id="s6_1_2"><label>6.1.2</label><title>TLR 7/8 agonist</title><p>TLR7/8, expressed intracellularly, was first proposed in 2000 (<xref rid="B162" ref-type="bibr">162</xref>). They jointly recognize ssRNA, triggering the immune response to identify pathogens. TLR7 is primarily expressed in plasmacytoid dendritic cells (pDC), while TLR8 is mainly expressed in myeloid dendritic cells (<xref rid="B163" ref-type="bibr">163</xref>, <xref rid="B164" ref-type="bibr">164</xref>). In recent years, TLR7/8 has gained popularity as an up-and-coming class of vaccine adjuvants due to their ability to directly activate antigen-presenting cells (APCs) and enhance cellular immunity.</p><p>Recent studies have utilized molecular dynamics simulations to investigate the selective mechanisms of structurally similar TLR7/8, which can be regarded as an advanced computational method (<xref rid="B165" ref-type="bibr">165</xref>). The integration of automation and data-driven design has further expanded the research parameters. By employing a combinatorial approach, TLR-7/8a binders that induce the desired T-cell immune responses and exhibit sufficient efficacy can be identified (<xref rid="B166" ref-type="bibr">166</xref>, <xref rid="B167" ref-type="bibr">167</xref>). The Rapid Overlay of Chemical Structures software (vROCS version 3.1.1. OpenEye Scientific Software, Santa Fe, NM. [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.eyesopen.com" ext-link-type="uri">http://www.eyesopen.com</ext-link>]) is a tool used in computational chemistry and drug discovery. By comparing the shapes of millions of compounds, researchers can quickly narrow down potential candidates. Urban &#352;vajger et&#160;al. employed the LVBS method to search for potential TLR7 ligands and discovered six new compounds, addressing the gap where only imidazoquinolines had been used as TLR7 modulators (<xref rid="B168" ref-type="bibr">168</xref>). To enhance the accuracy of flexible site binding, Duan et&#160;al. conducted enrichment evaluations of various virtual methods and proposed that a combination strategy can improve the effectiveness of virtual screening for TLR8 agonists (<xref rid="B169" ref-type="bibr">169</xref>).</p><p>However, a common drawback of TLR7/8 agonists is their reactogenicity. In recent years, many researchers have aimed to overcome this issue by encapsulating these small molecules in nanoparticles or covalently binding them to polymers. This approach can prevent harmful systemic reactions (<xref rid="B170" ref-type="bibr">170</xref>, <xref rid="B171" ref-type="bibr">171</xref>). AI is also used to design nanomedicines that effectively deliver TLR7/8 agonists. Nanoparticle-based delivery systems can enhance the stability and targeting of these compounds, improving their efficacy and reducing side effects. This approach is particularly valuable in cancer therapy, where precise targeting of tumor cells is crucial. Research by Hyunjoon and colleagues reported that subcutaneous injection of biodegradable polymer, poly(d,l-lactide-co-glycolide) (PLGA), and nanoparticles containing TLR7/8 agonists resulted in a potent antigen-specific immune response. Their experiments validated these effects in various tumor models, demonstrating the potential of TLR7/8 as effective vaccine adjuvants for cancer immunotherapy (<xref rid="B172" ref-type="bibr">172</xref>).</p><p>Furthermore, studies have suggested that tethering small molecule TLR-7/8a to polymer scaffolds can enhance the immunogenicity of vaccines. The formed polymer-TLR-7/8a complexes can restrict the distribution of adjuvants and prolong their retention in lymph nodes, providing new insights for optimizing adjuvant design (<xref rid="B172" ref-type="bibr">172</xref>). All these findings underscore the potential therapeutic benefits of TLR7/8 as vaccine adjuvants.</p></sec><sec id="s6_1_3"><label>6.1.3</label><title>TLR9</title><p>The innate immune system in humans can be activated by bacterial DNA (<xref rid="B173" ref-type="bibr">173</xref>). This discrimination is attributed to mammalian DNA having a low frequency of CpG dinucleotides, most of which are methylated (<xref rid="B174" ref-type="bibr">174</xref>). Recent research has shown that unmethylated CpG sequences with two purines at the 5&#8217; end and two pyrimidines at the 3&#8217; end are necessary for immune activation (<xref rid="B175" ref-type="bibr">175</xref>, <xref rid="B176" ref-type="bibr">176</xref>). TLR9 was discovered to specifically recognize the unmethylated CpG and initiated host immunity (<xref rid="B177" ref-type="bibr">177</xref>). Based on their immune-stimulatory functions, CpGs can be divided into CpG-A, CpG-B, and CpG-C. CpG-A mainly exists in double-stranded aggregates and comprises single CpG motifs with partial phosphorothioate (PS modification) and phosphodiester main chain bases. It is primarily responsible for activating the STING pathway, inducing the production of IFN-&#945; and IFN-&#946; by stimulating pDC, and can indirectly activate NK cells (<xref rid="B178" ref-type="bibr">178</xref>). CpG-B is composed of multiple CpG motifs entirely modified with PS. It can activate the TLR9 pathway to generate pro-inflammatory cytokines. Unlike class A, class B contains B cell activators and stimulates pDC maturation. CpG-C typically consists of fully PS-modified double-stranded palindromic motifs, exhibiting immunostimulatory effects similar to the first two classes; it can induce robust IFN-&#945; production, pDC maturation, and effective B cell stimulation (<xref rid="B179" ref-type="bibr">179</xref>).</p><p>Many studies have shown that CpG Oligodeoxynucleotides (ODNs) can expedite vaccine responses. For example, the hepatitis B vaccine HEPLISAV-B, approved by the FDA in 2017, was the first vaccine to use CpG-ODN 1018 as an adjuvant. Compared to the traditional aluminum hydroxide adjuvant in Engerix-B<sup>&#174;</sup>, HEPLISAV-B induced a faster and more sustained response and significantly improved immunogenicity (<xref rid="B180" ref-type="bibr">180</xref>). Furthermore, CpG-ODNs can induce Th1 responses, promote the generation of cytotoxic T lymphocytes (CTLs), and enhance the secretion of IFN-&#947; (<xref rid="B181" ref-type="bibr">181</xref>). Sayami et&#160;al. found that K3 (CpG-ODN) generated more antigen-specific antibodies than other TLR ligands and induced Th1 polarization. Their report on Transcutaneous immunization also indicated that K3 could promote B cell activation and differentiation, demonstrating the promising potential of K3 as a vaccine adjuvant (<xref rid="B182" ref-type="bibr">182</xref>).</p><p>In sum, with the continuous advancements in the PRR field, the strategic design of PRR-targeted adjuvants has emerged as a prominent area of research. This encompasses the combination and fine-tuning of methods. Such efforts hold promise for advancing the development of both preventive and therapeutic vaccines.</p></sec></sec><sec id="s6_2"><label>6.2</label><title>STING agonists</title><p>In recent years, Stimulator of interferon genes (STING) agonist stimulators have garnered significant interest as potential vaccine adjuvants and cancer therapeutics. The STING pathway is critical for immune responses against viruses and bacteria and contributes to antitumor immunity (<xref rid="B183" ref-type="bibr">183</xref>). It is an endoplasmic reticulum adapter that plays an essential role in the immune system (<xref rid="B184" ref-type="bibr">184</xref>). Cytoplasmic DNA activates the cyclic GMP-AMP synthase (cGAS)-STING pathway in this mechanism, triggering an immune response (<xref rid="B185" ref-type="bibr">185</xref>). DNA binding to cGAS activates its enzymatic activity, creating conditions for the formation of cyclic dinucleotide, 2&#8217;3&#8217;-cGAMP (<xref rid="B186" ref-type="bibr">186</xref>). This cyclic dinucleotide (CDN) can indirectly activate transcription factors in the STING pathway, including interferon regulatory factor 3 (IRF3) and nuclear factor-kappa B (NF-&#954;B) (<xref rid="B187" ref-type="bibr">187</xref>).</p><p>Most STING agonists are CDN compounds, widely proposed as adjuvants in vaccine administration and cancer therapy (<xref rid="B188" ref-type="bibr">188</xref>). Leveraging the characteristics of STING agonists, Fu et&#160;al. combined CDNs with a cancer vaccine called STINGVAX, finding it effective in multiple mouse tumor models (<xref rid="B189" ref-type="bibr">189</xref>). CDNs as adjuvants for developing infectious disease vaccines were initially validated in pneumococcus and Staphylococcus aureus infections (<xref rid="B190" ref-type="bibr">190</xref>, <xref rid="B191" ref-type="bibr">191</xref>). Since then, many teams have explored CDN applications in contagious diseases (<xref rid="B192" ref-type="bibr">192</xref>). Furthermore, nano adjuvants and nanomaterials have demonstrated significant advantages in vaccine design. For instance, CDN chemical modifications, such as fluorination and thiophosphorylation on the same side, have been found to activate STING with higher stability, cellular uptake, and immunostimulatory capacity for antitumor therapy (<xref rid="B193" ref-type="bibr">193</xref>). Additionally, combinations of nanoscale adjuvants have shown promise in enhancing innate immunity. For example, combining TLR7/8 and STING agonists as vaccine adjuvants encapsulated in polymer nanoparticles can further improve their effectiveness, demonstrating additive effects of adjuvant combinations (<xref rid="B194" ref-type="bibr">194</xref>).</p><p>However, clinical outcomes of STING agonists, whether used as monotherapy or combined with immune checkpoint inhibitors, have been disappointing (<xref rid="B195" ref-type="bibr">195</xref>&#8211;<xref rid="B197" ref-type="bibr">197</xref>). This indicates the presence of unknown mechanisms leading to adverse reactions. To go further, James J&#8217;s team revealed that reversing the methylation silencing of STING in mouse melanoma cell lines using clinically available DNA methylation inhibitors can enhance agonist-induced STING activation and type I IFN induction. This, in turn, can induce tumor regression in syngeneic mice through a CD8<sup>+</sup> T cell-dependent immune response. These findings shed light on the mechanisms of how functional impairments in STING signaling within tumor cells lead to compromised responses to STING agonist therapy (<xref rid="B198" ref-type="bibr">198</xref>). Moreover, the clinical application of CDN-like compounds still faces a series of inescapable challenges. Due to their damaging charge property, strong water solubility, and high polar surface area, these compounds exhibit poor membrane permeability, potentially diminishing the effectiveness of vaccines when used as adjuvants (<xref rid="B199" ref-type="bibr">199</xref>). In <xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref> we have also summarized the current clinical progress of STING as a vaccine adjuvant in clinical practice.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table&#160;3</label><caption><p>STING-based cancer vaccines adjuvant in clinical application.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Category</th><th valign="middle" align="center" rowspan="1" colspan="1">Biological</th><th valign="middle" align="center" rowspan="1" colspan="1">Status</th><th valign="middle" align="center" rowspan="1" colspan="1">Conditions</th><th valign="middle" align="center" rowspan="1" colspan="1">NCT code</th><th valign="top" align="center" rowspan="1" colspan="1">Reasons for use as an adjuvant</th><th valign="top" align="center" rowspan="1" colspan="1">AI tool</th></tr></thead><tbody><tr><td valign="middle" rowspan="5" align="center" colspan="1">CDNs</td><td valign="middle" align="center" rowspan="1" colspan="1">TAK-676</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Advanced or Metastatic Solid Tumors</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04420884">NCT04420884</ext-link></td><td valign="middle" rowspan="5" align="center" colspan="1">Anti-tumor immune response</td><td valign="top" align="center" rowspan="1" colspan="1">DeepChem</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">IMSA-101</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase II</td><td valign="middle" align="center" rowspan="1" colspan="1">Solid Tumor</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04020185">NCT04020185</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">PotentialNet</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">BI1387446</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Solid Tumors</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04147234">NCT04147234</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">DeepNeuralNetQSAR</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">BMS-986301</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">In participants with cancers that have failed to respond to T cell checkpoint-inhibiting antibodies</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03956680">NCT03956680</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">DeepTox</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">SB11285</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Advanced solid tumors</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04096638">NCT04096638</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">PotentialNet</td></tr><tr><td valign="middle" rowspan="5" align="center" colspan="1">Non-CDNs Small Molecules</td><td valign="middle" align="center" rowspan="1" colspan="1">GSK3745417</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Advanced Solid Tumors</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03843359">NCT03843359</ext-link></td><td valign="middle" rowspan="4" align="center" colspan="1">Anti-tumor immune response</td><td valign="top" align="center" rowspan="1" colspan="1">DeepChem</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">SNX281</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Advanced Solid Tumors and Lymphoma</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04609579">NCT04609579</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">GeneWays</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">HG381</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Advanced Solid Tumor</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04998422">NCT04998422</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">DeepTox</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="KL340399">KL340399</ext-link></td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Advanced Solid Tumors</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05549804">NCT05549804</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">PotentialNet</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">AZD6738</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase II</td><td valign="middle" align="center" rowspan="1" colspan="1">Breast Neoplasm</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03740893">NCT03740893</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">Anti-breast tumor immune response</td><td valign="top" align="center" rowspan="1" colspan="1">DeepChem</td></tr><tr><td valign="middle" rowspan="2" align="center" colspan="1">Other</td><td valign="middle" align="center" rowspan="1" colspan="1">STAV</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Increase the body&#8217;s ability to fight aggressive relapsed or refractory leukemias.</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05321940">NCT05321940</ext-link></td><td valign="middle" align="center" rowspan="1" colspan="1">Respond to GeneWays zrelapsed or refractory leukemia</td><td valign="top" align="center" rowspan="1" colspan="1">GeneWays</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">SYNB1891</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">Advanced/metastatic solid tumors and lymphoma</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04167137">NCT04167137</ext-link></td><td valign="middle" align="center" rowspan="1" colspan="1">Anti-tumor and anti-lymphoma immune responses</td><td valign="top" align="center" rowspan="1" colspan="1">DeepTox</td></tr></tbody></table></table-wrap><p>AI has made great progress in predicting and screening STING agonists as adjuvants. Ramanjulu et&#160;al. utilized high-throughput screening methods to discover ABZI (amidobenzimidazole). Intravenous injection of the STING agonist diABZI in immunocompetent mice with established syngeneic colon tumors resulted in complete tumor regression (<xref rid="B200" ref-type="bibr">200</xref>). Additionally, screening has shown that formulating STING agonists as nanoparticles can enhance drug stability and bioavailability (<xref rid="B201" ref-type="bibr">201</xref>).</p></sec><sec id="s6_3"><label>6.3</label><title>Programmed Cell Death Protein 1/Programmed Death-Ligand 1 inhibitor</title><p>PD-1 and PD-L1 immune checkpoint molecules play a role in balancing immune responses in the immune system (<xref rid="B202" ref-type="bibr">202</xref>, <xref rid="B203" ref-type="bibr">203</xref>). When excess PD-L1 is bound to PD-1 on T cells, it inhibits T cell activity, leading to a weakened immune response and immune escape (<xref rid="B204" ref-type="bibr">204</xref>, <xref rid="B205" ref-type="bibr">205</xref>).</p><p>Typically, cancer vaccines stimulate the immune system to generate a specific response against the tumor (<xref rid="B206" ref-type="bibr">206</xref>). By introducing tumor-associated antigens, the vaccine can identify and target tumor cells. However, once a tumor has formed, the immune system is suppressed, limiting the therapeutic effectiveness of vaccines (<xref rid="B207" ref-type="bibr">207</xref>). In clinical practice, combining PD-1/PD-L1 inhibitors with tumor vaccines aims to enhance immunotherapy. PD-1/PD-L1 inhibitors as adjuvants relieve immune suppression, thereby strengthening the attack on tumors (<xref rid="B208" ref-type="bibr">208</xref>). There are examples in clinical trials that its antibodies and tumor vaccines have shown synergistic effects. For instance, Patrick A. et&#160;al. reported the first Phase Ib clinical trial (Clinicaltrials.gov: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02897765">NCT02897765</ext-link>) using a neoantigen-based personalized vaccine called NEO-PV-01 in combination with PD-1 inhibitor Nivolumab to treat advanced melanoma non-small cell lung cancer, or bladder cancer (<xref rid="B209" ref-type="bibr">209</xref>). Compared to monoclonal antibodies, small molecules are cost-effective, have a shorter half-life, and can reduce sustained systemic side effects (<xref rid="B210" ref-type="bibr">210</xref>). Thus, they have become candidates for adjuvants. The design of small molecules targeting PD-1/PD-L1 typically involves disrupting protein-protein interactions (PPI) (<xref rid="B211" ref-type="bibr">211</xref>). Due to the lack of a prominent binding pocket, researchers have developed a series of biphenyl derivatives based on the mechanism of PD-1/PD-L1 interaction, including BMS-8, BMS-37, BMS-202, BMS-200, BMS-1001, BMS-1166 (<xref rid="B212" ref-type="bibr">212</xref>). PD-L1 dimerization is also a hot research area for small molecule PD-1/PD-L1 studies (<xref rid="B213" ref-type="bibr">213</xref>). For example, BMS&#8217;s small molecules tend to form stable dimers with PD-L1 monomers. BMS-1166 can specifically inhibit partial glycosylation of PD-L1, thereby blocking PD-L1 from moving to the Golgi apparatus from the endoplasmic reticulum, rendering it inactive (<xref rid="B214" ref-type="bibr">214</xref>). The first oral small molecule PD-L1 inhibitor that entered clinical trials is CA-170 (<xref rid="B215" ref-type="bibr">215</xref>). Its clinical trials have been conducted in lung cancer, head and neck cancer, and Hodgkin&#8217;s lymphoma (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02812875">NCT02812875</ext-link>, clinicaltrials.gov) (CTRI/2017/12/011026, ctri.nic.in), which may mark a new era for small molecule vaccine adjuvants. In <xref rid="T4" ref-type="table">
<bold>Table&#160;4</bold>
</xref>, we have summarized the clinical advancements of other PD-1/PD-L1 as small molecule adjuvants.</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table&#160;4</label><caption><p>PD-1/PD-L1-based cancer vaccines adjuvant in clinical application.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Category</th><th valign="middle" align="center" rowspan="1" colspan="1">Biological</th><th valign="middle" align="center" rowspan="1" colspan="1">Status</th><th valign="middle" align="center" rowspan="1" colspan="1">Conditions</th><th valign="middle" align="center" rowspan="1" colspan="1">Combination therapy</th><th valign="middle" align="center" rowspan="1" colspan="1">NCT code</th><th valign="top" align="center" rowspan="1" colspan="1">Reasons for use as an adjuvant</th><th valign="top" align="center" rowspan="1" colspan="1">AI tool</th></tr></thead><tbody><tr><td valign="middle" rowspan="5" align="center" colspan="1">PD-1/PD-L1<break/>inhibitor</td><td valign="middle" align="center" rowspan="1" colspan="1">CA-170</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I/II</td><td valign="middle" align="center" rowspan="1" colspan="1">advanced tumors and lymphomas</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02812875">NCT02812875</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">Anti-tumor immune escape</td><td valign="top" align="center" rowspan="1" colspan="1">DeepChem</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">INCB-086550</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase II</td><td valign="middle" align="center" rowspan="1" colspan="1">solid tumors</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04629339">NCT04629339</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="center" rowspan="1" colspan="1">PotentialNet</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">MX-10181</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">solid tumors</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04122339">NCT04122339</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">Enhance ICBs therapy</td><td valign="top" align="center" rowspan="1" colspan="1">DeepNeuralNetQSAR</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">GS-4224</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">solid tumors</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04049617">NCT04049617</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">Tumor identification and clearance</td><td valign="top" align="center" rowspan="1" colspan="1">DeepTox</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">IMMH-010</td><td valign="middle" align="center" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="center" rowspan="1" colspan="1">advanced solid tumors</td><td valign="middle" align="center" rowspan="1" colspan="1">N/A</td><td valign="middle" align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04343859">NCT04343859</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="center" rowspan="1" colspan="1">GeneWays</td></tr></tbody></table><table-wrap-foot><fn><p>N/A, Not Available.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s6_4"><label>6.4</label><title>Indoleamine 2,3-dioxygenase inhibitor</title><p>IDO is an enzyme responsible for converting tryptophan into kynurenine. Within the immune system, the primary role of IDO is to suppress T-cell activity, helping to maintain immune balance and prevent excessive immune responses. In recent years, IDO inhibitors have drawn significant attention in tumor immunotherapy. As reported, it can delay tumor growth and enhance the effect of dendritic cell vaccines (<xref rid="B216" ref-type="bibr">216</xref>). They are often used with other immunotherapies, such as PD-1/PD-L1 inhibitors, to bolster the immune response. Yao et&#160;al. introduced an <italic toggle="yes">in situ</italic> multifunctional vaccine utilizing bacterial outer membrane vesicles (OMVs, 1-MT@OMV-Mal) designed to encapsulate IDO inhibitors internally. The <italic toggle="yes">in situ</italic> injection of 1-MT@OMV-Mal effectively overcomes the immune suppression induced by IDO on effector T cells infiltrating the tumor, resulting in significant inhibition of both primary and distant tumors (<xref rid="B217" ref-type="bibr">217</xref>). Su et&#160;al. used polymer-lipid hybrid nanovesicle (P/LNV)&#8211;based liposomes to deliver IDO inhibitors and TLR9, enhancing antigen immunogenicity and simultaneously blocking immune checkpoints. Mechanistically, this approach significantly increases the infiltration of CD8<sup>+</sup> T cells in tumors and drains lymph nodes. Cationic liposomes delivered with tumor vaccines and IDO inhibitors provide a promising platform for cancer immunotherapy by provoking antitumor T-cell immunity and reversing the immunosuppressive tumor microenvironment (<xref rid="B218" ref-type="bibr">218</xref>). Troitskaya et&#160;al. demonstrated that IDO can enhance the efficacy of recombinant human milk peptide lactating (RL2) &#8212;treated cell vaccination. Their experimental results showed that additional IDO chemical inhibition exhibits better long-term antitumor responses than vaccination with RL2-treated cells alone (<xref rid="B219" ref-type="bibr">219</xref>).</p><p>Moreover, IDO as a cancer vaccine adjuvant also finds applications in the Human Papillomavirus (HPV) field. Recently, Pagni et&#160;al. developed a vaccine based on the genetic fusion of HSV-1 glycoprotein D (gD) with the HPV-16 E7 oncoprotein (gDE7 vaccine) for treating HPV-related tumors. They aimed to enhance the existing efficacy by incorporating an IDO inhibitor (<xref rid="B206" ref-type="bibr">206</xref>). <italic toggle="yes">In vivo</italic> experimental results showed that multitarget therapy improved the antitumor efficacy of the gDE7 protein vaccine, providing evidence for IDO as a therapeutic vaccine adjuvant for HPV tumors (<xref rid="B220" ref-type="bibr">220</xref>). Their earlier studies also indicated the significant role of IDO in HPV vaccines. They added two immune metabolic adjuvants, an IDO1 inhibitor, to the gDE7 vaccine and found that they enhanced the <italic toggle="yes">in vivo</italic> antitumor effect. In simple terms, combining IDO inhibitors with immunotherapy and reducing the negative impact of IDO1 expression on vaccine-induced protective immunity significantly increased the anticancer effect (<xref rid="B221" ref-type="bibr">221</xref>). Their experiments demonstrated that IDO1-targeted therapy could improve antitumor treatment by reprogramming inflammatory cells. These series of studies revealed a novel and promising approach to control HPV-related tumors and potentially other cancer types, providing substantial evidence to support further research.</p><p>Finally, a few IDO inhibitor has been tested in clinical. For example, Indoximod has been widely used in clinical settings. A phase I/II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01042535">NCT01042535</ext-link>) combining indoximod with adenovirus p53-Dendritic Cells (DC) vaccine in the treatment of invasive breast cancer showed a maximum tolerated dose (MTD) of 1600 mg BID, and the two drugs demonstrated significant synergistic effects. This proves that IDO inhibitors can effectively enhance the efficacy of vaccines (<xref rid="B222" ref-type="bibr">222</xref>). Therefore, the strategy of using indoximod as an adjuvant for tumor vaccines to enhance anti-tumor treatment is worthy of further exploration in subsequent clinical trials. In sum, we summarized the clinical trials of potential IDO inhibitors as adjuvants for tumor vaccines currently underway and presented them in <xref rid="T5" ref-type="table">
<bold>Table&#160;5</bold>
</xref>.</p><table-wrap position="float" id="T5" orientation="portrait"><label>Table&#160;5</label><caption><p>IDO-based cancer vaccines adjuvant in clinical application.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Category</th><th valign="middle" align="left" rowspan="1" colspan="1">Biological</th><th valign="middle" align="left" rowspan="1" colspan="1">Status</th><th valign="middle" align="left" rowspan="1" colspan="1">Conditions</th><th valign="middle" align="left" rowspan="1" colspan="1">Combination therapy</th><th valign="middle" align="left" rowspan="1" colspan="1">NCT code</th><th valign="top" align="left" rowspan="1" colspan="1">Reasons for use as an adjuvant</th><th valign="top" align="left" rowspan="1" colspan="1">AI tool</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">Epacadostat(INCB024360)</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase III</td><td valign="middle" align="left" rowspan="1" colspan="1">Cisplatin-ineligible Urothelial Carcinoma</td><td valign="middle" align="left" rowspan="1" colspan="1">Pembrolizumab&#12289;<break/>Epacadostat and<break/>Placebo</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03361865">NCT03361865</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor immune escape</td><td valign="top" align="left" rowspan="1" colspan="1">DeepChem</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">GDC-0919</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="left" rowspan="1" colspan="1">Solid tumor</td><td valign="middle" align="left" rowspan="1" colspan="1">N/A</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02048709">NCT02048709</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="left" rowspan="1" colspan="1">PotentialNet</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">1-methyl-D-tryptophan</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="left" rowspan="1" colspan="1">Solid tumor</td><td valign="middle" align="left" rowspan="1" colspan="1">N/A</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00739609">NCT00739609</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Inhibits IDO and increases T cell activity</td><td valign="top" align="left" rowspan="1" colspan="1">DeepNeuralNetQSAR</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">NLG802</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="left" rowspan="1" colspan="1">Solid tumor</td><td valign="middle" align="left" rowspan="1" colspan="1">N/A</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03164603">NCT03164603</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="left" rowspan="1" colspan="1">DeepTox</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">Docetaxel</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase II</td><td valign="middle" align="left" rowspan="1" colspan="1">Metastatic Breast Cancer</td><td valign="middle" align="left" rowspan="1" colspan="1">Indoximod in Combination With a Taxane Chemotherapy</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01792050">NCT01792050</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="left" rowspan="1" colspan="1">PotentialNet</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">KHK245</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="left" rowspan="1" colspan="1">Locally Advanced or Metastatic Urothelial Carcinoma</td><td valign="middle" align="left" rowspan="1" colspan="1">KHK2455 in combination with avelumab</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03915405">NCT03915405</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Enhanced immunotherapy</td><td valign="top" align="left" rowspan="1" colspan="1">DeepChem</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">Indoximod</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase I/II</td><td valign="middle" align="left" rowspan="1" colspan="1">Temozolomide-Refractory Primary Malignant Brain Tumors</td><td valign="middle" align="left" rowspan="1" colspan="1">Indoximod &#12289; Temozolomide and Bevacizumab</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02052648">NCT02052648</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Synergistic effect of chemotherapeutic agents</td><td valign="top" align="left" rowspan="1" colspan="1">GeneWays</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">Indoximod</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase I/II</td><td valign="middle" align="left" rowspan="1" colspan="1">Metastatic Melanoma</td><td valign="middle" align="left" rowspan="1" colspan="1">Indoximod&#12289;<break/>Ipilimumab&#12289;<break/>Nivolumab and<break/>Pembrolizumab</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02073123">NCT02073123</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Enhance ICBs therapy</td><td valign="top" align="left" rowspan="1" colspan="1">DeepTox</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">Indoximod</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase I/II</td><td valign="middle" align="left" rowspan="1" colspan="1">Metastatic Adenocarcinoma of the Pancreas</td><td valign="middle" align="left" rowspan="1" colspan="1">Indoximod in Combination With Gemcitabine and Nab-Paclitaxel</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02077881">NCT02077881</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Anti-tumor</td><td valign="top" align="left" rowspan="1" colspan="1">DeepChem</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">Indoximod</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase I</td><td valign="middle" align="left" rowspan="1" colspan="1">Progressive Primary Brain Tumors</td><td valign="middle" align="left" rowspan="1" colspan="1">Indoximod and Temozolomide</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02502708">NCT02502708</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Improving the efficacy of chemotherapy drugs</td><td valign="top" align="left" rowspan="1" colspan="1">PotentialNet</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">Epacadostat(INCB024360)</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase II</td><td valign="middle" align="left" rowspan="1" colspan="1">Advanced Melanoma</td><td valign="middle" align="left" rowspan="1" colspan="1">Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multi-peptide Melanoma Vaccine (MELITAC 12.1)</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01961115">NCT01961115</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">polypeptide vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">DeepNeuralNetQSAR</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">Epacadostat</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase III</td><td valign="middle" align="left" rowspan="1" colspan="1">Metastatic Disease</td><td valign="middle" align="left" rowspan="1" colspan="1">Pembrolizumab&#12289;<break/>Epacadostat</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03374488">NCT03374488</ext-link></td><td valign="top" rowspan="4" align="left" colspan="1">Enhance ICBs therapy</td><td valign="top" align="left" rowspan="1" colspan="1">DeepTox</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">Epacadostat</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase II</td><td valign="middle" align="left" rowspan="1" colspan="1">Non-Small Cell Lung Cancer</td><td valign="middle" align="left" rowspan="1" colspan="1">Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360)</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03322540">NCT03322540</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">PotentialNet</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">Epacadostat</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase II</td><td valign="middle" align="left" rowspan="1" colspan="1">Non-Small Cell Lung Cancer</td><td valign="middle" align="left" rowspan="1" colspan="1">Pembrolizumab&#12289;<break/>Epacadostat&#12289;<break/>Platinum-based chemotherapy</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03322566">NCT03322566</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">DeepChem</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">IDO inhibitor</td><td valign="middle" align="left" rowspan="1" colspan="1">Epacadostat</td><td valign="middle" align="left" rowspan="1" colspan="1">Phase I/II</td><td valign="middle" align="left" rowspan="1" colspan="1">Solid Tumors</td><td valign="middle" align="left" rowspan="1" colspan="1">Epacadostat&#12289;<break/>Pembrolizumab and<break/>Oxaliplatin</td><td valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03085914">NCT03085914</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">GeneWays</td></tr></tbody></table><table-wrap-foot><fn><p>N/A, Not Available.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusion" id="s7"><label>7</label><title>Conclusion</title><p>The development of new drugs is a lengthy and expensive process. The average cost of research and development is around $1.3 billion per drug (<xref rid="B223" ref-type="bibr">223</xref>). The average duration for developing oncology drugs is 13.1 years, with only 13.8% of all drug development projects ultimately gaining approval (<xref rid="B224" ref-type="bibr">224</xref>, <xref rid="B225" ref-type="bibr">225</xref>). These challenges are often attributed to inappropriate patient selection, outdated equipment, and technological limitations. With the application of AI in drug development, it is possible to reduce these figures (<xref rid="B226" ref-type="bibr">226</xref>). For example, AI can use patient genetic exposure profiles to screen for potential drug target populations (<xref rid="B226" ref-type="bibr">226</xref>). Predictive machine learning and alternative deductive methods also contribute to forecasting lead compounds, thereby reducing development costs (<xref rid="B226" ref-type="bibr">226</xref>).</p><p>To reduce the costs associated with drug development, there is an increasingly close collaboration between pharmaceutical companies and the field of AI, especially in the realm of target discovery. We have compiled a summary of projects launched in partnership between select AI companies and pharmaceutical firms from 2020 to the present. These initiatives aim to develop and predict viable drugs, ultimately streamlining the process of bringing drugs into clinical trials (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>). Current AI systems are mainly based on the deep learning method, the most popular machine learning method after the success of deep neural network (DNN) (<xref rid="B227" ref-type="bibr">227</xref>). Deep learning has been widely explored in various tasks (<xref rid="B228" ref-type="bibr">228</xref>&#8211;<xref rid="B230" ref-type="bibr">230</xref>), including drug design and molecular dynamics (MD) development (<xref rid="B231" ref-type="bibr">231</xref>). The MD development plays a crucial role in the small molecule adjuvant effect since it can explain how molecules interact at the atomic level during drug discovery (<xref rid="B232" ref-type="bibr">232</xref>). However, the MD process is known to be time-consuming and labor-intensive. The AI-based system can solve these issues and thus accelerate the MD process. For example, Drew Bennett et&#160;al. proposed an MD simulation that calculates the free energy of transferring 15,000 small molecules from water to cyclohexane (<xref rid="B233" ref-type="bibr">233</xref>). The research findings show that AI technology can speed up the MD simulations and enhance improvisation, however, at the cost of substantial model training, which is indispensable for deep learning-based AI systems.</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>The streamlining of the process of bringing drugs into clinical trials and the collaboration between artificial intelligence companies and pharmaceutical companies based on the years.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-15-1438030-g002.jpg"/></fig><p>The success of AI in developing adjuvants for cancer vaccines relies heavily on the availability of extensive data and well-trained models (<xref rid="B2" ref-type="bibr">2</xref>). Accessing various databases has introduced additional costs, and screening reliable and high-quality data is essential to ensure prediction accuracy. AI faces significant challenges in developing adjuvants for cancer vaccines and other drugs. These challenges include reducing the 2-3 year gap between prediction and drug development, a shortage of skilled personnel for AI-driven drug screening, ensuring the credibility of generated predictions, dealing with the &#8220;black box&#8221; phenomenon, and establishing reasonable regulations (<xref rid="B234" ref-type="bibr">234</xref>). While AI has been widely used in drug discovery and translational research over the past two decades, its progress in clinical operations and data analysis has been relatively slow.</p><p>While many challenges are associated with using AI in developing adjuvants for cancer vaccines, we anticipate that AI will become increasingly prevalent in this field, helping mitigate the risks associated with drug development (<xref rid="B235" ref-type="bibr">235</xref>, <xref rid="B236" ref-type="bibr">236</xref>). With the development of personalized medicine, AI can also assist in selecting the most suitable adjuvants for patients to achieve personalized immunotherapy plans. This will contribute to the advancement of precision medicine. Overall, AI has accelerated the research process in developing tumor vaccine adjuvants, improving the efficiency and effectiveness of adjuvant design. It can bring more innovation and breakthroughs to the future of global vaccine research and immunotherapy.</p></sec></body><back><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>WZ: Conceptualization, Data curation, Formal analysis, Investigation, Software, Visualization, Writing &#8211; original draft. XZ: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing &#8211; original draft. PC: Data curation, Formal analysis, Investigation, Writing &#8211; original draft. JC: Data curation, Formal Analysis, Investigation, Writing &#8211; original draft. BD: Conceptualization, Project administration, Supervision, Writing &#8211; review &amp; editing. XF: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Visualization, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z</given-names></name></person-group>. <article-title>Applying human-centered AI in developing effective human-AI teaming: A perspective of human-AI joint cognitive systems</article-title>. <source>ArXiv</source>. (<year>2023</year>), <fpage>abs/2307.03913</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.48550/arXiv.2307.03913</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smalley</surname><given-names>E</given-names></name></person-group>. <article-title>AI-powered drug discovery captures pharma interest</article-title>. <source>Nat Biotechnol</source>. (<year>2017</year>) <volume>35</volume>:<page-range>604&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nbt0717-604</pub-id><pub-id pub-id-type="pmid">28700560</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Askr</surname><given-names>H</given-names></name><name name-style="western"><surname>Elgeldawi</surname><given-names>E</given-names></name><name name-style="western"><surname>Ella</surname><given-names>HA</given-names></name><name name-style="western"><surname>Elshaier</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gomaa</surname><given-names>M</given-names></name><name name-style="western"><surname>Hassanien</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Deep learning in drug discovery: an integrative review and future challenges</article-title>. <source>Artif Intell Rev</source>. (<year>2022</year>) <volume>56</volume>:<fpage>5975</fpage>&#8211;<lpage>6037</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s10462-022-10306-1</pub-id><pub-id pub-id-type="pmid">36415536</pub-id><pub-id pub-id-type="pmcid">PMC9669545</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>G</given-names></name></person-group>. <article-title>Automating drug discovery</article-title>. <source>Nat Rev Drug Discovery</source>. (<year>2017</year>) <volume>17</volume>:<fpage>97</fpage>&#8211;<lpage>113</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrd.2017.232</pub-id><pub-id pub-id-type="pmid">29242609</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolff Sagy</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zucker</surname><given-names>R</given-names></name><name name-style="western"><surname>Hammerman</surname><given-names>A</given-names></name><name name-style="western"><surname>Markovits</surname><given-names>H</given-names></name><name name-style="western"><surname>Arieh</surname><given-names>NG</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>WA</given-names></name><etal/></person-group>. <article-title>Real-world effectiveness of a single dose of mpox vaccine in males</article-title>. <source>Nat Med</source>. (<year>2023</year>) <volume>29</volume>:<page-range>748&#8211;52</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41591-023-02229-3</pub-id><pub-id pub-id-type="pmcid">PMC9930701</pub-id><pub-id pub-id-type="pmid">36720271</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguas</surname><given-names>R</given-names></name><name name-style="western"><surname>Bharath</surname><given-names>A</given-names></name><name name-style="western"><surname>White</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Gao</surname><given-names>B</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>A</given-names></name><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine</article-title>. <source>Nat Commun</source>. (<year>2021</year>) <volume>12</volume>:<fpage>6370</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-021-26449-8</pub-id><pub-id pub-id-type="pmid">34737262</pub-id><pub-id pub-id-type="pmcid">PMC8569205</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozak</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name></person-group>. <article-title>The integrated consideration of vaccine platforms, adjuvants, and delivery routes for successful vaccine development</article-title>. <source>Vaccines (Basel)</source>. (<year>2023</year>) <volume>11</volume>:<page-range>1&#8211;16</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines11030695</pub-id><pub-id pub-id-type="pmcid">PMC10055765</pub-id><pub-id pub-id-type="pmid">36992279</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meneveau</surname><given-names>MO</given-names></name><name name-style="western"><surname>Petroni</surname><given-names>G</given-names></name><name name-style="western"><surname>Salerno</surname><given-names>EP</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>KT</given-names></name><name name-style="western"><surname>Smolkin</surname><given-names>MMH</given-names></name><name name-style="western"><surname>Woodson</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist</article-title>. <source>J Immunother Cancer</source>. (<year>2021</year>) <volume>9</volume>:<page-range>1&#8211;11</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1136/jitc-2020-002214</pub-id><pub-id pub-id-type="pmcid">PMC8154977</pub-id><pub-id pub-id-type="pmid">34035112</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>SP</given-names></name><name name-style="western"><surname>Petroni</surname><given-names>G</given-names></name><name name-style="western"><surname>Roszik</surname><given-names>J</given-names></name><name name-style="western"><surname>Olson</surname><given-names>W</given-names></name><name name-style="western"><surname>Wages</surname><given-names>N</given-names></name><name name-style="western"><surname>Chianese-Bullock</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma</article-title>. <source>J Immunother Cancer</source>. (<year>2021</year>) <volume>9</volume>:<page-range>1&#8211;12</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1136/jitc-2021-003220</pub-id><pub-id pub-id-type="pmcid">PMC8378357</pub-id><pub-id pub-id-type="pmid">34413169</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy</article-title>. <source>Cell Res</source>. (<year>2020</year>) <volume>30</volume>:<page-range>966&#8211;79</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41422-020-00395-4</pub-id><pub-id pub-id-type="pmcid">PMC7785004</pub-id><pub-id pub-id-type="pmid">32839553</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>DR</given-names></name><name name-style="western"><surname>Sen</surname><given-names>R</given-names></name><name name-style="western"><surname>Sunshine</surname><given-names>J</given-names></name><name name-style="western"><surname>Pardoll</surname><given-names>D</given-names></name><name name-style="western"><surname>Green</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy</article-title>. <source>Nanomedicine: Nanotechnology Biol Med</source>. (<year>2018</year>) <volume>14</volume>:<page-range>237&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.nano.2017.10.013</pub-id><pub-id pub-id-type="pmcid">PMC6035751</pub-id><pub-id pub-id-type="pmid">29127039</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prendergast</surname><given-names>GC</given-names></name><name name-style="western"><surname>Smith</surname><given-names>CM</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S</given-names></name><name name-style="western"><surname>Mandik-Nayak</surname><given-names>L</given-names></name><name name-style="western"><surname>Laury-Kleintop</surname><given-names>L</given-names></name><name name-style="western"><surname>Metz</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer</article-title>. <source>Cancer Immunol Immunother</source>. (<year>2014</year>) <volume>63</volume>:<page-range>721&#8211;35</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00262-014-1549-4</pub-id><pub-id pub-id-type="pmcid">PMC4384696</pub-id><pub-id pub-id-type="pmid">24711084</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibney</surname><given-names>GT</given-names></name><name name-style="western"><surname>Kudchadkar</surname><given-names>R</given-names></name><name name-style="western"><surname>Deconti</surname><given-names>R</given-names></name><name name-style="western"><surname>Thebeau</surname><given-names>M</given-names></name><name name-style="western"><surname>Czupryn</surname><given-names>MP</given-names></name><name name-style="western"><surname>Tetteh</surname><given-names>CL</given-names></name><etal/></person-group>. <article-title>Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma</article-title>. <source>Clin Cancer Res</source>. (<year>2015</year>) <volume>21</volume>:<page-range>712&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2468</pub-id><pub-id pub-id-type="pmcid">PMC4620684</pub-id><pub-id pub-id-type="pmid">25524312</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>A</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>J</given-names></name><name name-style="western"><surname>Brar</surname><given-names>DS</given-names></name><name name-style="western"><surname>Salunke</surname><given-names>D</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name></person-group>. <article-title>Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics</article-title>. <source>Curr Opin Chem Biol</source>. (<year>2022</year>) <volume>70</volume>:<fpage>102172</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cbpa.2022.102172</pub-id><pub-id pub-id-type="pmid">35785601</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gnjatic</surname><given-names>S</given-names></name><name name-style="western"><surname>Sawhney</surname><given-names>NB</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N</given-names></name></person-group>. <article-title>Toll-like receptor agonists: are they good adjuvants</article-title>? <source>Cancer J</source>. (<year>2010</year>) <volume>16</volume>:<page-range>382&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/PPO.0b013e3181eaca65</pub-id><pub-id pub-id-type="pmcid">PMC2922045</pub-id><pub-id pub-id-type="pmid">20693851</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabarsi</surname><given-names>P</given-names></name><name name-style="western"><surname>Anjidani</surname><given-names>N</given-names></name><name name-style="western"><surname>Shahpari</surname><given-names>R</given-names></name><name name-style="western"><surname>Mardani</surname><given-names>M</given-names></name><name name-style="western"><surname>Sabzvari</surname><given-names>A</given-names></name><name name-style="western"><surname>Yazdani</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of SpikoGen&#174;, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations</article-title>. <source>Clin Microbiol Infection</source>. (<year>2022</year>) <volume>28</volume>:<page-range>1263&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cmi.2022.04.004</pub-id><pub-id pub-id-type="pmcid">PMC9012510</pub-id><pub-id pub-id-type="pmid">35436611</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S</given-names></name><name name-style="western"><surname>Jogdand</surname><given-names>H</given-names></name><name name-style="western"><surname>Sarangi</surname><given-names>V</given-names></name><name name-style="western"><surname>Ganneru</surname><given-names>B</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial</article-title>. <source>Lancet Infect Dis</source>. (<year>2021</year>) <volume>21</volume>:<page-range>950&#8211;61</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1473-3099(21)00070-0</pub-id><pub-id pub-id-type="pmcid">PMC8221739</pub-id><pub-id pub-id-type="pmid">33705727</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>E</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name></person-group>. <article-title>Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases</article-title>. <source>Cell Mol Life Sci</source>. (<year>2022</year>) <volume>79</volume>:<page-range>1&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00018-022-04582-x</pub-id><pub-id pub-id-type="pmcid">PMC9555683</pub-id><pub-id pub-id-type="pmid">36224474</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahuja</surname><given-names>AS</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>VP</given-names></name><name name-style="western"><surname>Marques</surname><given-names>O</given-names></name></person-group>. <article-title>Artificial intelligence and COVID-19: A multidisciplinary approach</article-title>. <source>Integr Med Res</source>. (<year>2020</year>) <volume>9</volume>:<page-range>1&#8211;3</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.imr.2020.100434</pub-id><pub-id pub-id-type="pmcid">PMC7255319</pub-id><pub-id pub-id-type="pmid">32632356</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>S</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>A</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>J</given-names></name><name name-style="western"><surname>Piplani</surname><given-names>S</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name></person-group>. <article-title>Artificial intelligence in vaccine and drug design</article-title>. <source>Methods Mol Biol</source>. (<year>2021</year>) <volume>2410</volume>:<page-range>131&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-1-0716-1884-4_6</pub-id><pub-id pub-id-type="pmid">34914045</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakala</surname><given-names>IG</given-names></name><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>J</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name></person-group>. <article-title>A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization</article-title>. <source>Vaccine</source>. (<year>2021</year>) <volume>39</volume>:<page-range>5162&#8211;72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2021.07.037</pub-id><pub-id pub-id-type="pmid">34362601</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jelinkova</surname><given-names>L</given-names></name><name name-style="western"><surname>Jhun</surname><given-names>H</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>A</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name><name name-style="western"><surname>Zavala</surname><given-names>F</given-names></name><name name-style="western"><surname>Chackerian</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein</article-title>. <source>NPJ Vaccines</source>. (<year>2021</year>) <volume>6</volume>:<page-range>1&#8211;10</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41541-020-00274-4</pub-id><pub-id pub-id-type="pmcid">PMC7820318</pub-id><pub-id pub-id-type="pmid">33479242</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#246;rander</surname><given-names>S</given-names></name><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y</given-names></name><name name-style="western"><surname>B&#228;ckstr&#246;m</surname><given-names>M</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>J</given-names></name><name name-style="western"><surname>Bergstr&#246;m</surname><given-names>T</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection</article-title>. <source>Vaccine</source>. (<year>2021</year>) <volume>39</volume>:<page-range>5866&#8211;75</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2021.08.050</pub-id><pub-id pub-id-type="pmid">34456075</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>J</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name></person-group>. <article-title>Advax-cpG adjuvant provides antigen dose-sparing and enhanced immunogenicity for inactivated poliomyelitis virus vaccines</article-title>. <source>Pathogens</source>. (<year>2021</year>) <volume>10</volume>:<page-range>1&#8211;14</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/pathogens10050500</pub-id><pub-id pub-id-type="pmcid">PMC8143488</pub-id><pub-id pub-id-type="pmid">33919442</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jang</surname><given-names>H</given-names></name><name name-style="western"><surname>Carlock</surname><given-names>M</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection</article-title>. <source>Vaccine</source>. (<year>2021</year>) <volume>39</volume>:<page-range>5940&#8211;53</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2021.07.087</pub-id><pub-id pub-id-type="pmcid">PMC8328570</pub-id><pub-id pub-id-type="pmid">34420786</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>J</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>R</given-names></name><name name-style="western"><surname>Bielefeldt-Ohmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Covax-19/Spikogen&#174; vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters</article-title>. <source>Vaccine</source>. (<year>2022</year>) <volume>40</volume>:<page-range>3182&#8211;92</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2022.04.041</pub-id><pub-id pub-id-type="pmcid">PMC9013662</pub-id><pub-id pub-id-type="pmid">35465982</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y-J</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>JKB</given-names></name><name name-style="western"><surname>Sch&#252;lke</surname><given-names>S</given-names></name></person-group>. <article-title>Novel adjuvants in allergen-specific immunotherapy: where do we stand</article-title>? <source>Front Immunol</source>. (<year>2024</year>) <volume>15</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2024.1348305</pub-id><pub-id pub-id-type="pmcid">PMC10920236</pub-id><pub-id pub-id-type="pmid">38464539</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>PS</given-names></name><name name-style="western"><surname>O&#8217;hagan</surname><given-names>DT</given-names></name></person-group>. <article-title>Emerging concepts in the science of vaccine adjuvants</article-title>. <source>Nat Rev Drug Discovery</source>. (<year>2021</year>) <volume>20</volume>:<page-range>454&#8211;75</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id><pub-id pub-id-type="pmid">33824489</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Q</given-names></name><name name-style="western"><surname>Melino</surname><given-names>G</given-names></name><name name-style="western"><surname>Amelio</surname><given-names>I</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Recent advances in cancer immunotherapy</article-title>. <source>Discover Oncol</source>. (<year>2021</year>) <volume>12</volume>:<page-range>1&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12672-021-00422-9</pub-id><pub-id pub-id-type="pmcid">PMC8777500</pub-id><pub-id pub-id-type="pmid">35201440</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alaluf</surname><given-names>E</given-names></name><name name-style="western"><surname>Shalamov</surname><given-names>MM</given-names></name><name name-style="western"><surname>Sonnenblick</surname><given-names>A</given-names></name></person-group>. <article-title>Update on current and new potential immunotherapies in breast cancer, from bench to bedside</article-title>. <source>Front Immunol</source>. (<year>2024</year>) <volume>15</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2024.1287824</pub-id><pub-id pub-id-type="pmcid">PMC10905744</pub-id><pub-id pub-id-type="pmid">38433837</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becher</surname><given-names>B</given-names></name><name name-style="western"><surname>Tugues</surname><given-names>S</given-names></name><name name-style="western"><surname>Greter</surname><given-names>M</given-names></name></person-group>. <article-title>GM-CSF: from growth factor to central mediator of tissue inflammation</article-title>. <source>Immunity</source>. (<year>2016</year>) <volume>45</volume>:<page-range>963&#8211;73</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2016.10.026</pub-id><pub-id pub-id-type="pmid">27851925</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kantoff</surname><given-names>PW</given-names></name><name name-style="western"><surname>Higano</surname><given-names>C</given-names></name><name name-style="western"><surname>Shore</surname><given-names>N</given-names></name><name name-style="western"><surname>Berger</surname><given-names>E</given-names></name><name name-style="western"><surname>Small</surname><given-names>E</given-names></name><name name-style="western"><surname>Penson</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Sipuleucel-T immunotherapy for castration-resistant prostate cancer</article-title>. <source>New Engl J Med</source>. (<year>2010</year>) <volume>363</volume>:<page-range>411&#8211;22</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa1001294</pub-id><pub-id pub-id-type="pmid">20818862</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polyzoidis</surname><given-names>S</given-names></name><name name-style="western"><surname>Ashkan</surname><given-names>K</given-names></name></person-group>. <article-title>DCVax&#174;-L&#8212;Developed by northwest biotherapeutics</article-title>. <source>Hum Vaccines Immunotherapeutics</source>. (<year>2014</year>) <volume>10</volume>:<page-range>3139&#8211;45</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4161/hv.29276</pub-id><pub-id pub-id-type="pmcid">PMC4514134</pub-id><pub-id pub-id-type="pmid">25483653</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charych</surname><given-names>D</given-names></name><name name-style="western"><surname>Hoch</surname><given-names>U</given-names></name><name name-style="western"><surname>Langowski</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SR</given-names></name><name name-style="western"><surname>Addepalli</surname><given-names>M</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models</article-title>. <source>Clin Cancer Res</source>. (<year>2016</year>) <volume>22</volume>:<page-range>680&#8211;90</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-1631</pub-id><pub-id pub-id-type="pmid">26832745</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pettenati</surname><given-names>C</given-names></name><name name-style="western"><surname>Ingersoll</surname><given-names>MA</given-names></name></person-group>. <article-title>Mechanisms of BCG immunotherapy and its outlook for bladder cancer</article-title>. <source>Nat Rev Urol</source>. (<year>2018</year>) <volume>15</volume>:<page-range>615&#8211;25</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41585-018-0055-4</pub-id><pub-id pub-id-type="pmid">29991725</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sfakianos</surname><given-names>JP</given-names></name><name name-style="western"><surname>Salom&#233;</surname><given-names>B</given-names></name><name name-style="western"><surname>Daza</surname><given-names>J</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>&#193;</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N</given-names></name><name name-style="western"><surname>Horowitz</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer</article-title>. <source>Urologic Oncol</source>. (<year>2020</year>) <volume>39</volume>(<issue>2</issue>):<page-range>121&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.urolonc.2020.09.031</pub-id><pub-id pub-id-type="pmid">33262028</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>JC</given-names></name><name name-style="western"><surname>Yao</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Khan</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>RJ</given-names></name><etal/></person-group>. <article-title>CpG oligodeoxynucleotides for anticancer monotherapy from preclinical stages to clinical trials</article-title>. <source>Pharmaceutics</source>. (<year>2021</year>) <volume>14</volume>:<page-range>1&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/pharmaceutics14010073</pub-id><pub-id pub-id-type="pmcid">PMC8780291</pub-id><pub-id pub-id-type="pmid">35056969</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayart</surname><given-names>C</given-names></name><name name-style="western"><surname>Mularoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Hemmani</surname><given-names>N</given-names></name><name name-style="western"><surname>Kerachni</surname><given-names>S</given-names></name><name name-style="western"><surname>Jose</surname><given-names>J</given-names></name><name name-style="western"><surname>Gouet</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Tetanus toxin fragment C: structure, drug discovery research and production</article-title>. <source>Pharmaceuticals</source>. (<year>2022</year>) <volume>15</volume>:<page-range>1&#8211;28</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ph15060756</pub-id><pub-id pub-id-type="pmcid">PMC9227095</pub-id><pub-id pub-id-type="pmid">35745675</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name><name name-style="western"><surname>Xia</surname><given-names>T</given-names></name></person-group>. <article-title>Nanomaterial-based vaccine adjuvants</article-title>. <source>J materials Chem B</source>. (<year>2016</year>) <volume>4 33</volume>:<page-range>5496&#8211;509</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1039/C6TB01131D</pub-id><pub-id pub-id-type="pmcid">PMC6377210</pub-id><pub-id pub-id-type="pmid">30774955</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prygiel</surname><given-names>M</given-names></name><name name-style="western"><surname>Mosiej</surname><given-names>E</given-names></name><name name-style="western"><surname>G&#243;rska</surname><given-names>P</given-names></name><name name-style="western"><surname>Zasada</surname><given-names>A</given-names></name></person-group>. <article-title>Diphtheria-tetanus-pertussis vaccine: past, current &amp; future</article-title>. <source>Future Microbiol</source>. (<year>2021</year>) <volume>17</volume>(<issue>3</issue>):<page-range>185&#8211;97</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2217/fmb-2021-0167</pub-id><pub-id pub-id-type="pmid">34856810</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pattyn</surname><given-names>J</given-names></name><name name-style="western"><surname>Hendrickx</surname><given-names>G</given-names></name><name name-style="western"><surname>Vorsters</surname><given-names>A</given-names></name><name name-style="western"><surname>van Damme</surname><given-names>P</given-names></name></person-group>. <article-title>Hepatitis B vaccines</article-title>. <source>J Infect Dis</source>. (<year>2021</year>) <volume>224</volume>:<fpage>S343</fpage>&#8211;<lpage>S351</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/infdis/jiaa668</pub-id><pub-id pub-id-type="pmid">34590138</pub-id><pub-id pub-id-type="pmcid">PMC8482019</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>A-L</given-names></name></person-group>. <article-title>Recent developments in human papillomavirus (HPV) vaccinology</article-title>. <source>Viruses</source>. (<year>2023</year>) <volume>15</volume>:<page-range>1&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/v15071440</pub-id><pub-id pub-id-type="pmcid">PMC10384715</pub-id><pub-id pub-id-type="pmid">37515128</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>V</given-names></name><name name-style="western"><surname>Jung</surname><given-names>W</given-names></name><name name-style="western"><surname>Linde</surname><given-names>C</given-names></name><name name-style="western"><surname>Coates</surname><given-names>EE</given-names></name><name name-style="western"><surname>Ledgerwood</surname><given-names>J</given-names></name><name name-style="western"><surname>Costner</surname><given-names>PJM</given-names></name><etal/></person-group>. <article-title>Differences in HPV-specific antibody Fc-effector functions following Gardasil&#174; and Cervarix&#174; vaccination</article-title>. <source>NPJ Vaccines</source>. (<year>2023</year>) <volume>8</volume>:<page-range>1&#8211;11</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41541-023-00628-8</pub-id><pub-id pub-id-type="pmcid">PMC10017795</pub-id><pub-id pub-id-type="pmid">36922512</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#246;vgren Bengtsson</surname><given-names>K</given-names></name><name name-style="western"><surname>Morein</surname><given-names>B</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>ADME</given-names></name></person-group>. <article-title>ISCOM technology-based Matrix M&#8482; adjuvant: success in future vaccines relies on formulation</article-title>. <source>Expert Rev Vaccines</source>. (<year>2011</year>) <volume>10</volume>:<page-range>401&#8211;3</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1586/erv.11.25</pub-id><pub-id pub-id-type="pmid">21506635</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Gan</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Deng</surname><given-names>K</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Complete biosynthesis of QS-21 in engineered yeast</article-title>. <source>Nature</source>. (<year>2024</year>) <volume>629</volume>:<page-range>937&#8211;44</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-024-07345-9</pub-id><pub-id pub-id-type="pmcid">PMC11111400</pub-id><pub-id pub-id-type="pmid">38720067</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#252;</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Marin-Muller</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Current advances in research and clinical applications of PLGA-based nanotechnology</article-title>. <source>Expert Rev Mol Diagnostics</source>. (<year>2009</year>) <volume>9</volume>:<page-range>325&#8211;41</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1586/erm.09.15</pub-id><pub-id pub-id-type="pmcid">PMC2701163</pub-id><pub-id pub-id-type="pmid">19435455</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sledge</surname><given-names>G</given-names></name><name name-style="western"><surname>Loehrer</surname><given-names>P</given-names></name><name name-style="western"><surname>Roth</surname><given-names>B</given-names></name><name name-style="western"><surname>Einhorn</surname><given-names>L</given-names></name></person-group>. <article-title>Cisplatin as first-line therapy for metastatic breast cancer</article-title>. <source>J Clin Oncol</source>. (<year>1988</year>) <volume>6</volume>:<page-range>1811&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1200/JCO.1988.6.12.1811</pub-id><pub-id pub-id-type="pmid">3199166</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>L</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name></person-group>. <article-title>Recent advances in PLGA micro/nanoparticle delivery systems as novel therapeutic approach for drug-resistant tuberculosis</article-title>. <source>Front Bioengineering Biotechnol</source>. (<year>2022</year>) <volume>10</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fbioe.2022.941077</pub-id><pub-id pub-id-type="pmcid">PMC9355142</pub-id><pub-id pub-id-type="pmid">35935487</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>pH-responsive poly(D,L-lactic-co-glycolic acid) nanoparticles with rapid antigen release behavior promote immune response</article-title>. <source>ACS nano</source>. (<year>2015</year>) <volume>9</volume>:<page-range>4925&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/nn5066793</pub-id><pub-id pub-id-type="pmid">25898266</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wan</surname><given-names>T</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination</article-title>. <source>Nat materials</source>. (<year>2018</year>) <volume>17</volume>:<page-range>187&#8211;94</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nmat5057</pub-id><pub-id pub-id-type="pmid">29300052</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>SM</given-names></name><name name-style="western"><surname>Dhawan</surname><given-names>V</given-names></name><name name-style="western"><surname>Holm</surname><given-names>R</given-names></name><name name-style="western"><surname>Nagarsenker</surname><given-names>M</given-names></name><name name-style="western"><surname>Perrie</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Liposomes: Advancements and innovation in the manufacturing process</article-title>. <source>Advanced Drug delivery Rev</source>. (<year>2020</year>) <volume>154-155</volume>:<page-range>102&#8211;22</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.addr.2020.07.002</pub-id><pub-id pub-id-type="pmid">32650041</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meo</surname><given-names>S</given-names></name><name name-style="western"><surname>Bukhari</surname><given-names>I</given-names></name><name name-style="western"><surname>Akram</surname><given-names>J</given-names></name><name name-style="western"><surname>Meo</surname><given-names>A</given-names></name><name name-style="western"><surname>Klonoff</surname><given-names>D</given-names></name></person-group>. <article-title>COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. (<year>2021</year>) <volume>25</volume>:<page-range>1663&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.26355/eurrev_202102_24877</pub-id><pub-id pub-id-type="pmid">33629336</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinberger</surname><given-names>B</given-names></name></person-group>. <article-title>Adjuvant strategies to improve vaccination of the elderly population</article-title>. <source>Curr Opin Pharmacol</source>. (<year>2018</year>) <volume>41</volume>:<fpage>34</fpage>&#8211;<lpage>41</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.coph.2018.03.014</pub-id><pub-id pub-id-type="pmid">29677646</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goforth</surname><given-names>R</given-names></name><name name-style="western"><surname>Salem</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Miles</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>XQ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma</article-title>. <source>Cancer Immunology Immunotherapy</source>. (<year>2009</year>) <volume>58</volume>:<page-range>517&#8211;30</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00262-008-0574-6</pub-id><pub-id pub-id-type="pmcid">PMC11030463</pub-id><pub-id pub-id-type="pmid">18719913</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>JPM</given-names></name><name name-style="western"><surname>Figueroa</surname><given-names>ER</given-names></name><name name-style="western"><surname>Drezek</surname><given-names>RA</given-names></name></person-group>. <article-title>Gold nanoparticle mediated cancer immunotherapy</article-title>. <source>Nanomedicine: nanotechnology biology Med</source>. (<year>2014</year>) <volume>10</volume>:<page-range>503&#8211;14</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.nano.2013.09.011</pub-id><pub-id pub-id-type="pmcid">PMC3966952</pub-id><pub-id pub-id-type="pmid">24103304</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langermans</surname><given-names>JAM</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>T</given-names></name><name name-style="western"><surname>Vervenne</surname><given-names>R</given-names></name><name name-style="western"><surname>Laan</surname><given-names>TVD</given-names></name><name name-style="western"><surname>Lyashchenko</surname><given-names>K</given-names></name><name name-style="western"><surname>Greenwald</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6</article-title>. <source>Vaccine</source>. (<year>2005</year>) <volume>23</volume>:<page-range>2740&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2004.11.051</pub-id><pub-id pub-id-type="pmid">15780721</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>D</given-names></name><name name-style="western"><surname>Tae</surname><given-names>N</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name></person-group>. <article-title>Development of bispecific antibody for cancer immunotherapy: focus on T cell engaging antibody</article-title>. <source>Immune Network</source>. (<year>2022</year>) <volume>22</volume>:<page-range>1&#8211;22</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4110/in.2022.22.e4</pub-id><pub-id pub-id-type="pmcid">PMC8901699</pub-id><pub-id pub-id-type="pmid">35291652</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pagliuca</surname><given-names>S</given-names></name><name name-style="western"><surname>Gurnari</surname><given-names>C</given-names></name><name name-style="western"><surname>Rubio</surname><given-names>M</given-names></name><name name-style="western"><surname>Visconte</surname><given-names>V</given-names></name><name name-style="western"><surname>Lenz</surname><given-names>T</given-names></name></person-group>. <article-title>Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.944872</pub-id><pub-id pub-id-type="pmcid">PMC9483928</pub-id><pub-id pub-id-type="pmid">36131910</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macgillivray</surname><given-names>DM</given-names></name><name name-style="western"><surname>Kollmann</surname><given-names>TR</given-names></name></person-group>. <article-title>The role of environmental factors in modulating immune responses in early life</article-title>. <source>Front Immunol</source>. (<year>2014</year>) <volume>5</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2014.00434</pub-id><pub-id pub-id-type="pmcid">PMC4161944</pub-id><pub-id pub-id-type="pmid">25309535</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cisneros</surname><given-names>B</given-names></name><name name-style="western"><surname>Garc&#237;a-Aguirre</surname><given-names>I</given-names></name><name name-style="western"><surname>Unzueta</surname><given-names>J</given-names></name><name name-style="western"><surname>Arrieta-Cruz</surname><given-names>J</given-names></name><name name-style="western"><surname>Gonzalez-Morales</surname><given-names>O</given-names></name><name name-style="western"><surname>Dom&#237;nguez-Larrieta</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Immune system modulation in aging: Molecular mechanisms and therapeutic targets</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1059173</pub-id><pub-id pub-id-type="pmcid">PMC9797513</pub-id><pub-id pub-id-type="pmid">36591275</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>SL</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>KL</given-names></name></person-group>. <article-title>Sex differences in immune responses</article-title>. <source>Nat Rev Immunol</source>. (<year>2016</year>) <volume>16</volume>:<page-range>626&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nri.2016.90</pub-id><pub-id pub-id-type="pmid">27546235</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordakieva</surname><given-names>G</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>D</given-names></name></person-group>. <article-title>Editorial: Occupational immunology: current knowledge and future perspectives</article-title>. <source>Front Med</source>. (<year>2023</year>) <volume>10</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmed.2023.1322157</pub-id><pub-id pub-id-type="pmcid">PMC10667930</pub-id><pub-id pub-id-type="pmid">38020110</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name></person-group>. <article-title>Big data and artificial intelligence modeling for drug discovery</article-title>. <source>Annu Rev Pharmacol Toxicol</source>. (<year>2020</year>) <volume>60</volume>:<page-range>573&#8211;89</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010919-023324</pub-id><pub-id pub-id-type="pmcid">PMC7010403</pub-id><pub-id pub-id-type="pmid">31518513</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciallella</surname><given-names>HL</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name></person-group>. <article-title>Advancing computational toxicology in the big data era by artificial intelligence: data-driven and mechanism-driven modeling for chemical toxicity</article-title>. <source>Chem Res Toxicol</source>. (<year>2019</year>) <volume>32</volume>:<page-range>536&#8211;47</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.chemrestox.8b00393</pub-id><pub-id pub-id-type="pmcid">PMC6688471</pub-id><pub-id pub-id-type="pmid">30907586</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frolkis</surname><given-names>A</given-names></name><name name-style="western"><surname>Knox</surname><given-names>C</given-names></name><name name-style="western"><surname>Lim</surname><given-names>E</given-names></name><name name-style="western"><surname>Jewison</surname><given-names>T</given-names></name><name name-style="western"><surname>Law</surname><given-names>V</given-names></name><name name-style="western"><surname>Hau</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>SMPDB: the small molecule pathway database</article-title>. <source>Nucleic Acids Res</source>. (<year>2009</year>) <volume>38</volume>:<page-range>D480&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gkp1002</pub-id><pub-id pub-id-type="pmcid">PMC2808928</pub-id><pub-id pub-id-type="pmid">19948758</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shtar</surname><given-names>G</given-names></name><name name-style="western"><surname>Azulay</surname><given-names>L</given-names></name><name name-style="western"><surname>Nizri</surname><given-names>O</given-names></name><name name-style="western"><surname>Rokach</surname><given-names>L</given-names></name><name name-style="western"><surname>Shapira</surname><given-names>B</given-names></name></person-group>. <article-title>CDCDB: A large and continuously updated drug combination database</article-title>. <source>Sci Data</source>. (<year>2022</year>) <volume>9</volume>:<page-range>1&#8211;11</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41597-022-01360-z</pub-id><pub-id pub-id-type="pmcid">PMC9163158</pub-id><pub-id pub-id-type="pmid">35654801</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doms</surname><given-names>A</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>M</given-names></name></person-group>. <article-title>GoPubMed: exploring pubMed with the gene ontology</article-title>. <source>Nucleic Acids Res</source>. (<year>2005</year>) <volume>33</volume>:<page-range>W783&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gki470</pub-id><pub-id pub-id-type="pmcid">PMC1160231</pub-id><pub-id pub-id-type="pmid">15980585</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corney</surname><given-names>DPA</given-names></name><name name-style="western"><surname>Buxton</surname><given-names>B</given-names></name><name name-style="western"><surname>Langdon</surname><given-names>W</given-names></name><name name-style="western"><surname>Jones</surname><given-names>DT</given-names></name></person-group>. <article-title>BioRAT: extracting biological information from full-length papers</article-title>. <source>Bioinformatics</source>. (<year>2004</year>) <volume>20</volume>:<page-range>3206&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/bioinformatics/bth386</pub-id><pub-id pub-id-type="pmid">15231534</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>HCS</given-names></name><name name-style="western"><surname>Shan</surname><given-names>H</given-names></name><name name-style="western"><surname>Dahoun</surname><given-names>T</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>H</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name></person-group>. <article-title>Advancing drug discovery via artificial intelligence</article-title>. <source>Trends Pharmacol Sci</source>. (<year>2019</year>) <volume>40</volume>:<fpage>592</fpage>&#8211;<lpage>604</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.tips.2019.06.004</pub-id><pub-id pub-id-type="pmid">31320117</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Adelstein</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kassis</surname><given-names>AI</given-names></name></person-group>. <article-title>Target discovery from data mining approaches</article-title>. <source>Drug Discovery Today</source>. (<year>2009</year>) <volume>14</volume>:<page-range>147&#8211;54</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.drudis.2008.12.005</pub-id><pub-id pub-id-type="pmid">19135549</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feinberg</surname><given-names>EN</given-names></name><name name-style="western"><surname>Sur</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Husic</surname><given-names>B</given-names></name><name name-style="western"><surname>Mai</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>PotentialNet for molecular property prediction</article-title>. <source>ACS Cent Sci</source>. (<year>2018</year>) <volume>4</volume>:<page-range>1520&#8211;30</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acscentsci.8b00507</pub-id><pub-id pub-id-type="pmcid">PMC6276035</pub-id><pub-id pub-id-type="pmid">30555904</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>N</given-names></name></person-group>. <source>In Silico Medicinal Chemistry: Computational Methods to Support Drug Design</source>. <publisher-loc>Cambridge, UK</publisher-loc>: <publisher-name>The Royal Society of Chemistry</publisher-name> (<year>2015</year>).</mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>R</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>K</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>H</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>CancerDR: cancer drug resistance database</article-title>. <source>Sci Rep</source>. (<year>2013</year>) <volume>3</volume>:<fpage>1445</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/srep01445</pub-id><pub-id pub-id-type="pmid">23486013</pub-id><pub-id pub-id-type="pmcid">PMC3595698</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Thiessen</surname><given-names>P</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>EE</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Fu</surname><given-names>G</given-names></name><name name-style="western"><surname>Gindulyte</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>PubChem substance and compound databases</article-title>. <source>Nucleic Acids Res</source>. (<year>2015</year>) <volume>44</volume>:<fpage>D1202</fpage>&#8211;<lpage>D1213</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id><pub-id pub-id-type="pmid">26400175</pub-id><pub-id pub-id-type="pmcid">PMC4702940</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schomburg</surname><given-names>I</given-names></name><name name-style="western"><surname>Chang</surname><given-names>A</given-names></name><name name-style="western"><surname>Schomburg</surname><given-names>D</given-names></name></person-group>. <article-title>BRENDA, enzyme data and metabolic information</article-title>. <source>Nucleic Acids Res</source>. (<year>2002</year>) <volume>30</volume>:<page-range>47&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/30.1.47</pub-id><pub-id pub-id-type="pmcid">PMC99121</pub-id><pub-id pub-id-type="pmid">11752250</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>A</given-names></name><name name-style="western"><surname>Jeske</surname><given-names>L</given-names></name><name name-style="western"><surname>Ulbrich</surname><given-names>S</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Koblitz</surname><given-names>J</given-names></name><name name-style="western"><surname>Schomburg</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>BRENDA, the ELIXIR core data resource in 2021: new developments and updates</article-title>. <source>Nucleic Acids Res</source>. (<year>2020</year>) <volume>49</volume>:<page-range>D498&#8211;508</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gkaa1025</pub-id><pub-id pub-id-type="pmcid">PMC7779020</pub-id><pub-id pub-id-type="pmid">33211880</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>DS</given-names></name><name name-style="western"><surname>Feunang</surname><given-names>YD</given-names></name><name name-style="western"><surname>Guo</surname><given-names>A</given-names></name><name name-style="western"><surname>Lo</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Marcu</surname><given-names>A</given-names></name><name name-style="western"><surname>Grant</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res</source>. (<year>2017</year>) <volume>46</volume>:<page-range>D1074&#8211;82</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id><pub-id pub-id-type="pmcid">PMC5753335</pub-id><pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendez</surname><given-names>D</given-names></name><name name-style="western"><surname>Gaulton</surname><given-names>A</given-names></name><name name-style="western"><surname>Bento</surname><given-names>AP</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>J</given-names></name><name name-style="western"><surname>Veij</surname><given-names>M</given-names></name><name name-style="western"><surname>Felix</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>ChEMBL: towards direct deposition of bioassay data</article-title>. <source>Nucleic Acids Res</source>. (<year>2019</year>) <volume>47</volume>:<page-range>D930&#8211;40</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gky1075</pub-id><pub-id pub-id-type="pmcid">PMC6323927</pub-id><pub-id pub-id-type="pmid">30398643</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hastings</surname><given-names>J</given-names></name><name name-style="western"><surname>Matos</surname><given-names>P</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>A</given-names></name><name name-style="western"><surname>Ennis</surname><given-names>M</given-names></name><name name-style="western"><surname>Harsha</surname><given-names>B</given-names></name><name name-style="western"><surname>Kale</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>The ChEBI reference database and ontology for biologically relevant chemistry: enhancements for 2013</article-title>. <source>Nucleic Acids Res</source>. (<year>2012</year>) <volume>41</volume>:<page-range>D456&#8211;63</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gks1146</pub-id><pub-id pub-id-type="pmcid">PMC3531142</pub-id><pub-id pub-id-type="pmid">23180789</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irwin</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Tang</surname><given-names>KG</given-names></name><name name-style="western"><surname>Young</surname><given-names>J</given-names></name><name name-style="western"><surname>Dandarchuluun</surname><given-names>C</given-names></name><name name-style="western"><surname>Wong</surname><given-names>BR</given-names></name><name name-style="western"><surname>Khurelbaatar</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>ZINC20&#8212;A free ultralarge-scale chemical database for ligand discovery</article-title>. <source>J Chem Inf Modeling</source>. (<year>2020</year>) <volume>60</volume>:<page-range>6065&#8211;73</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.jcim.0c00675</pub-id><pub-id pub-id-type="pmcid">PMC8284596</pub-id><pub-id pub-id-type="pmid">33118813</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steiner</surname><given-names>S</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>JB</given-names></name><name name-style="western"><surname>Glatzel</surname><given-names>S</given-names></name><name name-style="western"><surname>Andreou</surname><given-names>A</given-names></name><name name-style="western"><surname>Granda</surname><given-names>J</given-names></name><name name-style="western"><surname>Keenan</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Organic synthesis in a modular robotic system driven by a chemical programming language</article-title>. <source>Science</source>. (<year>2019</year>) <volume>363</volume>:<elocation-id>eaav2211</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.aav2211</pub-id><pub-id pub-id-type="pmid">30498165</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Bombarelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Duvenaud</surname><given-names>D</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Lobato</surname><given-names>JM</given-names></name><name name-style="western"><surname>Aguilera-Iparraguirre</surname><given-names>J</given-names></name><name name-style="western"><surname>Hirzel</surname><given-names>TD</given-names></name><name name-style="western"><surname>Adams</surname><given-names>RP</given-names></name><etal/></person-group>. <article-title>Automatic chemical design using a data-driven continuous representation of molecules</article-title>. <source>ACS Cent Sci</source>. (<year>2018</year>) <volume>4</volume>:<page-range>268&#8211;76</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acscentsci.7b00572</pub-id><pub-id pub-id-type="pmcid">PMC5833007</pub-id><pub-id pub-id-type="pmid">29532027</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tevosyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Khondkaryan</surname><given-names>L</given-names></name><name name-style="western"><surname>Khachatrian</surname><given-names>H</given-names></name><name name-style="western"><surname>Tadevosyan</surname><given-names>G</given-names></name><name name-style="western"><surname>Apresyan</surname><given-names>L</given-names></name><name name-style="western"><surname>Babayan</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Improving VAE based molecular representations for compound property prediction</article-title>. <source>J Cheminformatics</source>. (<year>2022</year>) <volume>14</volume>:<fpage>69</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13321-022-00648-x</pub-id><pub-id pub-id-type="pmcid">PMC9569108</pub-id><pub-id pub-id-type="pmid">36242073</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>XM</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group>. (<year>2022</year>). <article-title>Co-VAE: drug-target binding affinity prediction by co-regularized variational autoencoders</article-title>, in: <conf-name>IEEE Transactions on Pattern Analysis and Machine Intelligence</conf-name>, (<publisher-loc>New York, USA</publisher-loc>: <publisher-name>IEEE</publisher-name>), Vol. <volume>44</volume>. pp. <page-range>8861&#8211;73</page-range>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TPAMI.2021.3120428</pub-id><pub-id pub-id-type="pmid">34652996</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y-L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Shi</surname><given-names>XX</given-names></name><name name-style="western"><surname>Jia</surname><given-names>CY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>FX</given-names></name><name name-style="western"><surname>Hao</surname><given-names>GF</given-names></name><etal/></person-group>. <article-title>Cloud 3D-QSAR: a web tool for the development of quantitative structure&#8211;activity relationship models in drug discovery</article-title>. <source>Briefings Bioinf</source>. (<year>2021</year>) <volume>22</volume>:<fpage>bbaa276</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/bib/bbaa276</pub-id><pub-id pub-id-type="pmid">33140820</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duvenaud</surname><given-names>D</given-names></name><name name-style="western"><surname>Maclaurin</surname><given-names>D</given-names></name><name name-style="western"><surname>Aguilera-Iparraguirre</surname><given-names>J</given-names></name><name name-style="western"><surname>G&#243;mez-Bombarelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Hirzel</surname><given-names>T</given-names></name><name name-style="western"><surname>Aspuru-Guzik</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Convolutional networks on graphs for learning molecular fingerprints</article-title>. <source>Adv Neural Inf Process Syst</source>. (<year>2015</year>) <volume>28</volume>:<page-range>2224&#8211;32</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.48550/arXiv.1509.09292</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilson</surname><given-names>MK</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Baitaluk</surname><given-names>M</given-names></name><name name-style="western"><surname>Nicola</surname><given-names>G</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chong</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology</article-title>. <source>Nucleic Acids Res</source>. (<year>2016</year>) <volume>44</volume>:<page-range>D1045&#8211;53</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gkv1072</pub-id><pub-id pub-id-type="pmcid">PMC4702793</pub-id><pub-id pub-id-type="pmid">26481362</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lian</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents</article-title>. <source>Nucleic Acids Res</source>. (<year>2021</year>) <volume>50</volume>:<page-range>D1398&#8211;407</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/nar/gkab953</pub-id><pub-id pub-id-type="pmcid">PMC8728281</pub-id><pub-id pub-id-type="pmid">34718717</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groom</surname><given-names>CR</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Lightfoot</surname><given-names>MP</given-names></name><name name-style="western"><surname>Ward</surname><given-names>SC</given-names></name></person-group>. <article-title>The Cambridge structural database</article-title>. <source>Acta Crystallographica Section B Struct Science Crystal Eng Materials</source>. (<year>2016</year>) <volume>72</volume>:<page-range>171&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1107/S2052520616003954</pub-id><pub-id pub-id-type="pmcid">PMC4822653</pub-id><pub-id pub-id-type="pmid">27048719</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>FH</given-names></name></person-group>. <article-title>The Cambridge Structural Database: a quarter of a million crystal structures and rising</article-title>. <source>Acta crystallographica Section B Struct Sci</source>. (<year>2002</year>) <volume>58 Pt 3 Pt 1</volume>:<page-range>380&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1107/s0108768102003890</pub-id><pub-id pub-id-type="pmid">12037359</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Nicklaus</surname><given-names>M</given-names></name></person-group>. <source>Downloadable structure files of nci open database compounds</source>. <publisher-loc>Bethesda, Maryland, USA</publisher-loc>: <publisher-name>national cancer institute</publisher-name> (<year>2016</year>).</mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veber</surname><given-names>DF</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>SR</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>HY</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B</given-names></name><name name-style="western"><surname>Ward</surname><given-names>K</given-names></name><name name-style="western"><surname>Kopple</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Molecular properties that influence the oral bioavailability of drug candidates</article-title>. <source>J medicinal Chem</source>. (<year>2002</year>) <volume>45</volume>:<page-range>2615&#8211;23</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/jm020017n</pub-id><pub-id pub-id-type="pmid">12036371</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>AMTDB: A comprehensive database of autophagic modulators for anti-tumor drug discovery</article-title>. <source>Front Pharmacol</source>. (<year>2022</year>) <volume>13</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fphar.2022.956501</pub-id><pub-id pub-id-type="pmcid">PMC9395961</pub-id><pub-id pub-id-type="pmid">36016573</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pence</surname><given-names>HE</given-names></name><name name-style="western"><surname>Williams</surname><given-names>AJ</given-names></name></person-group>. <article-title>ChemSpider:: an online chemical information resource</article-title>. <source>J Chem Educ</source>. (<year>2010</year>) <volume>87</volume>:<page-range>1123&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/ed100697w</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danziger</surname><given-names>D</given-names></name><name name-style="western"><surname>Dean</surname><given-names>PM</given-names></name></person-group>. <article-title>Automated site-directed drug design: a general algorithm for knowledge acquisition about hydrogen-bonding regions at protein surfaces</article-title>. <source>Proc R Soc London B Biol Sci</source>. (<year>1989</year>) <volume>236</volume>:<page-range>101&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1098/rspb.1989.0015</pub-id><pub-id pub-id-type="pmid">2565575</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>RA</given-names></name><name name-style="western"><surname>Dean</surname><given-names>PM</given-names></name></person-group>. <article-title>Automated site-directed drug design: the concept of spacer skeletons for primary structure generation</article-title>. <source>Proc R Soc London B Biol Sci</source>. (<year>1989</year>) <volume>236</volume>:<page-range>125&#8211;40</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1098/rspb.1989.0017</pub-id><pub-id pub-id-type="pmid">2565577</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>RA</given-names></name><name name-style="western"><surname>Dean</surname><given-names>PM</given-names></name></person-group>. <article-title>Automated site-directed drug design: the formation of molecular templates in primary structure generation</article-title>. <source>Proc R Soc London B Biol Sci</source>. (<year>1989</year>) <volume>236</volume>:<page-range>141&#8211;62</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1098/rspb.1989.0018</pub-id><pub-id pub-id-type="pmid">2565578</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartenfeller</surname><given-names>M</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>G</given-names></name></person-group>. <article-title>Enabling future drug discovery by de novo design</article-title>. <source>Wiley Interdiscip Reviews: Comput Mol Sci</source>. (<year>2011</year>) <volume>1</volume>:<page-range>742&#8211;59</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/wcms.49</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popova</surname><given-names>M</given-names></name><name name-style="western"><surname>Isayev</surname><given-names>O</given-names></name><name name-style="western"><surname>Tropsha</surname><given-names>A</given-names></name></person-group>. <article-title>Deep reinforcement learning for de novo drug design</article-title>. <source>Sci Adv</source>. (<year>2017</year>) <volume>4</volume>:<page-range>1&#8211;14</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/sciadv.aap7885</pub-id><pub-id pub-id-type="pmcid">PMC6059760</pub-id><pub-id pub-id-type="pmid">30050984</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Genheden</surname><given-names>S</given-names></name><name name-style="western"><surname>Thakkar</surname><given-names>A</given-names></name><name name-style="western"><surname>Chadimov&#225;</surname><given-names>V</given-names></name><name name-style="western"><surname>Reymond</surname><given-names>J</given-names></name><name name-style="western"><surname>Engkvist</surname><given-names>O</given-names></name><name name-style="western"><surname>Bjerrum</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>AiZynthFinder: a fast, robust and flexible open-source software for retrosynthetic planning</article-title>. <source>J Cheminformatics</source>. (<year>2020</year>) <volume>12</volume>:<page-range>1&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13321-020-00472-1</pub-id><pub-id pub-id-type="pmcid">PMC7672904</pub-id><pub-id pub-id-type="pmid">33292482</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhavoronkov</surname><given-names>A</given-names></name><name name-style="western"><surname>Ivanenkov</surname><given-names>YA</given-names></name><name name-style="western"><surname>Aliper</surname><given-names>A</given-names></name><name name-style="western"><surname>Veselov</surname><given-names>MS</given-names></name><name name-style="western"><surname>Aladinskiy</surname><given-names>VA</given-names></name><name name-style="western"><surname>Aladinskaya</surname><given-names>AV</given-names></name><etal/></person-group>. <article-title>Deep learning enables rapid identification of potent DDR1 kinase inhibitors</article-title>. <source>Nat Biotechnol</source>. (<year>2019</year>) <volume>37</volume>:<page-range>1038&#8211;40</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41587-019-0224-x</pub-id><pub-id pub-id-type="pmid">31477924</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goris</surname><given-names>A</given-names></name><name name-style="western"><surname>Vandebergh</surname><given-names>M</given-names></name><name name-style="western"><surname>McCauley</surname><given-names>J</given-names></name><name name-style="western"><surname>Saarela</surname><given-names>J</given-names></name><name name-style="western"><surname>Cotsapas</surname><given-names>C</given-names></name></person-group>. <article-title>Genetics of multiple sclerosis: lessons from polygenicity</article-title>. <source>Lancet Neurol</source>. (<year>2022</year>) <volume>21</volume>:<page-range>830&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1474-4422(22)00255-1</pub-id><pub-id pub-id-type="pmid">35963264</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sastry</surname><given-names>GM</given-names></name><name name-style="western"><surname>Adzhigirey</surname><given-names>M</given-names></name><name name-style="western"><surname>Day</surname><given-names>T</given-names></name><name name-style="western"><surname>Annabhimoju</surname><given-names>R</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>W</given-names></name></person-group>. <article-title>Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments</article-title>. <source>J Computer-Aided Mol Design</source>. (<year>2013</year>) <volume>27</volume>:<page-range>221&#8211;34</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s10822-013-9644-8</pub-id><pub-id pub-id-type="pmid">23579614</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19</article-title>. <source>bioRxiv</source>. (<year>2020</year>) <volume>582</volume>:<page-range>289&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Boosting protein-ligand binding pose prediction and virtual screening based on residue-atom distance likelihood potential and graph transformer</article-title>. <source>J medicinal Chem</source>. (<year>2022</year>) <volume>65</volume>(<issue>15</issue>):<page-range>10691&#8211;706</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c00991</pub-id><pub-id pub-id-type="pmid">35917397</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giordano</surname><given-names>D</given-names></name><name name-style="western"><surname>Biancaniello</surname><given-names>C</given-names></name><name name-style="western"><surname>Argenio</surname><given-names>MA</given-names></name><name name-style="western"><surname>Facchiano</surname><given-names>A</given-names></name></person-group>. <article-title>Drug design by pharmacophore and virtual screening approach</article-title>. <source>Pharmaceuticals</source>. (<year>2022</year>) <volume>15</volume>:<page-range>1&#8211;16</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ph15050646</pub-id><pub-id pub-id-type="pmcid">PMC9145410</pub-id><pub-id pub-id-type="pmid">35631472</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Chung</surname><given-names>TDY</given-names></name><name name-style="western"><surname>Oldenburg</surname><given-names>KR</given-names></name></person-group>. <article-title>A simple statistical parameter for use in evaluation and validation of high throughput screening assays</article-title>. <source>J Biomolecular Screening</source>. (<year>1999</year>) <volume>4</volume>:<fpage>67</fpage>&#8211;<lpage>73</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1177/108705719900400206</pub-id><pub-id pub-id-type="pmid">10838414</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kontoyianni</surname><given-names>M</given-names></name></person-group>. <article-title>Docking and virtual screening in drug discovery</article-title>. <source>Methods Mol Biol</source>. (<year>2017</year>) <volume>1647</volume>:<page-range>255&#8211;66</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-1-4939-7201-2_18</pub-id><pub-id pub-id-type="pmid">28809009</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JW</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S-W</given-names></name></person-group>. (<year>2019</year>). <article-title>Ligand- and structure-based virtual screening studies for the discovery of selective inhibitors</article-title>, in: <conf-name>2019 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)</conf-name>, (<publisher-loc>New York, USA</publisher-loc>: <publisher-name>IEEE</publisher-name>). pp. <page-range>1235&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1109/BIBM47256.2019.8983013</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bologa</surname><given-names>CG</given-names></name><name name-style="western"><surname>Ursu</surname><given-names>O</given-names></name><name name-style="western"><surname>Oprea</surname><given-names>TI</given-names></name></person-group>. <article-title>How to prepare a compound collection prior to virtual screening</article-title>. <source>Methods Mol Biol</source>. (<year>2019</year>) <volume>1939</volume>:<page-range>119&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-1-4939-9089-4_7</pub-id><pub-id pub-id-type="pmid">30848459</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banegas-Luna</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Cer&#243;n-Carrasco</surname><given-names>JP</given-names></name><name name-style="western"><surname>P&#233;rez-S&#225;nchez</surname><given-names>H</given-names></name></person-group>. <article-title>A review of ligand-based virtual screening web tools and screening algorithms in large molecular databases in the age of big data</article-title>. <source>Future medicinal Chem</source>. (<year>2018</year>) <volume>10</volume>:<page-range>2641&#8211;58</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4155/fmc-2018-0076</pub-id><pub-id pub-id-type="pmid">30499744</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badrinarayan</surname><given-names>P</given-names></name><name name-style="western"><surname>Sastry</surname><given-names>GN</given-names></name></person-group>. <article-title>Virtual high throughput screening in new lead identification</article-title>. <source>Combinatorial Chem High throughput screening</source>. (<year>2011</year>) <volume>14</volume>:<page-range>840&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2174/138620711797537102</pub-id><pub-id pub-id-type="pmid">21843146</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Luca</surname><given-names>L</given-names></name><name name-style="western"><surname>Vittorio</surname><given-names>S</given-names></name><name name-style="western"><surname>Pe&#241;a-D&#237;az</surname><given-names>S</given-names></name><name name-style="western"><surname>Pitasi</surname><given-names>G</given-names></name><name name-style="western"><surname>Fornt-Su&#241;&#233;</surname><given-names>M</given-names></name><name name-style="western"><surname>Bucolo</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Ligand-based discovery of a small molecule as inhibitor of &#945;-synuclein amyloid formation</article-title>. <source>Int J Mol Sci</source>. (<year>2022</year>) <volume>23</volume>:<page-range>1&#8211;14</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms232314844</pub-id><pub-id pub-id-type="pmcid">PMC9738895</pub-id><pub-id pub-id-type="pmid">36499173</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zarei</surname><given-names>O</given-names></name><name name-style="western"><surname>Faham</surname><given-names>N</given-names></name><name name-style="western"><surname>Vankayalapati</surname><given-names>H</given-names></name><name name-style="western"><surname>Raeppel</surname><given-names>S</given-names></name><name name-style="western"><surname>Welm</surname><given-names>A</given-names></name><name name-style="western"><surname>Hamzeh-Mivehroud</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Ligand-based discovery of novel small molecule inhibitors of RON receptor tyrosine kinase</article-title>. <source>Mol Inf</source>. (<year>2020</year>) <volume>41</volume>:<page-range>1&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/minf.202000181</pub-id><pub-id pub-id-type="pmid">33274845</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haider</surname><given-names>S</given-names></name><name name-style="western"><surname>Barakat</surname><given-names>A</given-names></name><name name-style="western"><surname>Ul-Haq</surname><given-names>Z</given-names></name></person-group>. <article-title>Discovery of potential chemical probe as inhibitors of CXCL12 using ligand-based virtual screening and molecular dynamic simulation</article-title>. <source>Molecules</source>. (<year>2020</year>) <volume>25</volume>:<page-range>1&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/molecules25204829</pub-id><pub-id pub-id-type="pmcid">PMC7594044</pub-id><pub-id pub-id-type="pmid">33092204</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Brunger</surname><given-names>AT</given-names></name></person-group>. <source>X-PLOR Version 3.1: A System for X-ray Crystallography and NMR</source>. (<year>1992</year>) (<publisher-loc>New Haven, Connecticut, USA</publisher-loc>: <publisher-name>Yale University Press</publisher-name>).</mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>W&#252;thrich</surname><given-names>K</given-names></name></person-group>. <article-title>Nuclear magnetic resonance (NMR) spectroscopy</article-title>. <source>Int Tables Crystallogr</source>. (<year>2012</year>), <page-range>464&#8211;79</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1107/97809553602060000704</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>N</given-names></name></person-group>. <article-title>A comprehensive survey of prospective structure-based virtual screening for early drug discovery in the past fifteen years</article-title>. <source>Int J Mol Sci</source>. (<year>2022</year>) <volume>23</volume>:<page-range>1&#8211;18</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms232415961</pub-id><pub-id pub-id-type="pmcid">PMC9781938</pub-id><pub-id pub-id-type="pmid">36555602</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>LLG</given-names></name><name name-style="western"><surname>Santos</surname><given-names>RND</given-names></name><name name-style="western"><surname>Oliva</surname><given-names>G</given-names></name><name name-style="western"><surname>Andricopulo</surname><given-names>A</given-names></name></person-group>. <article-title>Molecular docking and structure-based drug design strategies</article-title>. <source>Molecules</source>. (<year>2015</year>) <volume>20</volume>:<page-range>13384&#8211;421</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/molecules200713384</pub-id><pub-id pub-id-type="pmcid">PMC6332083</pub-id><pub-id pub-id-type="pmid">26205061</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Abdalla</surname><given-names>M</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>M</given-names></name><name name-style="western"><surname>Madhavi</surname><given-names>M</given-names></name><name name-style="western"><surname>Bhrdwaj</surname><given-names>A</given-names></name><name name-style="western"><surname>Khandelwal</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Structure-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation of VEGF inhibitors for the clinical treatment of Ovarian Cancer</article-title>. <source>J Mol Modeling</source>. (<year>2022</year>) <volume>28</volume>:<page-range>1&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00894-022-05081-3</pub-id><pub-id pub-id-type="pmid">35325303</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Z-S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Yi</surname><given-names>H</given-names></name><name name-style="western"><surname>Xue</surname><given-names>ST</given-names></name><name name-style="western"><surname>Li</surname><given-names>ZR</given-names></name><etal/></person-group>. <article-title>Structure-based virtual screening towards the discovery of novel FOXM1 inhibitors</article-title>. <source>Future medicinal Chem</source>. (<year>2021</year>). doi:&#160;<pub-id pub-id-type="doi">10.4155/fmc-2021-0282</pub-id><pub-id pub-id-type="pmid">34809496</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellver-Sanchis</surname><given-names>A</given-names></name><name name-style="western"><surname>Choudhary</surname><given-names>BS</given-names></name><name name-style="western"><surname>Companys-Alemany</surname><given-names>J</given-names></name><name name-style="western"><surname>&#193;vila-L&#243;pez</surname><given-names>SP</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>ALM</given-names></name><etal/></person-group>. <article-title>Structure&#8208;Based Virtual Screening and in vitro and in vivo Analyses Revealed Potent Methyltransferase G9a Inhibitors as Prospective Anti&#8208;Alzheimer's Agents</article-title>. <source>Chemmedchem</source>. (<year>2022</year>) <volume>17</volume>:<page-range>1&#8211;10</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/cmdc.202200002</pub-id><pub-id pub-id-type="pmcid">PMC9401600</pub-id><pub-id pub-id-type="pmid">35413149</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies</article-title>. <source>Eur J Medicinal Chem</source>. (<year>2021</year>) <volume>228</volume>:<elocation-id>114022</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ejmech.2021.114022</pub-id><pub-id pub-id-type="pmid">34871843</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>TE</given-names></name><name name-style="western"><surname>Sung</surname><given-names>L</given-names></name><name name-style="western"><surname>Chao</surname><given-names>MW</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>JH</given-names></name><name name-style="western"><surname>Sung</surname><given-names>TY</given-names></name><etal/></person-group>. <article-title>Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors</article-title>. <source>J Enzyme Inhibition Medicinal Chem</source>. (<year>2021</year>) <volume>37</volume>:<page-range>226&#8211;35</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/14756366.2021.1999237</pub-id><pub-id pub-id-type="pmcid">PMC8667945</pub-id><pub-id pub-id-type="pmid">34894949</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>T</given-names></name></person-group>. <article-title>Structure-based pharmacophore modeling, virtual screening, molecular docking, ADMET, and molecular dynamics (MD) simulation of potential inhibitors of PD-L1 from the library of marine natural products</article-title>. <source>Mar Drugs</source>. (<year>2021</year>) <volume>20</volume>:<page-range>1&#8211;18</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/md20010029</pub-id><pub-id pub-id-type="pmcid">PMC8777599</pub-id><pub-id pub-id-type="pmid">35049884</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>H-j</given-names></name><name name-style="western"><surname>Mao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>D</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays</article-title>. <source>J Computer-Aided Mol Design</source>. (<year>2021</year>) <volume>35</volume>:<page-range>679&#8211;94</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s10822-021-00386-6</pub-id><pub-id pub-id-type="pmid">33905074</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>MB</given-names></name><name name-style="western"><surname>Lin</surname><given-names>JP</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name></person-group>. <article-title>Quantitative structure&#8211;activity relationship: promising advances in drug discovery platforms</article-title>. <source>Expert Opin Drug Discovery</source>. (<year>2015</year>) <volume>10</volume>:<page-range>1283&#8211;300</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1517/17460441.2015.1083006</pub-id><pub-id pub-id-type="pmid">26358617</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansch</surname><given-names>C</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>T</given-names></name></person-group>. <article-title>p-&#963;-&#960; Analysis. A method for the correlation of biological activity and chemical structure</article-title>. <source>J Am Chem Soc</source>. (<year>1964</year>) <volume>86</volume>:<page-range>1616&#8211;26</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/ja01062a035</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasegawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Arakawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Funatsu</surname><given-names>K</given-names></name></person-group>. <article-title>Rational choice of bioactive conformations through use of conformation analysis and 3-way partial least squares modeling</article-title>. <source>Chemometrics Intelligent Lab Syst</source>. (<year>2000</year>) <volume>50</volume>:<page-range>253&#8211;61</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0169-7439(99)00063-5</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Podlogar</surname><given-names>BL</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>DM</given-names></name></person-group>. <article-title>QSAR and CoMFA: a perspective on the practical application to drug discovery</article-title>. <source>Drug design Discovery</source>. (<year>2000</year>) <volume>17</volume>:<fpage>4</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">10928446</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y-L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Shi</surname><given-names>XX</given-names></name><name name-style="western"><surname>Jia</surname><given-names>CY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>FX</given-names></name><name name-style="western"><surname>Hao</surname><given-names>GF</given-names></name><etal/></person-group>. <article-title>Cloud 3D-QSAR: a web tool for the development of quantitative structure-activity relationship models in drug discovery</article-title>. <source>Briefings Bioinf</source>. (<year>2020</year>) <volume>22</volume>(<issue>4</issue>):<page-range>1&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/bib/bbaa276</pub-id><pub-id pub-id-type="pmid">33140820</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damale</surname><given-names>MG</given-names></name><name name-style="western"><surname>Harke</surname><given-names>S</given-names></name><name name-style="western"><surname>Khan</surname><given-names>FAK</given-names></name><name name-style="western"><surname>Shinde</surname><given-names>D</given-names></name><name name-style="western"><surname>Sangshetti</surname><given-names>J</given-names></name></person-group>. <article-title>Recent advances in multidimensional QSAR (4D-6D): a critical review</article-title>. <source>Mini Rev medicinal Chem</source>. (<year>2014</year>) <volume>14</volume>:<fpage>35</fpage>&#8211;<lpage>55</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.2174/13895575113136660104</pub-id><pub-id pub-id-type="pmid">24195665</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Duvenaud</surname><given-names>DK</given-names></name><name name-style="western"><surname>Maclaurin</surname><given-names>D</given-names></name><name name-style="western"><surname>Aguilera-Iparraguirre</surname><given-names>J</given-names></name><name name-style="western"><surname>G&#243;mez-Bombarelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Hirzel</surname><given-names>TD</given-names></name><name name-style="western"><surname>Aspuru-Guzik</surname><given-names>A</given-names></name><etal/></person-group>. <source>Convolutional Networks on Graphs for Learning Molecular Fingerprints</source>. <publisher-loc>Vancouver, Canada</publisher-loc>: <publisher-name>NIPS</publisher-name> (<year>2015</year>).</mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coley</surname><given-names>CW</given-names></name><name name-style="western"><surname>Barzilay</surname><given-names>R</given-names></name><name name-style="western"><surname>Green</surname><given-names>W</given-names></name><name name-style="western"><surname>Jaakkola</surname><given-names>T</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>K</given-names></name></person-group>. <article-title>Convolutional embedding of attributed molecular graphs for physical property prediction</article-title>. <source>J Chem Inf modeling</source>. (<year>2017</year>) <volume>57</volume>:<page-range>1757&#8211;72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.jcim.6b00601</pub-id><pub-id pub-id-type="pmid">28696688</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urban</surname><given-names>G</given-names></name><name name-style="western"><surname>Subrahmanya</surname><given-names>NA</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>P</given-names></name></person-group>. <article-title>Inner and outer recursive neural networks for chemoinformatics applications</article-title>. <source>J Chem Inf modeling</source>. (<year>2018</year>) <volume>58</volume>:<page-range>207&#8211;11</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.jcim.7b00384</pub-id><pub-id pub-id-type="pmid">29320180</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scialli</surname><given-names>AR</given-names></name><name name-style="western"><surname>Daston</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CL</given-names></name><name name-style="western"><surname>Coder</surname><given-names>P</given-names></name><name name-style="western"><surname>Euling</surname><given-names>S</given-names></name><name name-style="western"><surname>Foreman</surname><given-names>JE</given-names></name><etal/></person-group>. <article-title>Rethinking developmental toxicity testing: Evolution or revolution</article-title>? <source>Birth defects Res</source>. (<year>2018</year>) <volume>110</volume>:<page-range>840&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/bdr2.1212</pub-id><pub-id pub-id-type="pmcid">PMC6624839</pub-id><pub-id pub-id-type="pmid">29436169</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>WMS</given-names></name><name name-style="western"><surname>Burch</surname><given-names>RL</given-names></name></person-group>. <article-title>The principles of humane experimental technique</article-title>. <source>Med J Aust</source>. (<year>1960</year>) <page-range>1&#8211;238</page-range>.</mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curzer</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>M</given-names></name><name name-style="western"><surname>Perry</surname><given-names>D</given-names></name></person-group>. <article-title>The three rs of animal research: what they mean for the institutional animal care and use committee and why</article-title>. <source>Sci Eng Ethics</source>. (<year>2016</year>) <volume>22</volume>:<page-range>549&#8211;65</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s11948-015-9659-8</pub-id><pub-id pub-id-type="pmid">26026966</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayr</surname><given-names>A</given-names></name><name name-style="western"><surname>Klambauer</surname><given-names>G</given-names></name><name name-style="western"><surname>Unterthiner</surname><given-names>T</given-names></name><name name-style="western"><surname>Hochreiter</surname><given-names>S</given-names></name></person-group>. <article-title>DeepTox: toxicity prediction using deep learning</article-title>. <source>Front Environ Sci</source>. (<year>2016</year>) <volume>3</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fenvs.2015.00080</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pu</surname><given-names>L</given-names></name><name name-style="western"><surname>Naderi</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>HC</given-names></name><name name-style="western"><surname>Mukhopadhyay</surname><given-names>S</given-names></name><name name-style="western"><surname>Brylinski</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>eToxPred: a machine learning-based approach to estimate the toxicity of drug candidates</article-title>. <source>BMC Pharmacol Toxicol</source>. (<year>2019</year>) <volume>20</volume>(<issue>1</issue>):<page-range>1&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s40360-018-0282-6</pub-id><pub-id pub-id-type="pmcid">PMC6325674</pub-id><pub-id pub-id-type="pmid">30621790</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lysenko</surname><given-names>A</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Boroevich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Tsunoda</surname><given-names>T</given-names></name></person-group>. <article-title>An integrative machine learning approach for prediction of toxicity-related drug safety</article-title>. <source>Life Sci Alliance</source>. (<year>2018</year>) <volume>1</volume>(<issue>6</issue>). doi:&#160;<pub-id pub-id-type="doi">10.1101/455667</pub-id><pub-id pub-id-type="pmcid">PMC6262234</pub-id><pub-id pub-id-type="pmid">30515477</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pushpakom</surname><given-names>SP</given-names></name><name name-style="western"><surname>Iorio</surname><given-names>F</given-names></name><name name-style="western"><surname>Eyers</surname><given-names>P</given-names></name><name name-style="western"><surname>Escott</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Hopper</surname><given-names>S</given-names></name><name name-style="western"><surname>Wells</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Drug repurposing: progress, challenges and recommendations</article-title>. <source>Nat Rev Drug Discovery</source>. (<year>2018</year>) <volume>18</volume>:<fpage>41</fpage>&#8211;<lpage>58</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrd.2018.168</pub-id><pub-id pub-id-type="pmid">30310233</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martorana</surname><given-names>A</given-names></name><name name-style="western"><surname>Perricone</surname><given-names>U</given-names></name><name name-style="western"><surname>Lauria</surname><given-names>A</given-names></name></person-group>. <article-title>The repurposing of old drugs or unsuccessful lead compounds by in silico approaches: new advances and perspectives</article-title>. <source>Curr topics medicinal Chem</source>. (<year>2016</year>) <volume>16</volume>:<page-range>2088&#8211;106</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2174/1568026616666160216153457</pub-id><pub-id pub-id-type="pmid">26881716</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rumienczyk</surname><given-names>I</given-names></name><name name-style="western"><surname>Kulecka</surname><given-names>M</given-names></name><name name-style="western"><surname>Statkiewicz</surname><given-names>M</given-names></name><name name-style="western"><surname>Ostrowski</surname><given-names>J</given-names></name><name name-style="western"><surname>Miku&#322;a</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Oncology drug repurposing for sepsis treatment</article-title>. <source>Biomedicines</source>. (<year>2022</year>) <volume>10</volume>:<fpage>921</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/biomedicines10040921</pub-id><pub-id pub-id-type="pmid">35453671</pub-id><pub-id pub-id-type="pmcid">PMC9030585</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Monneret</surname><given-names>C</given-names></name><name name-style="western"><surname>Bohuon</surname><given-names>C</given-names></name></person-group>. <source>Fabuleux hasards: histoire de la d&#233;couverte de m&#233;dicaments</source>. <publisher-loc>Les Ulis, France</publisher-loc>: <publisher-name>L'Editeur: EDP Sciences</publisher-name> (<year>2009</year>).</mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothwell</surname><given-names>PM</given-names></name><name name-style="western"><surname>Fowkes</surname><given-names>GR</given-names></name><name name-style="western"><surname>Belch</surname><given-names>J</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Warlow</surname><given-names>C</given-names></name><name name-style="western"><surname>Meade</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials</article-title>. <source>Lancet</source>. (<year>2011</year>) <volume>377</volume>:<fpage>31</fpage>&#8211;<lpage>41</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(10)62110-1</pub-id><pub-id pub-id-type="pmid">21144578</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>R&#252;schoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Wallinger</surname><given-names>S</given-names></name><name name-style="western"><surname>Dietmaier</surname><given-names>W</given-names></name><name name-style="western"><surname>Bocker</surname><given-names>T</given-names></name><name name-style="western"><surname>Brockhoff</surname><given-names>G</given-names></name><name name-style="western"><surname>Hofst&#228;dter</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection</article-title>. <source>Proc Natl Acad Sci</source>. (<year>1998</year>) <volume>95</volume>:<page-range>11301&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.95.19.11301</pub-id><pub-id pub-id-type="pmcid">PMC21637</pub-id><pub-id pub-id-type="pmid">9736731</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavalla</surname><given-names>D</given-names></name><name name-style="western"><surname>Singal</surname><given-names>C</given-names></name></person-group>. <article-title>Retrospective clinical analysis for drug rescue: for new indications or stratified patient groups</article-title>. <source>Drug Discovery Today</source>. (<year>2012</year>) <volume>17</volume>:<page-range>104&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.drudis.2011.09.019</pub-id><pub-id pub-id-type="pmid">22001144</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raje</surname><given-names>N</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>K</given-names></name></person-group>. <article-title>Thalidomide&#8212;a revival story</article-title>. <source>Mass Med Soc</source>. (<year>1999</year>) <volume>341</volume>(<issue>21</issue>):<page-range>1606&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJM199911183412110</pub-id><pub-id pub-id-type="pmid">10564693</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name></person-group>. <article-title>A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data</article-title>. <source>Nat Mach Intell</source>. (<year>2021</year>) <volume>3</volume>:<fpage>68</fpage>&#8211;<lpage>75</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s42256-020-00276-w</pub-id><pub-id pub-id-type="pmid">35603127</pub-id><pub-id pub-id-type="pmcid">PMC9119409</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Southall</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yasgar</surname><given-names>A</given-names></name><name name-style="western"><surname>Shinn</surname><given-names>P</given-names></name><name name-style="western"><surname>Jadhav</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The NCGC pharmaceutical collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics</article-title>. <source>Sci Trans Med</source>. (<year>2011</year>) <volume>3</volume>:<fpage>80ps16</fpage>&#8211;<lpage>80ps16</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.3001862</pub-id><pub-id pub-id-type="pmcid">PMC3098042</pub-id><pub-id pub-id-type="pmid">21525397</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finak</surname><given-names>G</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>BT</given-names></name><name name-style="western"><surname>Fulp</surname><given-names>W</given-names></name><name name-style="western"><surname>Obrecht</surname><given-names>P</given-names></name><name name-style="western"><surname>Sato</surname><given-names>A</given-names></name><name name-style="western"><surname>Chung</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>DataPackageR: Reproducible data preprocessing, standardization and sharing using R/Bioconductor for collaborative data analysis</article-title>. <source>Gates Open Res</source>. (<year>2018</year>) <volume>2</volume>:<page-range>1&#8211;17</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.12688/gatesopenres</pub-id><pub-id pub-id-type="pmcid">PMC6139382</pub-id><pub-id pub-id-type="pmid">30234197</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uechi</surname><given-names>L</given-names></name><name name-style="western"><surname>Galas</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Sakhanenko</surname><given-names>NA</given-names></name></person-group>. <article-title>Multivariate analysis of data sets with missing values: an information theory-based reliability function</article-title>. <source>J Comput Biol</source>. (<year>2019</year>) <volume>26</volume>:<page-range>152&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1089/cmb.2018.0179</pub-id><pub-id pub-id-type="pmcid">PMC6383577</pub-id><pub-id pub-id-type="pmid">30495984</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>AtChad&#233;</surname><given-names>MN</given-names></name><name name-style="western"><surname>Sokadjo</surname><given-names>YM</given-names></name><name name-style="western"><surname>Moussa</surname><given-names>AD</given-names></name><name name-style="western"><surname>Kurisheva</surname><given-names>S</given-names></name><name name-style="western"><surname>Bochenina</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cross-validation comparison of COVID-19 forecast models</article-title>. <source>Sn Comput Sci</source>. (<year>2021</year>) <volume>2</volume>:<page-range>1&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s42979-021-00699-1</pub-id><pub-id pub-id-type="pmcid">PMC8150153</pub-id><pub-id pub-id-type="pmid">34056624</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westerlund</surname><given-names>AM</given-names></name><name name-style="western"><surname>Barge</surname><given-names>B</given-names></name><name name-style="western"><surname>Mervin</surname><given-names>L</given-names></name><name name-style="western"><surname>Genheden</surname><given-names>S</given-names></name></person-group>. <article-title>Data&#8208;driven approaches for identifying hyperparameters in multi&#8208;step retrosynthesis</article-title>. <source>Mol Inf</source>. (<year>2023</year>) <volume>42</volume>:<page-range>1&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/minf.202300128</pub-id><pub-id pub-id-type="pmid">37679293</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zha</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Learning a data-driven policy network for pre-training automated feature engineering</article-title>, in: <conf-name>International Conference on Learning Representations</conf-name>.</mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vamathevan</surname><given-names>J</given-names></name><name name-style="western"><surname>Clark</surname><given-names>D</given-names></name><name name-style="western"><surname>Czodrowski</surname><given-names>P</given-names></name><name name-style="western"><surname>Dunham</surname><given-names>I</given-names></name><name name-style="western"><surname>Ferran</surname><given-names>E</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Applications of machine learning in drug discovery and development</article-title>. <source>Nat Rev Drug Discovery</source>. (<year>2019</year>) <volume>18</volume>:<page-range>463&#8211;77</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41573-019-0024-5</pub-id><pub-id pub-id-type="pmcid">PMC6552674</pub-id><pub-id pub-id-type="pmid">30976107</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brubaker</surname><given-names>SW</given-names></name><name name-style="western"><surname>Bonham</surname><given-names>K</given-names></name><name name-style="western"><surname>Zanoni</surname><given-names>I</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>JC</given-names></name></person-group>. <article-title>Innate immune pattern recognition: a cell biological perspective</article-title>. <source>Annu Rev Immunol</source>. (<year>2015</year>) <volume>33</volume>:<page-range>257&#8211;90</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1146/annurev-immunol-032414-112240</pub-id><pub-id pub-id-type="pmcid">PMC5146691</pub-id><pub-id pub-id-type="pmid">25581309</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>T</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xing</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>RF</given-names></name><etal/></person-group>. <article-title>Toll-like receptor signaling and its role in cell-mediated immunity</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>812774</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.812774</pub-id><pub-id pub-id-type="pmid">35309296</pub-id><pub-id pub-id-type="pmcid">PMC8927970</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veneziani</surname><given-names>I</given-names></name><name name-style="western"><surname>Alicata</surname><given-names>C</given-names></name><name name-style="western"><surname>Moretta</surname><given-names>L</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>E</given-names></name></person-group>. <article-title>The latest approach of immunotherapy with endosomal TLR agonists improving NK cell function: an overview</article-title>. <source>Biomedicines</source>. (<year>2022</year>) <volume>11</volume>:<page-range>1&#8211;17</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/biomedicines11010064</pub-id><pub-id pub-id-type="pmcid">PMC9855813</pub-id><pub-id pub-id-type="pmid">36672572</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chin</surname><given-names>AI</given-names></name><name name-style="western"><surname>Miyahira</surname><given-names>AK</given-names></name><name name-style="western"><surname>Covarrubias</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Teague</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>B</given-names></name><name name-style="western"><surname>Dempsey</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance</article-title>. <source>Cancer Res</source>. (<year>2010</year>) <volume>70</volume>:<page-range>2595&#8211;603</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1162</pub-id><pub-id pub-id-type="pmcid">PMC2995454</pub-id><pub-id pub-id-type="pmid">20233880</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Poltorak</surname><given-names>A</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Beutler</surname><given-names>B</given-names></name></person-group>. <article-title>Three novel mammalian toll-like receptors: gene structure, expression, and evolution</article-title>. <source>Eur Cytokine Netw</source>. (<year>2000</year>) <volume>11</volume>:<page-range>362&#8211;71</page-range>.<pub-id pub-id-type="pmid">11022119</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasilakos</surname><given-names>JP</given-names></name><name name-style="western"><surname>Tomai</surname><given-names>MA</given-names></name></person-group>. <article-title>The use of Toll-like receptor 7/8 agonists as vaccine adjuvants</article-title>. <source>Expert Rev Vaccines</source>. (<year>2013</year>) <volume>12</volume>:<page-range>809&#8211;19</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1586/14760584.2013.811208</pub-id><pub-id pub-id-type="pmid">23885825</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cervantes</surname><given-names>JL</given-names></name><name name-style="western"><surname>Weinerman</surname><given-names>B</given-names></name><name name-style="western"><surname>Basole</surname><given-names>CP</given-names></name><name name-style="western"><surname>Salaza</surname><given-names>J</given-names></name></person-group>. <article-title>TLR8: the forgotten relative revindicated</article-title>. <source>Cell Mol Immunol</source>. (<year>2012</year>) <volume>9</volume>:<page-range>434&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/cmi.2012.38</pub-id><pub-id pub-id-type="pmcid">PMC3498840</pub-id><pub-id pub-id-type="pmid">23085951</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Xing</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives</article-title>. <source>biomark Res</source>. (<year>2022</year>) <volume>10</volume>:<page-range>1&#8211;19</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s40364-022-00436-7</pub-id><pub-id pub-id-type="pmcid">PMC9727882</pub-id><pub-id pub-id-type="pmid">36476317</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lynn</surname><given-names>GM</given-names></name><name name-style="western"><surname>Chytil</surname><given-names>P</given-names></name><name name-style="western"><surname>Francica</surname><given-names>J</given-names></name><name name-style="western"><surname>Lagov&#225;</surname><given-names>A</given-names></name><name name-style="western"><surname>Kueberuwa</surname><given-names>G</given-names></name><name name-style="western"><surname>Ishizuka</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Impact of polymer-TLR-7/8 agonist (Adjuvant) morphology on the potency and mechanism of CD8 T cell induction</article-title>. <source>Biomacromolecules</source>. (<year>2019</year>) <volume>20</volume>:<page-range>854&#8211;70</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.biomac.8b01473</pub-id><pub-id pub-id-type="pmid">30608149</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lynn</surname><given-names>GM</given-names></name><name name-style="western"><surname>Laga</surname><given-names>R</given-names></name><name name-style="western"><surname>Darrah</surname><given-names>P</given-names></name><name name-style="western"><surname>Ishizuka</surname><given-names>A</given-names></name><name name-style="western"><surname>Balaci</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Dulcey</surname><given-names>AE</given-names></name><etal/></person-group>. <article-title>In vivo characterization of the physicochemical properties of TLR agonist delivery that enhance vaccine immunogenicity</article-title>. <source>Nat Biotechnol</source>. (<year>2015</year>) <volume>33</volume>:<page-range>1201&#8211;10</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nbt.3371</pub-id><pub-id pub-id-type="pmcid">PMC5842712</pub-id><pub-id pub-id-type="pmid">26501954</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#352;vajger</surname><given-names>U</given-names></name><name name-style="western"><surname>Horvat</surname><given-names>&#381;</given-names></name><name name-style="western"><surname>Knez</surname><given-names>D</given-names></name><name name-style="western"><surname>Ro&#382;man</surname><given-names>P</given-names></name><name name-style="western"><surname>Turk</surname><given-names>S</given-names></name><name name-style="western"><surname>Gobec</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>New antagonists of toll-like receptor 7 discovered through 3D ligand-based virtual screening</article-title>. <source>Medicinal Chem Res</source>. (<year>2014</year>) <volume>24</volume>:<page-range>362&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00044-014-1127-5</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>J</given-names></name><name name-style="western"><surname>Sastry</surname><given-names>G</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>SL</given-names></name><name name-style="western"><surname>Lowrie</surname><given-names>J</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods</article-title>. <source>J Cheminformatics</source>. (<year>2010</year>) <volume>3</volume>:<page-range>P1&#8211;1</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1186/1758-2946-3-S1-P1</pub-id><pub-id pub-id-type="pmid">20579912</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Auderset</surname><given-names>F</given-names></name><name name-style="western"><surname>Belnoue</surname><given-names>E</given-names></name><name name-style="western"><surname>Mastelic-Gavillet</surname><given-names>B</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>P</given-names></name><name name-style="western"><surname>Siegrist</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>A TLR7/8 agonist-including DOEPC-based cationic liposome formulation mediates its adjuvanticity through the sustained recruitment of highly activated monocytes in a type I IFN-independent but NF-kappaB-dependent manner</article-title>. <source>Front Immunol</source>. (<year>2020</year>) <volume>11</volume>:<elocation-id>580974</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2020.580974</pub-id><pub-id pub-id-type="pmid">33262759</pub-id><pub-id pub-id-type="pmcid">PMC7686571</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liong</surname><given-names>CS</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AAA</given-names></name><name name-style="western"><surname>Mann</surname><given-names>JL</given-names></name><name name-style="western"><surname>Roth</surname><given-names>GA</given-names></name><name name-style="western"><surname>Gale</surname><given-names>EC</given-names></name><name name-style="western"><surname>Maikawa</surname><given-names>CL</given-names></name><etal/></person-group>. <article-title>Enhanced humoral immune response by high density TLR agonist presentation on hyperbranched polymers</article-title>. <source>Advanced Ther</source>. (<year>2021</year>) <volume>4</volume>:<page-range>1&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/adtp.202000081</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Niu</surname><given-names>L</given-names></name><name name-style="western"><surname>Larson</surname><given-names>PG</given-names></name><name name-style="western"><surname>Kucaba</surname><given-names>T</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>K</given-names></name><name name-style="western"><surname>James</surname><given-names>BR</given-names></name><etal/></person-group>. <article-title>Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy</article-title>. <source>Biomaterials</source>. (<year>2018</year>) <volume>164</volume>:<fpage>38</fpage>&#8211;<lpage>53</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.02.034</pub-id><pub-id pub-id-type="pmid">29482062</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messina</surname><given-names>JP</given-names></name><name name-style="western"><surname>Gilkeson</surname><given-names>GS</given-names></name><name name-style="western"><surname>Pisetsky</surname><given-names>DS</given-names></name></person-group>. <article-title>Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA</article-title>. <source>J Immunol</source>. (<year>1991</year>) <volume>147</volume>:<page-range>1759&#8211;64</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.147.6.1759</pub-id><pub-id pub-id-type="pmid">1890302</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sparwasser</surname><given-names>T</given-names></name><name name-style="western"><surname>Koch</surname><given-names>E</given-names></name><name name-style="western"><surname>Vabulas</surname><given-names>R</given-names></name><name name-style="western"><surname>Heeg</surname><given-names>K</given-names></name><name name-style="western"><surname>Lipford</surname><given-names>G</given-names></name><name name-style="western"><surname>Ellwart</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells</article-title>. <source>Eur J Immunol</source>. (<year>1998</year>) <volume>28</volume>:<page-range>2045&#8211;54</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/(ISSN)1521-4141</pub-id><pub-id pub-id-type="pmid">9645386</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krieg</surname><given-names>AM</given-names></name><name name-style="western"><surname>Yi</surname><given-names>A</given-names></name><name name-style="western"><surname>Matson</surname><given-names>S</given-names></name><name name-style="western"><surname>Waldschmidt</surname><given-names>T</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>G</given-names></name><name name-style="western"><surname>Teasdale</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>CpG motifs in bacterial DNA trigger direct B-cell activation</article-title>. <source>Nature</source>. (<year>1995</year>) <volume>374</volume>:<page-range>546&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/374546a0</pub-id><pub-id pub-id-type="pmid">7700380</pub-id></mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krieg</surname><given-names>AM</given-names></name></person-group>. <article-title>CpG motifs in bacterial DNA and their immune effects</article-title>. <source>Annu Rev Immunol</source>. (<year>2002</year>) <volume>20</volume>:<page-range>709&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1146/annurev.immunol.20.100301.064842</pub-id><pub-id pub-id-type="pmid">11861616</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashkar</surname><given-names>AA</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>KL</given-names></name></person-group>. <article-title>Toll-like receptor 9, CpG DNA and innate immunity</article-title>. <source>Curr Mol Med</source>. (<year>2002</year>) <volume>2</volume>:<page-range>545&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2174/1566524023362159</pub-id><pub-id pub-id-type="pmid">12243247</pub-id></mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothenfusser</surname><given-names>S</given-names></name><name name-style="western"><surname>Hornung</surname><given-names>V</given-names></name><name name-style="western"><surname>Ayyoub</surname><given-names>M</given-names></name><name name-style="western"><surname>Britsch</surname><given-names>S</given-names></name><name name-style="western"><surname>Towarowski</surname><given-names>A</given-names></name><name name-style="western"><surname>Krug</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro</article-title>. <source>Blood</source>. (<year>2004</year>) <volume>103</volume>:<page-range>2162&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1182/blood-2003-04-1091</pub-id><pub-id pub-id-type="pmid">14630815</pub-id></mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bode</surname><given-names>C</given-names></name><name name-style="western"><surname>Poth</surname><given-names>J</given-names></name><name name-style="western"><surname>Fox</surname><given-names>M</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>S</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Cytosolic d&#8208;type CpG&#8208;oligonucleotides induce a type I interferon response by activating the cGAS&#8208;STING signaling pathway</article-title>. <source>Eur J Immunol</source>. (<year>2021</year>) <volume>51</volume>:<page-range>1686&#8211;97</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/eji.202048810</pub-id><pub-id pub-id-type="pmid">33860535</pub-id></mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>JD</given-names></name></person-group>. <article-title>Development of the cpG adjuvant 1018: A case study</article-title>. <source>Methods Mol Biol</source>. (<year>2017</year>) <volume>1494</volume>:<fpage>15</fpage>&#8211;<lpage>27</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/978-1-4939-6445-1_2</pub-id><pub-id pub-id-type="pmid">27718183</pub-id></mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipford</surname><given-names>GB</given-names></name><name name-style="western"><surname>Sparwasser</surname><given-names>T</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>S</given-names></name><name name-style="western"><surname>Heeg</surname><given-names>K</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>H</given-names></name></person-group>. <article-title>CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses</article-title>. <source>J Immunol</source>. (<year>2000</year>) <volume>165</volume>:<page-range>1228&#8211;35</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.165.3.1228</pub-id><pub-id pub-id-type="pmid">10903720</pub-id></mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ito</surname><given-names>S</given-names></name><name name-style="western"><surname>Hirobe</surname><given-names>S</given-names></name><name name-style="western"><surname>Kawakita</surname><given-names>T</given-names></name><name name-style="western"><surname>Saito</surname><given-names>M</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kamiyama</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Characteristic of K3 (CpG-ODN) as a transcutaneous vaccine formulation adjuvant</article-title>. <source>Pharmaceutics</source>. (<year>2020</year>) <volume>12</volume>:<page-range>1&#8211;17</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/pharmaceutics12030267</pub-id><pub-id pub-id-type="pmcid">PMC7151019</pub-id><pub-id pub-id-type="pmid">32183437</pub-id></mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>SR</given-names></name><name name-style="western"><surname>Fuertes</surname><given-names>M</given-names></name><name name-style="western"><surname>Corrales</surname><given-names>L</given-names></name><name name-style="western"><surname>Spranger</surname><given-names>S</given-names></name><name name-style="western"><surname>Furdyna</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Leung</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors</article-title>. <source>Immunity</source>. (<year>2014</year>) <volume>41</volume>:<page-range>830&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2014.10.017</pub-id><pub-id pub-id-type="pmcid">PMC4384884</pub-id><pub-id pub-id-type="pmid">25517615</pub-id></mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temizoz</surname><given-names>B</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>E</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>KJ</given-names></name></person-group>. <article-title>Vaccine adjuvants as potential cancer immunotherapeutics</article-title>. <source>Int Immunol</source>. (<year>2016</year>) <volume>28</volume>:<page-range>329&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/intimm/dxw015</pub-id><pub-id pub-id-type="pmcid">PMC4922024</pub-id><pub-id pub-id-type="pmid">27006304</pub-id></mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ZJ</given-names></name></person-group>. <article-title>The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer</article-title>. <source>J Exp Med</source>. (<year>2018</year>) <volume>215</volume>:<page-range>1287&#8211;99</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.20180139</pub-id><pub-id pub-id-type="pmcid">PMC5940270</pub-id><pub-id pub-id-type="pmid">29622565</pub-id></mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Du</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ZJ</given-names></name></person-group>. <article-title>Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway</article-title>. <source>Science</source>. (<year>2013</year>) <volume>339</volume>:<page-range>786&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.1232458</pub-id><pub-id pub-id-type="pmcid">PMC3863629</pub-id><pub-id pub-id-type="pmid">23258413</pub-id></mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Barber</surname><given-names>GN</given-names></name></person-group>. <article-title>STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling</article-title>. <source>Nature</source>. (<year>2008</year>) <volume>455</volume>:<page-range>674&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nature07317</pub-id><pub-id pub-id-type="pmcid">PMC2804933</pub-id><pub-id pub-id-type="pmid">18724357</pub-id></mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Kuolee</surname><given-names>R</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name></person-group>. <article-title>The potential of 3',5'-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant</article-title>. <source>Vaccine</source>. (<year>2010</year>) <volume>28</volume>:<page-range>3080&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2010.02.081</pub-id><pub-id pub-id-type="pmid">20197136</pub-id></mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><name name-style="western"><surname>Kanne</surname><given-names>D</given-names></name><name name-style="western"><surname>Leong</surname><given-names>M</given-names></name><name name-style="western"><surname>Glickman</surname><given-names>L</given-names></name><name name-style="western"><surname>McWhirter</surname><given-names>S</given-names></name><name name-style="western"><surname>Lemmens</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade</article-title>. <source>Sci Transl Med</source>. (<year>2015</year>) <volume>7</volume>:<fpage>283ra52</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.aaa4306</pub-id><pub-id pub-id-type="pmcid">PMC4504692</pub-id><pub-id pub-id-type="pmid">25877890</pub-id></mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karaolis</surname><given-names>DK</given-names></name><name name-style="western"><surname>Means</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>M</given-names></name><name name-style="western"><surname>Yoshimura</surname><given-names>T</given-names></name><name name-style="western"><surname>Muraille</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Bacterial c-di-GMP is an immunostimulatory molecule</article-title>. <source>J Immunol</source>. (<year>2007</year>) <volume>178</volume>:<page-range>2171&#8211;81</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.178.4.2171</pub-id><pub-id pub-id-type="pmid">17277122</pub-id></mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogunniyi</surname><given-names>AD</given-names></name><name name-style="western"><surname>Paton</surname><given-names>J</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>A</given-names></name><name name-style="western"><surname>McCullers</surname><given-names>J</given-names></name><name name-style="western"><surname>Cook</surname><given-names>J</given-names></name><name name-style="western"><surname>Hyodo</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection</article-title>. <source>Vaccine</source>. (<year>2008</year>) <volume>26</volume>:<page-range>4676&#8211;85</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2008.06.099</pub-id><pub-id pub-id-type="pmcid">PMC2647696</pub-id><pub-id pub-id-type="pmid">18640167</pub-id></mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name></person-group>. <article-title>The promise and challenges of cyclic dinucleotides as molecular adjuvants for vaccine development</article-title>. <source>Vaccines (Basel)</source>. (<year>2021</year>) <volume>9</volume>:<page-range>1&#8211;31</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9080917</pub-id><pub-id pub-id-type="pmcid">PMC8402453</pub-id><pub-id pub-id-type="pmid">34452042</pub-id></mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>WH</given-names></name><name name-style="western"><surname>Su</surname><given-names>JY</given-names></name><name name-style="western"><surname>Li</surname><given-names>YM</given-names></name></person-group>. <article-title>Rational design of T-cell- and B-cell-based therapeutic cancer vaccines</article-title>. <source>Acc Chem Res</source>. (<year>2022</year>) <volume>55</volume>:<page-range>2660&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.accounts.2c00360</pub-id><pub-id pub-id-type="pmid">36048514</pub-id></mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatnagar</surname><given-names>S</given-names></name><name name-style="western"><surname>Revuri</surname><given-names>V</given-names></name><name name-style="western"><surname>Shah</surname><given-names>MD</given-names></name><name name-style="western"><surname>Larson</surname><given-names>PG</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>D</given-names></name><name name-style="western"><surname>Panyam</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Combination of STING and TLR 7/8 agonists as vaccine adjuvants for cancer immunotherapy</article-title>. <source>Cancers (Basel)</source>. (<year>2022</year>) <volume>14</volume>:<page-range>1&#8211;18</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/cancers14246091</pub-id><pub-id pub-id-type="pmcid">PMC9777055</pub-id><pub-id pub-id-type="pmid">36551577</pub-id></mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrington</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Brody</surname><given-names>J</given-names></name><name name-style="western"><surname>Ingham</surname><given-names>M</given-names></name><name name-style="western"><surname>Strauss</surname><given-names>J</given-names></name><name name-style="western"><surname>Cemerski</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas</article-title>. <source>Ann Oncol</source>. (<year>2018</year>) <volume>29 Suppl 8</volume>:<fpage>viii712</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/annonc/mdy424.015</pub-id></mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Zanden</surname><given-names>SY</given-names></name><name name-style="western"><surname>Luimstra</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Neefjes</surname><given-names>J</given-names></name><name name-style="western"><surname>Borst</surname><given-names>J</given-names></name><name name-style="western"><surname>Ovaa</surname><given-names>H</given-names></name></person-group>. <article-title>Opportunities for small molecules in cancer immunotherapy</article-title>. <source>Trends Immunol</source>. (<year>2020</year>) <volume>41</volume>(<issue>6</issue>):<page-range>493&#8211;511</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.it.2020.04.004</pub-id><pub-id pub-id-type="pmid">32381382</pub-id></mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name name-style="western"><surname>Sweis</surname><given-names>R</given-names></name><name name-style="western"><surname>Hodi</surname><given-names>F</given-names></name><name name-style="western"><surname>Messersmith</surname><given-names>W</given-names></name><name name-style="western"><surname>Andtbacka</surname><given-names>R</given-names></name><name name-style="western"><surname>Ingham</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas</article-title>. <source>Clin Cancer Res</source>. (<year>2021</year>) <page-range>677&#8211;88</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-1963</pub-id><pub-id pub-id-type="pmid">34716197</pub-id></mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falahat</surname><given-names>R</given-names></name><name name-style="western"><surname>Berglund</surname><given-names>A</given-names></name><name name-style="western"><surname>Perez-Villarroel</surname><given-names>P</given-names></name><name name-style="western"><surname>Putney</surname><given-names>RM</given-names></name><name name-style="western"><surname>Hamaidi</surname><given-names>I</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Epigenetic state determines the in vivo efficacy of STING agonist therapy</article-title>. <source>Nat Commun</source>. (<year>2023</year>) <volume>14</volume>:<page-range>1&#8211;16</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-023-37217-1</pub-id><pub-id pub-id-type="pmcid">PMC10033671</pub-id><pub-id pub-id-type="pmid">36949064</pub-id></mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leach</surname><given-names>DG</given-names></name><name name-style="western"><surname>Dharmaraj</surname><given-names>N</given-names></name><name name-style="western"><surname>Piotrowski</surname><given-names>S</given-names></name><name name-style="western"><surname>Lopez-Silva</surname><given-names>T</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sikora</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy</article-title>. <source>Biomaterials</source>. (<year>2018</year>) <volume>163</volume>:<fpage>67</fpage>&#8211;<lpage>75</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.01.035</pub-id><pub-id pub-id-type="pmid">29454236</pub-id><pub-id pub-id-type="pmcid">PMC5840037</pub-id></mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramanjulu</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pesiridis</surname><given-names>GS</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Concha</surname><given-names>N</given-names></name><name name-style="western"><surname>Singhaus</surname><given-names>RR</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Design of amidobenzimidazole STING receptor agonists with systemic activity</article-title>. <source>Nature</source>. (<year>2018</year>) <volume>564</volume>:<page-range>439&#8211;43</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-018-0705-y</pub-id><pub-id pub-id-type="pmid">30405246</pub-id></mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>HL</given-names></name><name name-style="western"><surname>Kiss-Toth</surname><given-names>E</given-names></name></person-group>. <article-title>Regulating STING in health and disease</article-title>. <source>J Inflammation (London England)</source>. (<year>2017</year>) <volume>14</volume>:<page-range>1&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12950-017-0159-2</pub-id><pub-id pub-id-type="pmcid">PMC5463399</pub-id><pub-id pub-id-type="pmid">28596706</pub-id></mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Agata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shibahara</surname><given-names>K</given-names></name><name name-style="western"><surname>Honjo</surname><given-names>T</given-names></name></person-group>. <article-title>Induced expression of PD&#8208;1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death</article-title>. <source>EMBO J</source>. (<year>1992</year>) <volume>11</volume>:<page-range>3887&#8211;95</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/embj.1992.11.issue-11</pub-id><pub-id pub-id-type="pmcid">PMC556898</pub-id><pub-id pub-id-type="pmid">1396582</pub-id></mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W</given-names></name></person-group>. <article-title>PD-L1 distribution and perspective for cancer immunotherapy&#8212;Blockade, knockdown, or inhibition</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.02022</pub-id><pub-id pub-id-type="pmcid">PMC6718566</pub-id><pub-id pub-id-type="pmid">31507611</pub-id></mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Chan</surname><given-names>LC</given-names></name><name name-style="western"><surname>Li</surname><given-names>CW</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>J</given-names></name><name name-style="western"><surname>Hung</surname><given-names>M</given-names></name></person-group>. <article-title>Mechanisms controlling PD-L1 expression in cancer</article-title>. <source>Mol Cell</source>. (<year>2019</year>) <volume>76</volume>(<issue>3</issue>):<page-range>359&#8211;70</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.molcel.2019.09.030</pub-id><pub-id pub-id-type="pmcid">PMC6981282</pub-id><pub-id pub-id-type="pmid">31668929</pub-id></mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mocellin</surname><given-names>S</given-names></name><name name-style="western"><surname>Nitti</surname><given-names>D</given-names></name></person-group>. <article-title>Therapeutics targeting tumor immune escape: Towards the development of new generation anticancer vaccines</article-title>. <source>Medicinal Res Rev</source>. (<year>2008</year>) <volume>28</volume>:<page-range>413&#8211;44</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/med.20110</pub-id><pub-id pub-id-type="pmid">17694549</pub-id></mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morse</surname><given-names>MA</given-names></name><name name-style="western"><surname>Gwin</surname><given-names>WR</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>DA</given-names></name></person-group>. <article-title>Vaccine therapies for cancer: then and now</article-title>. <source>Targeted Oncol</source>. (<year>2021</year>) <volume>16</volume>:<page-range>121&#8211;52</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s11523-020-00788-w</pub-id><pub-id pub-id-type="pmcid">PMC7845582</pub-id><pub-id pub-id-type="pmid">33512679</pub-id></mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igarashi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sasada</surname><given-names>T</given-names></name></person-group>. <article-title>Cancer vaccines: toward the next breakthrough in cancer immunotherapy</article-title>. <source>J Immunol Res</source>. (<year>2020</year>) <volume>2020</volume>:<page-range>1&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2020/5825401</pub-id><pub-id pub-id-type="pmcid">PMC7685825</pub-id><pub-id pub-id-type="pmid">33282961</pub-id></mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuol</surname><given-names>N</given-names></name><name name-style="western"><surname>Stojanovska</surname><given-names>L</given-names></name><name name-style="western"><surname>Nurgali</surname><given-names>K</given-names></name><name name-style="western"><surname>Apostolopoulos</surname><given-names>V</given-names></name></person-group>. <article-title>PD-1/PD-L1 in disease</article-title>. <source>Immunotherapy</source>. (<year>2018</year>) <volume>10</volume>:<page-range>149&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2217/imt-2017-0120</pub-id><pub-id pub-id-type="pmid">29260623</pub-id></mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ott</surname><given-names>PA</given-names></name><name name-style="western"><surname>Hu-Lieskovan</surname><given-names>S</given-names></name><name name-style="western"><surname>Chmielowski</surname><given-names>B</given-names></name><name name-style="western"><surname>Govindan</surname><given-names>R</given-names></name><name name-style="western"><surname>Naing</surname><given-names>A</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>183</volume>:<fpage>347</fpage>&#8211;<lpage>62.e24</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2020.08.053</pub-id><pub-id pub-id-type="pmid">33064988</pub-id></mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K</given-names></name><name name-style="western"><surname>Bi</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group>. <article-title>Small molecule-based immunomodulators for cancer therapy</article-title>. <source>Acta Pharm Sinica. B</source>. (<year>2022</year>) <volume>12</volume>:<page-range>4287&#8211;308</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.apsb.2022.11.007</pub-id><pub-id pub-id-type="pmcid">PMC9764074</pub-id><pub-id pub-id-type="pmid">36562003</pub-id></mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>CG</given-names></name><name name-style="western"><surname>Arkin</surname><given-names>MR</given-names></name></person-group>. <article-title>Probing structural adaptivity at PPI interfaces with small molecules</article-title>. <source>Drug Discovery Today Technol</source>. (<year>2013</year>) <volume>10</volume>:<page-range>e501&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.ddtec.2012.10.009</pub-id><pub-id pub-id-type="pmid">24451641</pub-id></mixed-citation></ref><ref id="B212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zak</surname><given-names>KM</given-names></name><name name-style="western"><surname>Grudnik</surname><given-names>P</given-names></name><name name-style="western"><surname>Guzik</surname><given-names>K</given-names></name><name name-style="western"><surname>Zi&#281;ba</surname><given-names>B</given-names></name><name name-style="western"><surname>Musielak</surname><given-names>B</given-names></name><name name-style="western"><surname>D&#246;mling</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)</article-title>. <source>Oncotarget</source>. (<year>2016</year>) <volume>7</volume>:<page-range>30323&#8211;35</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.18632/oncotarget.v7i21</pub-id><pub-id pub-id-type="pmcid">PMC5058683</pub-id><pub-id pub-id-type="pmid">27083005</pub-id></mixed-citation></ref><ref id="B213"><label>213</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zak</surname><given-names>KM</given-names></name><name name-style="western"><surname>Grudnik</surname><given-names>P</given-names></name><name name-style="western"><surname>Guzik</surname><given-names>K</given-names></name><name name-style="western"><surname>Zi&#281;ba</surname><given-names>B</given-names></name><name name-style="western"><surname>Musielak</surname><given-names>B</given-names></name><name name-style="western"><surname>D&#246;mling</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2</article-title>. <source>Structure</source>. (<year>2017</year>) <volume>25</volume>:<page-range>1163&#8211;74</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.str.2017.06.011</pub-id><pub-id pub-id-type="pmid">28768162</pub-id></mixed-citation></ref><ref id="B214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bailly</surname><given-names>C</given-names></name><name name-style="western"><surname>Vergoten</surname><given-names>G</given-names></name></person-group>. <article-title>Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer</article-title>. <source>Biochem Pharmacol</source>. (<year>2020</year>) <volume>178</volume>:<fpage>114042</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.bcp.2020.114042</pub-id><pub-id pub-id-type="pmid">32445869</pub-id></mixed-citation></ref><ref id="B215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasikumar</surname><given-names>PGN</given-names></name><name name-style="western"><surname>Sudarshan</surname><given-names>N</given-names></name><name name-style="western"><surname>Adurthi</surname><given-names>S</given-names></name><name name-style="western"><surname>Ramachandra</surname><given-names>R</given-names></name><name name-style="western"><surname>Samiulla</surname><given-names>D</given-names></name><name name-style="western"><surname>Lakshminarasimhan</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy</article-title>. <source>Commun Biol</source>. (<year>2021</year>) <volume>4</volume>:<page-range>1&#8211;12</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s42003-021-02191-1</pub-id><pub-id pub-id-type="pmcid">PMC8187357</pub-id><pub-id pub-id-type="pmid">34103659</pub-id></mixed-citation></ref><ref id="B216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soliman</surname><given-names>H</given-names></name><name name-style="western"><surname>Mediavilla-Varela</surname><given-names>M</given-names></name><name name-style="western"><surname>Antonia</surname><given-names>S</given-names></name></person-group>. <article-title>Indoleamine 2,3-dioxygenase: is it an immune suppressor</article-title>? <source>Cancer J</source>. (<year>2010</year>) <volume>16</volume>:<page-range>354&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/PPO.0b013e3181eb3343</pub-id><pub-id pub-id-type="pmcid">PMC3850167</pub-id><pub-id pub-id-type="pmid">20693847</pub-id></mixed-citation></ref><ref id="B217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Antigen capture and immune modulation by bacterial outer membrane vesicles as in situ vaccine for cancer immunotherapy post-photothermal therapy</article-title>. <source>Small</source>. (<year>2022</year>) <volume>18</volume>(<issue>14</issue>):<elocation-id>e2107461</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1002/smll.202107461</pub-id><pub-id pub-id-type="pmid">35152555</pub-id></mixed-citation></ref><ref id="B218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Song</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy</article-title>. <source>J materials Chem B</source>. (<year>2021</year>) <volume>9</volume>:<page-range>3892&#8211;99</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1039/D1TB00256B</pub-id><pub-id pub-id-type="pmid">33928989</pub-id></mixed-citation></ref><ref id="B219"><label>219</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troitskaya</surname><given-names>O</given-names></name><name name-style="western"><surname>Varlamov</surname><given-names>M</given-names></name><name name-style="western"><surname>Nushtaeva</surname><given-names>A</given-names></name><name name-style="western"><surname>Richter</surname><given-names>V</given-names></name><name name-style="western"><surname>Koval</surname><given-names>O</given-names></name></person-group>. <article-title>Recombinant lactaptin induces immunogenic cell death and creates an antitumor vaccination effect in vivo with enhancement by an IDO inhibitor</article-title>. <source>Molecules</source>. (<year>2020</year>) <volume>25</volume>:<page-range>1&#8211;17</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3390/molecules25122804</pub-id><pub-id pub-id-type="pmcid">PMC7355630</pub-id><pub-id pub-id-type="pmid">32560527</pub-id></mixed-citation></ref><ref id="B220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pagni</surname><given-names>RL</given-names></name><name name-style="western"><surname>Souza</surname><given-names>PC</given-names></name><name name-style="western"><surname>Pegoraro</surname><given-names>R</given-names></name><name name-style="western"><surname>Porchia</surname><given-names>BF</given-names></name><name name-style="western"><surname>Silva</surname><given-names>JR</given-names></name><name name-style="western"><surname>Aps</surname><given-names>LR</given-names></name><etal/></person-group>. <article-title>Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1005937</pub-id><pub-id pub-id-type="pmcid">PMC9668887</pub-id><pub-id pub-id-type="pmid">36405719</pub-id></mixed-citation></ref><ref id="B221"><label>221</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno</surname><given-names>ACR</given-names></name><name name-style="western"><surname>Porchia</surname><given-names>BF</given-names></name><name name-style="western"><surname>Pagni</surname><given-names>R</given-names></name><name name-style="western"><surname>Souza</surname><given-names>PC</given-names></name><name name-style="western"><surname>Pegoraro</surname><given-names>R</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>KB</given-names></name><etal/></person-group>. <article-title>The combined use of melatonin and an indoleamine 2,3-dioxygenase-1 inhibitor enhances vaccine-induced protective cellular immunity to HPV16-associated tumors</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2018.01914</pub-id><pub-id pub-id-type="pmcid">PMC6113858</pub-id><pub-id pub-id-type="pmid">30186285</pub-id></mixed-citation></ref><ref id="B222"><label>222</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soliman</surname><given-names>HH</given-names></name><name name-style="western"><surname>Khambati</surname><given-names>F</given-names></name><name name-style="western"><surname>Han</surname><given-names>H</given-names></name><name name-style="western"><surname>Ismail-Khan</surname><given-names>R</given-names></name><name name-style="western"><surname>Bui</surname><given-names>M</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer</article-title>. <source>Oncotarget</source>. (<year>2015</year>) <volume>9</volume>:<page-range>10110&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.18632/oncotarget.v9i11</pub-id><pub-id pub-id-type="pmcid">PMC5839376</pub-id><pub-id pub-id-type="pmid">29515795</pub-id></mixed-citation></ref><ref id="B223"><label>223</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiMasi</surname><given-names>JA</given-names></name><name name-style="western"><surname>Grabowski</surname><given-names>HG</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>RW</given-names></name></person-group>. <article-title>Innovation in the pharmaceutical industry: New estimates of R&amp;D costs</article-title>. <source>J Health economics</source>. (<year>2016</year>) <volume>47</volume>:<fpage>20</fpage>&#8211;<lpage>33</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jhealeco.2016.01.012</pub-id><pub-id pub-id-type="pmid">26928437</pub-id></mixed-citation></ref><ref id="B224"><label>224</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>CH</given-names></name><name name-style="western"><surname>Siah</surname><given-names>KW</given-names></name><name name-style="western"><surname>Lo</surname><given-names>AW</given-names></name></person-group>. <article-title>Estimation of clinical trial success rates and related parameters</article-title>. <source>Biostatistics (Oxford England)</source>. (<year>2018</year>) <volume>20</volume>:<page-range>273&#8211;86</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/biostatistics/kxx069</pub-id><pub-id pub-id-type="pmcid">PMC6409418</pub-id><pub-id pub-id-type="pmid">29394327</pub-id></mixed-citation></ref><ref id="B225"><label>225</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hay</surname><given-names>M</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>DW</given-names></name><name name-style="western"><surname>Craighead</surname><given-names>JC</given-names></name><name name-style="western"><surname>Economides</surname><given-names>C</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Clinical development success rates for investigational drugs</article-title>. <source>Nat Biotechnol</source>. (<year>2014</year>) <volume>32</volume>:<fpage>40</fpage>&#8211;<lpage>51</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nbt.2786</pub-id><pub-id pub-id-type="pmid">24406927</pub-id></mixed-citation></ref><ref id="B226"><label>226</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrer</surname><given-names>S</given-names></name><name name-style="western"><surname>Shah</surname><given-names>P</given-names></name><name name-style="western"><surname>Antony</surname><given-names>B</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name></person-group>. <article-title>Artificial intelligence for clinical trial design</article-title>. <source>Trends Pharmacol Sci</source>. (<year>2019</year>) <volume>40</volume>(<issue>8</issue>):<page-range>577&#8211;91</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1109/SPMB50085.2020.9353614</pub-id><pub-id pub-id-type="pmid">31326235</pub-id></mixed-citation></ref><ref id="B227"><label>227</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heaton</surname><given-names>J</given-names></name></person-group>. <article-title>Ian Goodfellow, Yoshua Bengio, and Aaron Courville: deep learning</article-title>. <source>Genet Programming Evolvable Machines</source>. (<year>2018</year>) <volume>19</volume>:<page-range>305&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s10710-017-9314-z</pub-id></mixed-citation></ref><ref id="B228"><label>228</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>K</given-names></name><name name-style="western"><surname>Woodland</surname><given-names>PC</given-names></name></person-group>. (<year>2023</year>). <article-title>Adaptable end-to-end ASR models using replaceable internal LMs and residual softmax</article-title>, in: <conf-name>ICASSP 2023</conf-name>, <publisher-loc>New York, USA</publisher-loc>: <publisher-name>IEEE</publisher-name>. doi:&#160;<pub-id pub-id-type="doi">10.1109/ICASSP49357.2023.10095860</pub-id></mixed-citation></ref><ref id="B229"><label>229</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dara</surname><given-names>S</given-names></name><name name-style="western"><surname>Dhamercherla</surname><given-names>S</given-names></name><name name-style="western"><surname>Jadav</surname><given-names>SS</given-names></name><name name-style="western"><surname>Babu</surname><given-names>CM</given-names></name><name name-style="western"><surname>Ahsan</surname><given-names>M</given-names></name></person-group>. <article-title>Machine learning in drug discovery: A review</article-title>. <source>Artif Intell Rev</source>. (<year>2021</year>) <volume>55</volume>:<page-range>1947&#8211;99</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s10462-021-10058-4</pub-id><pub-id pub-id-type="pmcid">PMC8356896</pub-id><pub-id pub-id-type="pmid">34393317</pub-id></mixed-citation></ref><ref id="B230"><label>230</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ren</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name></person-group>. (<year>2015</year>). <article-title>Deep residual learning for image recognition</article-title>, in: <conf-name>2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR)</conf-name>, <publisher-loc>New York, USA</publisher-loc>: <publisher-name>IEEE</publisher-name>. pp. <page-range>770&#8211;8</page-range>.</mixed-citation></ref><ref id="B231"><label>231</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipinski</surname><given-names>CF</given-names></name><name name-style="western"><surname>Maltarollo</surname><given-names>V</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>PR</given-names></name><name name-style="western"><surname>Silva</surname><given-names>ABF</given-names></name><name name-style="western"><surname>Hon&#243;rio</surname><given-names>KM</given-names></name></person-group>. <article-title>Advances and perspectives in applying deep learning for drug design and discovery</article-title>. <source>Front Robotics AI</source>. (<year>2019</year>) <volume>6</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3389/frobt.2019.00108</pub-id><pub-id pub-id-type="pmcid">PMC7805776</pub-id><pub-id pub-id-type="pmid">33501123</pub-id></mixed-citation></ref><ref id="B232"><label>232</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gastegger</surname><given-names>M</given-names></name><name name-style="western"><surname>McSloy</surname><given-names>A</given-names></name><name name-style="western"><surname>Luya</surname><given-names>M</given-names></name><name name-style="western"><surname>Sch&#252;tt</surname><given-names>KT</given-names></name><name name-style="western"><surname>Maure</surname><given-names>R</given-names></name></person-group>. <article-title>A deep neural network for molecular wave functions in quasi-atomic minimal basis representation</article-title>. <source>J Chem Phys</source>. (<year>2020</year>) <volume>153</volume>:<fpage>044123</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1063/5.0012911</pub-id><pub-id pub-id-type="pmid">32752663</pub-id></mixed-citation></ref><ref id="B233"><label>233</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>WFD</given-names></name><name name-style="western"><surname>He</surname><given-names>S</given-names></name><name name-style="western"><surname>Bilodeau</surname><given-names>CL</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name></person-group>. <article-title>Predicting small molecule transfer free energies by combining molecular dynamics simulations and deep learning</article-title>. <source>J Chem Inf modeling</source>. (<year>2020</year>) <volume>60</volume>(<issue>11</issue>):<page-range>5375&#8211;81</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.jcim.0c00318</pub-id><pub-id pub-id-type="pmid">32794768</pub-id></mixed-citation></ref><ref id="B234"><label>234</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamberti</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>M</given-names></name><name name-style="western"><surname>Donzanti</surname><given-names>BA</given-names></name><name name-style="western"><surname>Wohlhieter</surname><given-names>GE</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>S</given-names></name><name name-style="western"><surname>Wilkins</surname><given-names>RG</given-names></name><etal/></person-group>. <article-title>A study on the application and use of artificial intelligence to support drug development</article-title>. <source>Clin Ther</source>. (<year>2019</year>) <volume>41</volume>(<issue>8</issue>):<page-range>1414&#8211;26</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.clinthera.2019.05.018</pub-id><pub-id pub-id-type="pmid">31248680</pub-id></mixed-citation></ref><ref id="B235"><label>235</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voosen</surname><given-names>P</given-names></name></person-group>. <article-title>The AI detectives</article-title>. <source>Science</source>. (<year>2017</year>) <volume>357</volume>:<page-range>22&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.357.6346.22</pub-id><pub-id pub-id-type="pmid">28684483</pub-id></mixed-citation></ref><ref id="B236"><label>236</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baig</surname><given-names>MH</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>K</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>JM</given-names></name><name name-style="western"><surname>Adil</surname><given-names>M</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>Computer aided drug design: success and limitations</article-title>. <source>Curr Pharm design</source>. (<year>2016</year>) <volume>22</volume>:<page-range>572&#8211;81</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2174/1381612822666151125000550</pub-id><pub-id pub-id-type="pmid">26601966</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>